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ABSTRACT
HRSV is the leading cause o f  lower respiratory tract (LTR) infection in the new-bom 
and during early childhood, accounting for approximately 90% o f  the reported cases 
of bronchiolitis in infancy. The WHO estimates that o f  the 12.2 million annual deaths 
in children under five years o f  age, a third is due to acute infections of the LRT. RSV 
may also be the cause o f  up to 2.4 % community-acquired LRT infections in adults o f  
less than 60 years o f  age and in elderly people.
The fusion (F) and attachment (G) proteins are the major protective antigens in 
RSV. Almost all the available F-specific monoclonal antibodies efficiently neutralize 
RSV in vitro and monoclonal antibodies have been successfully used for in vivo 
treatment o f human RSV infection. Since the F-protein is genetically more stable than 
the G-protein it represents a better candidate for vaccine development. Immunity to 
RSV includes serum antibody, secretory antibody, and cytotoxic T-cell responses. 
Secretory antibodies are mainly effective in the upper respiratory tract, while serum 
antibodies are the key for resolution o f  LRT infection. However, immunity to RSV is 
incomplete and re-infections occur throughout life. The work described in this thesis 
was designed to:
A: Identify both linear and conformational B-cell epitopes o f  the fusion protein of 
human RSV as a part o f  a programme o f work to develop an epitope based vaccine 
against RSV. 55 overlapping peptides covering the whole o f  the fusion protein o f  RSV 
were synthesized by solid phase synthesis using the RAM Ps system these peptides 
were used to screen sera from RSV-infectcd individuals (9 adults and 49 infants) for 
reactivity with linear epitopes using an Enzyme Linked Immunosorbent Assay 
(ELISA). In addition, a human monoclonal antibody (RF2) that recognizes a 
conformational epitope on the fusion protein o f HRSV was used to screen a
2
combinatorial peptide library to identify mimotopes o f this conformational epitope. 
The linear epitopes and the mimotopes identified in this way were used in vivo 
experiments to assess their ability to induce anti-peptide antibodies that can cross- 
react with RSV.
B. In an attempt to throw light on the question o f how RSV can re-infect the same 
individual, serial serum samples were obtained from infants prior to exposure to RSV 
at 6 months o f age, following primary exposure at 9-12 months and following second 
exposure at 12-18 months. The reactivity o f  these sera with the 55 overlapping 
peptides from the F protein was assessed by ELISA to determine if  there were 
differences in the pattern o f peptide recognition at different stages o f exposure to 
RSV.
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CHAPTER 1
INTRODUCTION
1.1 Human Respiratory Syncytial virus
Human Respiratory Syncytial Virus (RSV) is the single most important cause of lower 
respiratory tract infection (LRI) in newborn infants and immuno-suppressed 
individuals worldwide (WHO 2002).
The virus was first isolated in 1956 as the cause o f chimpanzee coryza (symptoms that 
are similar to the common cold) and subsequently it was repeatedly isolated in 
Baltimore from a group of children with pneumonia (Morris, Blunt et al. 1956; 
Chanock, Roizman et al. 1957; Simoes 1999). It accounted for virtually up to 98% of 
reported cases o f LRI in the USA, and total medical costs for all RSV-related 
hospitalisations for children <5 years old were estimated at SUS652 million in the 
year 2000 (Paramore, Ciuryla et al. 2004). In a survey carried out in Maryland -USA 
between 1997 to 2000, an estimated 390 RSV-related deaths occurred in 1999 only 
(Leader S 2003). In the UK around 20000 infants are hospitalized result of an RSV 
infection annually (Handforth, Friedland et al. 2000). The WHO estimates that there 
are repectively 160000 annual deaths in children less than 5 years o f  age caused by 
RSV, and up to 64 million worldwide infections (WHO 2002). This has made the 
WHO to assign the virus for rapid vaccine development.
Although traditionally it is considered a pediatric pathogen, RSV infection can 
lead to a life-threatening disease in immuno-compromised individuals and in the 
elderly (Webster 1999). Although the severity of disease declines with repeated 
infection, p revious i nfection d oes n ot p revent d iseasc and any i mmunity d eveloped 
therefore appears to be incomplete (Hall, Walsh et al. 1991).
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RSV is a member o f the genus Pneumovirus o f the family Paramyxoviridae; which 
are enveloped non-segmented negative-stranded RNA viruses. Negative-stranded 
RNA viruses encode and contain their own RNA transcriptase but mRNAs are only 
synthesized once the virus has been uncoated in the infected cell. Viral replication 
occurs after synthesis o f the mRNAs and requires the continuous synthesis o f viral 
proteins (Fields and Howley 2001) (Figure. 1.1). The RSV genome is a single strand o f  
RNA composed o f  approximately 15,000 nucleotides that are transcribed into 10 
major sub-genomic mRNAs that encodes 11 major viral proteins.
Cross-neutralization studies have shown that RSV isolates can be classified 
into two groups, RSVA&RSVB o f roughly equivalent virulence (Anderson, 
Hierholzer et al. 1985; Mufson, rvell et al. 1985).
The development o f  an effective vaccine against RSV could reduce RSV- 
related mortality and although the importance of RSV has been known for more than 
30 years and the virus targets a wide range of high-risk groups, there is still no 
approved vaccine nor a highly effective antiviral therapy against this pathogen (Polack 
and Karron 2004).
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Figure 1.1
The structu re  of re sp ira to ry  syncytial virus.
The KSV virion is about 200 nni in size and consists of a nucleocapsid within a lipid 
envelope. The nucleocapsid is a sym m etrical helix w ith a helical d iam eter of 12-1S inn. 
The lipid h ilayer is derived from the host plasm a m em brane and contains virally 
encoded transm em brane surface glycoproteins which arc 11-20 nm in size and closely 
spaced at in tervals of 6-10 nm. (from  H acking and Hull 2002).
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1.2 The Virus
RSV virion consists of the nucleocapsid enclosed within a lipid envelope that is 
derived from the plasma membrane o f the target cell. The virions are irregular in 
shape, range in diameter from 15-300 nm and can be seen by electron microscopy or 
when negatively stained. They can be visualized in the tissue culture as filamentous 
forms which are 60 to 100 nm in diameter and up to 400 nm in length. Enclosed in the 
envelope are three viral trans-membrane surface glycoproteins: the attachment protein 
G, the fusion protein F, and the small hydrophobic protein SH (Fields and Howley 
2001) (Figure. 1.1).
The RSV genome is a single-stranded negative sense RNA o f 15,200 
nucleotides that is transcribed into 10 sub-genomic mRNAs. Transcription is initiated 
from the 3’ end with only a fraction of the polymerase moving on to the next gene 
(Figure 1.2).
RSV encodes 11 proteins: (Figure. 1.3).
• Four proteins are associated with the genomic RNA to form the viral 
nucleocapsid (N, P, and L) and M2. The RSV M2 gene contains two partially 
overlapping open reading frames (ORFs), designated M2-1 and M2-2, which 
give rise to two proteins, M2-1 (194 amino acids) and M2-2 (90 amino acids), 
M2 ORF-2 is a second distinct protein transcribed from the M2 gene, which 
has a defined function in transcription regulation. The mechanism for 
translating the M2-2 ORF is not clear, but it may involve a ribosomal stop- 
restart. The M2-1 protein is an essential transcriptional elongation factor and in 
its absence, the polymerase does not transcribe beyond the NS1 and NS2 
genes. The M2-1 gene also increases RNAP processivity across the gene 
junctions, attenuating transcription termination. The M2-2 gene is not essential 
for RSV growth, as it can be deleted from a recombinant RSV. However, the
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M2-2 deficient virus grows slowly in tissue culture and there is an increase in 
transcription and decrease in RNA replication, suggesting that the M2-2 
protein is involved in regulating transcription and RNA replication.
• The N protein (391 amino acids) binds tightly along the entire length of 
genomic RNA to form an RNAse-resistant nucleocapsid.
• L is the major polymerase subunit- it contains six discrete segments, are highly 
conserved and represent the functional domains o f  the protein (polymerase 
motifs).
• The P protein is about 507 to 603 amino acids long and is thought to associate 
with free N and L to maintain them in soluble forms and might also participate 
as a cofactor in RNA synthesis (Fields and Howley 2001).The three proteins 
N, P and L form a complex that is essentially adequate to direct RNA 
replication.
• Three major proteins o f RSV are the trans-membrane surface proteins G, F, 
and SH. The surface fusion (F) protein and the attachment (G) glyco-protein 
are the two major immunogenic proteins. Both proteins induce the production 
of RSV neutralizing antibody responses and they are therefore important 
targets for vaccine development (Fields and Howley 2001).
• One protein is a non-glycosylated virion matrix protein (M), which is about 
341 to 375 amino acid long.
• Finally, there are two non-structural proteins that accumulate in infected cells 
but arc present in only trace amounts in mature virions the NS1 and NS2 
proteins. T he R SV N SI (139) amino acids) and NS2 (124 amino acids) are 
considered to be non-structural proteins. Neither protein is thought to be 
essential for virus growth in cultured cells or in chimpanzees, as the genes can
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Figure 1.2
The replicative cycle o f RSV.
KSV attachm ent occurs via the G protein. Fusion is m ediated by the F protein after 
which the viral envelope is incorporated  into the cell m em brane and the nuclcocapsid is 
released into the cytoplasm . KSV mRNA accum ulates for about 15 h after infection and 
then rem ains a t constant levels thereby allowing for RNA replication and subsequent 
viral assembly. T he M2-2 gene governs this transition  from transcrip tion  to production 
o f genomic RNA. The M protein and m em brane-destined G protein meet in the Golgi 
and can in teract through a six amino acid motif at the cytoplasmic end of the G protein. 
It is likely th a t the F and  G proteins interact w ith each o ther via their cytoplasmic 
domains. M eanw hile the N, P, L and M2-1 proteins form inclusions in the cytoplasm  and 
it is then thought that M2-1 in teracts with the M protein. Through these series of 
interactions the M proteins can be seen to co-ordinate the assembly of the envelope 
proteins F and G with the nuclcocapsid proteins N P and M2-1. Budding appears to be 
the reverse o f penetration  and occurs in vitro on the apical cell surface (from  Hacking 
and Hull 2002).
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L
Non-structural proteins 
anti-interferon u and [} activity
Nucleocapsid protein Nucleoprotein 
essential for transcriptional activity
Nucleocapsid protein Phosphoprotein 
essential for transcriptional activity
Matrix protein viral assembly
Small hydrophobic protein: function unknown
Glycoprotein viral attachment to the cell
Fusion protein
viral entry and syncytia formation
M2-1 : transcnption elongation factor 
M2-2 regulation of viral transcription
Nucleocapsid protein: RNA polymerase
Figure 1.3
Proteins encoded by RSV (from  H acking and Hull 2002)
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.3 Fusion Protein
The F protein is responsible for virus penetration through fusion between viral and 
host cell plasma membrane. It was first identified when anti F-specific monoclonal 
antibodies (Mabs) inhibited syncytium formation in tissue culture (Walsh and FIruska 
1983). While the F protein is able to mediate fusion in recombinant viruses lacking G 
and SH, efficient fusion occurs only when all the three proteins are expressed (Karron, 
Wright et al. 1997). The F protein o f  RSV shares structural and functional features 
with the F-proteins o f  Paramyxoviruses for example: the size o f  the protein (the 
Paramyxovirus F genes encode 540 to 580 amino acids residues), the location of the 
hydrophobic domains, the cleavage peptide and the cysteine residues (mostly 
clustered in a 150 amino acid long segment o fth e FI subunit) (Walsh and Hruska 
1983).
The fusion process starts by the fusion peptides being inserted into the target 
membranes, later in the course of the infection the F proteins at the membrane of an 
infected cell fuse with the nearby cells forming syncytia (giant cell formation), and 
viral spread (Fields and Howley 2001).
F is a type 1 glycoprotein, which is synthesized as a precursor o f  574 aa, the precursor 
(Fo) needs to protcolytically cleaved to form the disulphide linked-biologically active 
protein ( F|- F2 ) ( Vey, Schafer et al. 1 994). This cleavage o f F() i s believed to take 
place in the Golgi or trans Golgi network (Collins and Mottet 1991; Bolt, Pedersen et 
al. 2000), where it is glycosylated and results in the release o f the biologically active 
protein c onsisting o f  t he d ¡sulphide-linked c hains F i a n d F 2 : t h c F 2 d omain ( amino 
acid 1 to 1 30), the cleavage peptide ( amino acids 131 to 1 36), and the F 1 domain 
(amino acids 137 to 574) (Fields and Howley 2001). Recent data show that this 
cleavage process o f Fo is a unique feature of RSV. The furin-like protease cleaves the
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molecule at two sites (furin consensus sequences) RAR/KR109 (FCS-2) and 
KKRKRR136 (FCS-1), which release the region between the two cleavage sites as a 
separate peptide that consist o f  27 amino acids (pep27) (Calder, Gonzalez-Reyes et al. 
2000; Zimmer G 2001). Data from Calder et al., 2000 suggest that this third peptide is 
released from the processed molecule and its function is unknown.
Structural studies on the F protein
The F2 is the most divergent fragment o f  the F molecule. It has the bulk o f the 
carbohydrate content and therefor; it is a potential site for N glycosylation in the F 
protein. A region o f 28 hydrophilic amino acids that is unique to HRSV is located at 
the N-terminal end o f the F2 (Lopez, Bustos et al. 1998).
The model o f the secondary structure of the protein shows:
■ Three hydrophobic regions; the first is the signal peptide, located at the N 
terminus o f the F2 chain. The second is the fusion peptide at the N terminus o f  
the FI chain, and the third is the transmembrane region, located near the C 
terminus o f FI (Lopez, Bustos et al. 1998).
• Two heptad repeat sequences; two sequences, HRA and HRB are located next 
to the fusion peptide.
■ A third heptad repeat region (residues 53-100) is within the sequence o f the F2 
chain o f RSV-F (Lambert, Barney et al. 1996).
■ A cluster o f cysteines region is located between the two heptad repeat in the 
middle o f the FI chain (Lopez, Bustos ct al. 1998).
Calder et al.2000 recently suggested two morphologic shapes that the protein takes- 
the full-length F formed rosettes that had two types of protein rods, one cone-shaped 
and the other lollipop shaped. The secreted form of the protein formed individual
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cone-shaped rods. These authors suggeste that the morphologic shapes might play role
in membrane fusion (Calder, Gonzalez-Reyes et al. 2000).
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Figure 1.4
Predicted secondary-structure «»f the F protein.
This figure den ionstratvs the location of secondary - s tru c tu re  motifs o f the K pro tein  and 
shows cysteine residues (e) ,  potential IN-glycosylation sites (vy), site of proteolytic 
processing (1) (2), am in o  arid changes in escape m u tan ts  (▼) hydrophobic regions (— ) 
and S-S, disulphide b ridge . The predicted secondary -structu re  elem ents of the K protein 
arc: u-hcliccs (cylinders), p-shccts (rectangles) and loops (turns).Thc segment between 
residues 255 and 275 (F255-275) arc  predicted to fold in  u-hclis-loop-helix s tru c tu re , is 
boxed. F lh  and K2h a rc  am phipathic u-hcliccs in the FI and F2 chains, respectively 
(I.opez, Bustos et al. 1998).
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RSV has seasonal epidemics which occur annually. Peak rates o f infection occur in 
the winter months in areas of temperate climate while in tropical or hot climates the 
outbreaks are expected during the rainy summer season (Glezen and Denny 1973).
RSV is highly infectious and it spreads via personal contact or through exposure to 
contaminated surfaces, for example bedding and sheets. The virus is inactivated in an 
aerosol so there is a very limited chance o f  transmission through aerosol droplets 
(Collins and Pollard 2002). Infected respiratory secretions can transmit RSV, not by 
small droplets but by contamination o f environmental surfaces such as hands or 
bedding (Simoes 1999; Webster 1999). By the age o f  one, 50 % o f all children will 
have b een i nfected w ith R SV a nd b y 2 4 m onths, 9 5% o f a II c hildren will b e s ero- 
positive for RSV; half of these children will have been exposed to the virus twice 
(Kim, Arrobio et al. 1973).
High-risk groups include infants with a history o f premature birth; those with 
bronchopulmonary dysphasia, congenital heart disease, cystic fibrosis, immuno- 
suppressed patients, and those with underlying disorders o f cellular immunity. 
Furthermore, individuals living in institutions and elderly people are at particular risk. 
During epidemics, spread within hospitals and day nurseries often takes place, 
facilitated by close personal contact and the ability o f  those infected to shed virus for 
up to 3 weeks after the acute phase (Simoes 1999).
RSV A and B viruses co-circulate during epidemics, with group A being 
predominant (Hall, Walsh et al. 1990). The impact o f antigenic diversity on RSV 
epidemiology is not completely understood, but it may partly be explained by the 
susceptibility to  re-infection through 1 ife and the yearly variation i n the severity o f  
epidemics within communities. Epidemiological studies have highlighted several 
factors that could be involved in increasing the risk o f infections. In developing
1 .4  E p i d e m i o l o g y
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countries, risk factors have not been defined; although overcrowding, indoor pollution 
and malnutrition may play a part in the development o f more severe disease. In a 
recent study carried out in the Gambia, a higher incidence o f lower respiratory 
infection (LRI) was found in boys than in girls and case incidence of infection was 
greater in small or rural villages than in urban or large villages, possibly due to 
poverty (Weber 2002).A very interesting observation was made in this study-the 
possibility o f  cross- protection between RSV and the measles virus. After 3 years o f  
regular outbreaks o f RSV, a low number o f cases were then observed associated with 
a measles epidemic that followed several years of low numbers o f measles cases. This 
observation was supported by the results from a study in the US that suggested that an 
increase in RSV cases was correlated with the use o f  measles vaccination to control 
measles infection (Weber 2002).
In developed countries, factors that can increase the risk o f infection include: 
family history o f atopy, having a sibling in school, exposure to passive cigarette 
smoking, and attendance at a day care centre or a child minder (Simoes 1999).
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Although RSV was discovered 25 years ago and bronchiolitis caused by RSV remains 
the most common disease in infants and childhood against this virus infection, up to 
the present time there is neither a vaccine nor effective treatment (Kimpen 2001).
An early study showed that infants under 2 months o f age were relatively 
spared from infection which was confirmed by the results o f a later study showing the 
inverse correlation between the severity o f  RSV and pneumonia, and the level o f  
neutralizing maternal antibodies (Bruhn and Yeager 1977). In another study by Ward 
et al.1983, sera from 100 new- bom babies and maternal antenatal sera were tested. 
The infants o f  mothers who had higher titres o f  neutralizing antibodies remained 
protected from infection. In contrast, infants o f mothers who had lower levels o f  
neutralizing maternal antibodies caught RSV infection before 6 months o f  age (Ward, 
Lambden et al. 1983).
Data from humans and animal models highlighting a protective role for 
antibodies in RSV infection initiated research that focused on passive immunization o f  
high risk groups. Thus research focused on the preparation and use o f  immuno­
globulin obtained from individuals with high anti-RSV antibody titres. Three trials 
were carried using RSV-IG (Groothuis, Simoes et al. 1993). It was concluded from 
these trials that during the RSV season, the monthly administration of 750mg/kg body 
weight RSVIG was safe. RSVIG administration was tolerated by infants and was 
effective in reducing the incidence and severity o f  RSV LRI in high risk infants.
On the basis o f  these trials, the product was approved for use in the USA in 1996, and 
later, the American Academy of Pediatrics (AAP) produced guidelines for the use of 
the product. Potential disadvantages associated with the use o f RSIG include the risk 
of blood-bom disease contamination, unreliability o f the supply, and the possibility of 
interference with childhood vaccination (Rodriguez, Gruber et al. 1997).
1.5  M a n a g e m e n t  o f  R S V
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All these factors resulted in efforts to develop humanized monoclonal 
antibodies against RSV that could be used in therapy. Palivizumab (MEDI-493, 
Medimmune Inc) was produced. This is an IgG-1 humanized monoclonal antibody 
against the fusion protein of RSV. The antibody was tested in premature infants with 
or without chronic lung disease and its use resulted in the reduction RSV-related 
hospitalization by 55 % (IMPACT RSV Study Group 1998), which was comparable to 
data from using RSVIG. Based on this study, AAP approved and updated the 
guidelines for the use o f RSVIG in 1998 (Rodriguez, Gruber et al. 1997) (IMPACT 
RSV Study Group 1998).
Antiviral therapy
Antiviral therapy against RSV includes the use o f  ribavirin and corticosteroids. 
Ribavirin first showed promising in-vitro antiviral activity but was stopped because of 
its financial costs. Subsequently, the use o f ribavirin w as reviewed between 1975- 
1996 and it was concluded that there was not enough data to support the benefits o f 
using Ribavirin in infants with bronchiolitis (AAP 1996). Still, the AAP advised the 
use of Ribavirin in infants with underlying diseases and severe cases of bronchiolitis, 
as well as children receiving ventilation. The use o f  corticosteroids was mainly 
considered because o f  the similarity of bronchiolitis and asthma syndromes. Since the 
1960s, six trails have been carried out to test the use o f  corticosteroids (Kimpen 2001). 
Data from these six studies suggest significant improvement in the clinical symptoms 
and the duration o f  symptoms in RSV bronchiolitis. Corticosteroids were also 
assessed for the prevention o f  wheezing after an RSV episode and the data were 
conflicting. Data so far suggest that only severe cases in which mechanical ventilation 
was required could benefit from the use o f corticosteroids, but still guidelines are 
needed (Hemming, Prince et al. 1995; Kimpen 2001).
35
Immunity to RSV is mediated first via humoral and later via cellular immune 
mechanisms. Immunity thus includes serum antibody (induced following infection or 
maternally-derived in young infants), secretory antibody and major histo­
compatibility complex class I-restricted cytotoxic T lymphocytes (CTL) (Dudas and 
Karron 1998). Exposure to RSV gives only partial immunity and it is incomplete, 
short lived, and re-infection occurs throughout life, as demonstrated by 
epidemiological studies and challenge studies in healthy young adults (Crowcroft,
Cutts et al. 1999; Simoes 1999).
1.6.1 Innate immunity
RSV mainly infects epithelial cells in the nasal airways and induces the enhancement 
of the expression o f  i ntercellular adhesion molecule-1 ( ICAM-1) on epithelial cells 
(Patel, Kunimoto et al. 1995). Therefore the respiratory tract is the major site o f  
inflammation. Respiratory epithelial cells produce opsonins and collectins as well as 
several cytokines and chemokines such as RANTES and IL-18 (Noah, Ivins et al. 
2002) that attract neutrophils, CD4 helper cells and eosinophils (Figurel.5). Studies 
on the lungs o f  the children who died from RSV infection following immunization 
with formalin inactivated vaccine (FI) - showed strong lymphocytic infiltration around 
small airways, cell debris in the airway lumen and a large number o f  neutrophils in the 
lungs (Prince, Curtis et al. 2001).Using a murine macrophage-like cell line (P388D1) 
RSV showed viral persistence, enhanced phagocytosis and an increase in the 
expression o f  Fc-y receptors and production o f  1L-1 (3 and IL-6. These results indicate 
that respiratory macrophages play a role in the innate response to RSV infection 
(Guerrero-Plata, Ortega et al. 2001). Bartz et al, (Bartz, Buning-Pfaue et al. 2002) 
investigated the consequence o f  the early interactions between RSV and macrophages 
or dendritic cells (DCs), using in vitro cultured human cord blood-derived DCs and
1 .6  I m m u n i t y  t o  R S V
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macrophages. Both DCs and macrophages were infected with RSV and macrophages 
appeared to be more effective than DCs in taking up the virus. Analysis of the cell 
surface marker expression showed that both DCs and macrophages infected with RSV 
had high levels o f  co-stimulatory and adhesion molecules following infection, and a 
significant increase of MHC class II expression was also observed following infection. 
The up-regulation of these surface markers in infected c ells highlights the need for 
antigen presenting cells to mature following RSV infection, and to present antigen to 
T lymphocytes. The cytokine profile was also analyzed in supernatants o f RSV- 
infccted macrophages and DCs. IL-6 was produced by macrophages as well as by DCs 
while IL-12p75 was produced by dendritic cells but not by macrophages. Results from 
this study are in agreement with previously published work (Bartz, Buning-Pfaue et al. 
2002). Monocytes from RSV infected infants exhibit increased production of IL-10 by 
macrophages, associated with RSV infection but not by influenza or para-influenza 
virus. 1L-11 and PGE2 were also produced in large quantities by macrophages as well 
as by DCs. Although IL-11 has been detected before in nasal aspirates from RSV 
infected infants and in biopsies from adult asthmatics (Bartz, Buning-Pfaue et al. 
2002), its production following RSV infection o f  DCs was a novel finding in this 
study. Overall, enhanced IL-10 production by macrophages and enhanced IL-11 and 
PGE2 production by DCs in vivo could explain the dominant Th2-type response seen 
in ongoing RSV bronchiolitis and might also contribute to the delayed development o f  
a protective RSV specific immune response (Bartz, Buning-Pfaue ct al. 2002).
Several RSV proteins have been shown to modify or influence the innate immune 
response. For example, RSV F induced IL-6 production by CD14 and Toll-like 
receptor 4 (TLR4) expressing monocytes. When purified RSV F (purified by cither 
immunoaffinity or by lectin chromatography) was incubated with cither human 
(PBMC) or mouse peritoneal macrophages, a noticeable increase in the production of
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IL-6, IL-8, and TNF-a and IL-lp was observed. Furthermore, IL-6 production was 
blocked by mAb to CD14 (Kurt-Jones, Popova et al. 2000). Macrophages from CD14 
or TLR4 knockout mice could not produce IL-6 (Kurt-Jones, Popova et al. 2000). This 
study suggested the role o f  TLR4 as a receptor for innate immune recognition o f RSV 
F protein since TLR4 deficient mice had higher levels o f RSV in their lungs and were 
either unable to clear the virus or the virus was present a few days longer than in the 
control mice.This suggests that the inflammatory response to the infection is mediated 
by TLR4 and CD 14 expression or signaling. In a further investigation by the same 
group, it was shown that in the absence o f TLR4, there was a reduction in IL-12 
expression. In the lungs o f  RSV infected mice (TLR4 nu" ) only a limited number o f  
NK and CD14+ cells had trafficked to the site o f infection and had a significantly 
reduced c ytotoxic activity r esulting i n their d ecreased ability t o c lear t he i nfection 
(Kurt-Jones, Popova et al. 2000; Haynes, Moore et al. 2001).
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D. Hacking and J .  Hull
RSV Infection o f the respiratory epithelium.
RSV is bound by surfactant protein A and engulfed by macrophages which leads to IL- 
ip . IL-8, IL-6 and TNF-a release. Infection o f epithelial cells stimulates release of a 
number o f cytokines including the neutrophil and macrophage chemoattractants IL-8 
and MCP-1. IL-I secretion leads to the up-regulation of ICAM -1, a receptor that is vital 
for neutrophil adherence and activation. IFN a  /ß secretion causes the up-regulation of 
the major histocompatibility complex I (M H C -I) expression. (From Hacking and Hull 
2002).
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1.6.2. Cellular immunity
CD4+ Lymphocytes
CD4+T-cells normally play an important role in immunity against viruses by 
providing help to B-cells in the process o f  antibody production and by the synthesis 
o f important anti-viral and inflammatory cytokines such as IFN-a and TNF-a . 
However, their role in immunity to RSV has not been fully studied. The first evidence 
for the role o f CD4+T-cells and the cell-mediated immune response to RSV was 
observed following lung autopsies from the children who received the FI-RSV 
vaccine. In the lungs o f the children who died, a strong eosinophilic infiltrate was seen 
along with another strong cellular infiltrate composed o f mainly lymphocytes. The 
virus was also isolated at up to 104 TCID50 per gram tissue from the lungs (Kim, 
Canchola et al. 1969).
Pathology was also enhanced in BALB/c mice following RSV challenge of 
mice previously immunized with a recombinant vaccinia (vv) expressing the G protein 
(Openshaw, Clarke et al. 1992). Challenge o f mice immunized with vv expressing F 
or M2 also produced pulmonary inflammation associated with a memory T-cell 
response but without the development o f  lung eosinophilia (Openshaw, Clarke et al. 
1992). It has also been demonstrated that CD4+cells specific for the G protein can 
mediate pathology and exacerbation o f  the disease (Varga and Braciale 2002). 
Furthermore, when G-specific Th2 CD4+T-cell lines were passively transferred to 
naïve mice, the same pattern o f enhanced disease that was observed in FI-RSV 
immunized children was seen in the challenged, immunized animals. These and other 
data suggest that the development o f  lung pathology and eosinophilia is driven by 
CD4* Th2 cytokine- producing T cells (IL-4, IL-5, and IL-13) that are directed 
towards the G-protein o f  RSV(Hussell, Khan et al. 1997). The role o f G protein- 
specific CD4+cclls has been further evaluated (Srikiatkhachom, Chang et al. 1999;
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Varga, Wissinger et al. 2000; Tripp, Hou et al. 2001; Varga, Wang et al. 2001), and 
this work showed that the Th-2 biased response to the G-protein is directed towards an 
immuno-dominant epitope on the protein represented by amino acids (aal 83-195) that 
elicits b oth T h 1 -and T h2 C D4+ e ffector c ells. T he s tudy s howed t hat C D4+IFN-y - 
secreting cells are predominant in the G-protein specific CD4+-memory cell 
population in mice immunized with G and challenged with RSV. However, it is not 
clear why, among a population o f cells directed to one epitope in the presence o f Thl 
CD4+ cells, the rest o f the CD4+cells develop into Th2 cytokine -secreting cells.
CD8+ Cytotoxic T-lymphocytes (CTL)
As mentioned above, the first evidence for the involvement o f the cellular immune 
response to RSV was observed in the FI-RSV vaccination trail in 1960. CTLs are now 
thought to be the major effectors for the resolution of established primary infections 
with respiratory viruses. The first indication for the role o f CD8+ CTL in RSV 
infection was seen in patients with congenital heart immune deficiency in whom the 
virus continued to be shed for longer than in controls and highlights the need o f  an 
intact cell-mediated immune response for viral clearance (Fishaut, Tubergen et al. 
1980).
The d ominant role o f  C TLs i n the resolution o f  i nfection i s s uggested most 
strongly by the incidence o f extended RSV shedding in immuno-suppressed rodents 
and in immuno-deficient human patients lacking T-cell mediated immunity (Dudas 
and Karron 1998; Domachowske and Rosenberg 1999). Other supporting evidence for 
the primary role o f CD8* T cells in the resolution o f RSV infection includes:
1. The early detection of CTLs in infants with primary RSV infection in whom 
CTL responses are detectable within the first 10 days o f  the infection. CTL activity in 
PBMCs from infants with acute RSV infection peaks early and can usually be 
detected within 1 week after infection (Chiba, Higashidate et al. 1989).
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2. The restriction o f virus replication following the passive transfer o f  virus- 
specific CTL clones into RSV-infected immuno-deficient mice and the temporal 
relationship between peak CTL activity and virus clearance in mice (Pemberton, 
Cannon et al. 1987; Anderson, Norden et al. 1990; Dudas and Karron 1998).
3. Although CD8+T-cell epitopes on the G protein have not been identified so 
far, CD8+ epitopes expressed on the N, and M protein have been identified. Alwan et 
al showed that CD8+ cells directed towards an epitope on the M2 protein reduced the 
eosinophilia i n m ice t hat h ad r eceived p assively-transferred T h2-G s pecific C D4+T 
cell (Alwan, Kozlowska et al. 1994). In addition, insertion o f  a CD8+/M2 T-cell 
epitope into the G protein used to prime mice prevented the induction o f  pulmonary 
eosinophilia (Srikiatkhachom and Braciale 1997).
4. T he C TL epitope from t he M 2 o f  R SV h as been s hown t o i nduce v irus- 
specific CTL responses in mice (Hsu, Obeid et al. 1998). Chimeric peptides in which 
the CTL epitope from the RSV M2 protein (amino acids 81-95) was covalently linked 
to a fusion peptide from the F protein o f  measles virus (Fl-aa 113-131) were used to 
immunize m ice i ntra-nasally t hree t imes w ith 7 d ays i ntervals w ithout an a djuvant. 
Mice were then challenged with RSV at 1, 3, or 6 weeks after the last immunization. 
Immunization with the chimeric peptides induced both a peptide and RSV-specific 
CTL responses. The CTL response was correlated with a significant reduction in the 
viral load in the immunized mice but it was short lived and declined within 6 weeks of  
the last dose (Hsu, Obeid et al. 1998).
5. The first CTL epitope to be described from the fusion protein o f  RSV was 
defined by Jiang et al.2002. The epitope was a 15-mer peptide from the F protein 
(F92-106). BALB/c mice were immunized with this peptide, and both peptide -and 
RSV-specific CTL responses were induced. When the immunized animals were 
challenged intranasally with RSV, a reduction in viral load was observed in the lungs
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of the peptide-immunized mice compared to those in the control group. Furthermore, 
naive mice passively receiving purified CD8+ cells from peptide immunized animals 
showed a reduction in the viral load following challenge with RSV, again indicating 
the importance o f CD8+ cells in the response to the virus (Jiang, Borthwick et al.
2002).
6. Deletion o f F protein- specific CD8+ T cells from F-sensitized mice resulted 
in the induction o f pulmonary eosinophilia in the F immunized mice following RSV 
challenge. Further work showed the importance of IFN-y production by the CD8+ T 
cells for the prevention o f pulmonary eosinophilia produced by F-specific CD4 T- 
cells (Hussell, Baldwin et al. 1997).
7. More Recent work by Braciale et al. 2002 investigating the role o f CD8+ 
cells during an RSV infection, showed an important role o f  M2-specific CD8+ cells in 
the RSV infected lungs o f Balb /c mice in terms o f their effector-cell activity and their 
ability to produce cytokines. This activity was restricted to lung lymphocytes and was 
not seen in splenocytes from these animals (Varga and Braciale 2002).
All these data and the observed failure to produce a CD8+ response to the G 
protein in the FI-RSV vaccinated children give a potential explanation for the 
development o f  the serious immuno-pathology seen in the lungs o f  the children who 
died. It seems likely that CTLs have a crucial role in the resolution o f infection in 
addition maintaining some kind o f balance between Thl and Th2- type responses.
In a publication o f  work on bovine RSV infection, Viuff et al, (2002) showed 
that the virus w as c leared by neutrophils in the lumen by apoptosis o f the infected 
epithelial cells and subsequent phagocytosis o f  these cells. Both CD4+ and CD8+ cell 
numbers increased during the acute phase but most interestingly, no CD4*nor CD8* 
cells could be detected between the infected epithelial cells o f the bronchi and T cells 
were only seen when apoptosis was no longer demonstrable (Viuff, Tjomehoj et al.
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2002). This set of data and those from Braciale et al. 2002 imply that there is a role for 
intact CTLs in the resolution o f the infection and that, other factors such as TCR 
signalling or an RSV gene product may underlie the inhibition o f  CD8+ effector cell 
activity. The inhibition o f  the CD8+ cell activity was seen only in the lungs and was 
not seen in the spleen, a secondary lymphoid organ. This means that RSV has a 
selective capability o f  inhibiting CD8+ cell activity in the primary infection and 
subsequently memory development, and this may lead to re-infection o f  the host.
These data are recently supported by results from a study carried on 
hospitalized children with RSV bronchiolitis and rotavirus infected infants. IFN-y, and 
IL-4 producing y8 cells were measured in the peripheral blood o f  these infants. The 
number o f  IFN-y producing y8 cells was reduced during the RSV infection compared 
to a n i ncrease i n IL-4 producing y8 cells, while the IFN-y producing y8 cells from 
rotavirus infected infants were not affected. Furthermore, during the convalescent 
phase, levels of IFN-y producing y8 cells returned to normal. Further work carried out 
by the same group showed that when cytokine production by y8 T- cells was measured 
in school children with different acute respiratory infections (excluding R SV ) there 
was no inhibition o f  the production o f  IFN-y producing y8 T-cells (Aoyagi, Shimojo et 
al. 2003).
These studies clearly demonstrate the suppressive effect o f  RSV infection on 
the production o f y8 cells and may thus explain the relatively Th2-biased r esponse 
during primary RSV infection (Aoyagi, Shimojo et al. 2003). Growing evidence for a 
role for CTLs in cell injury or immunopathology has been obtained in several studies. 
For example, Scott et al showed that CTL responses in infants included in their study 
could be detected in 78% o f infants under 6 months o f  age while CTL responses were 
only detected in 46% of the children greater than 6 months o f age (Scott, Kaul et al.
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1978). The greater CTL activity found in the age group predominantly affected by the 
virus indicates a role for CTL in pathogenesis (Scott, Kaul et al. 1978).
The role of IFN-y
[FN-y is a type II interferon (IFN) produced by T and NK cells that has direct anti­
viral activity and provides help for the generation and activation o f  CTLs. It also 
stimulates antigen presentation through up-regulating the expression o f MHC Class I 
and II. IFN-y also activates NK cells and has a role in antibody isotype switching 
(IgM to IgG2a) and thus it is considered as one of the crucial cytokines in protective 
immune response to viruses.
The role o f IFN-y in RSV pathogenesis is not very clear. Many studies have 
shown that the Th-2 driven immune response and the eosinophilic lung damage are 
associated with exposure to either FI-RSV or G protein (Hussell, Baldwin et al. 1997) 
showed that the development o f lung eosinophilia was diminished by IFN-y 
production by CTLs and enhanced by treatment with anti-IFN-y or anti CD8+ 
antibodies. Similar data were obtained by (Srikiatkhachom and Braciale 1997) who 
showed the development o f lung pathology in I FN-y deficient animals. In a further 
study, it was shown that in the absence o f  IFN-aB and IFN-y signaling, or Stat-11, 
mice developed an enhanced eosinophilic lung response and a strong Th-2 cytokine 
profile (Durbin, Johnson et al. 2002). The pro-inflammatory response to RSV 
infection in these animals suggests that IFN-aB which is produced in response to viral 
infection along with IFN-y (produced by activated NK or T cells), not only limits 
virus replication but also has a role in moderating or controlling a biased Th2- type 
response (Durbin, Johnson et al. 2002). Hsu et al (1998) showed that spleen cells from 
mice immunized with a plasmid encoding a single CTL epitope from the M2 protein 
of RSV (pSecTag-M2) re-stimulated with the synthetic peptide that represent a CTL
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epitope M2:82-90 in vitro produced significant amounts o f IFN-y. Also the reduction 
in viral load in the lungs o f  plasmid-immunized mice was abolished by in vitro 
treatment with anti-IFN-y antibody on the day before challenge. The results indicate 
that the clearance o f RSV from the lungs by plasmid DNA induced immunity 
involved t he p roduction o f  IFN-y (Hsu, Obeid et al. 1 998; H su, C hargelegue et al. 
1999).
The role ofIL-12
IL-12 is an important cytokine in the response to virus infection and in the 
development o f  Thl-type responses. It normally drives viral clearance and host 
recovery from viral infection. In RSV, the development o f  a Thl-type response was 
associated with termination o f  infection and with mild RSV infection. The role o f  IL- 
12 has been examined in C57BL/6 mice, which develop a milder airway infection 
with RSV than do BALB/c mice. C57BL/6 mice showed a fourfold increase in IL-12 
levels post-RSV infection with very little inflammation. However, when these animals 
were treated with anti-IL-12 antibody, an increase in airway hyperactivity and the 
production o f  eosinophilia was observed. Since IL-12 activation is dependent on Stat- 
4 signaling, a similar experiment was carried out on Stat-4 deficient mice: there was 
an exacerbation in the inflammation seen in the airways which supports the need for 
balancing o f  Thl-type cytokines in controlling the disease (Tekkanat, Maassab et al. 
2001). The same group showed that IL-13 is produced in high levels in BALB/c and 
DBA/2 mice during the course o f  the RSV infection. Neutralization o f IL-13 
eliminates airway hyperreactivity, decreased mucus production, and increases IL-12 
production. This suggested that IL-13 production is inversely associated with IL-12 
production and highlights the importance o f  IL-12/IL-13 balance during an RSV 
infection.
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Antibodies play an important role in limiting the infectivity o f  respiratory viruses. 
However, the mechanisms which contribute to resolution of or protection against viral 
infection and diseases caused by these viruses are only partly understood. There are 
four principal ways in which antibodies contribute to immunity to viruses: a) 
neutralization, b) prevention o f endocytosis o f the virus c) inhibition o f fusion, and d) 
inhibition of the un-coating o f virus inside the endosome. In addition, there are the 
other general anti-microbial functions o f antibodies including; i) promoting 
phagocytosis or opsonisation; ii) activation of the complement system; iii) induction 
of inflammatory responses and attracting phagocytes and further serum antibodies to 
the site of the infection;and iv) antibody-dependent cell cytotoxicity (ADCC) via IgG 
attached to the surface of the target cell (Crowe 1996). Several observations from the 
natural infection with RSV highlight the role of antibodies in resolving RSV infection 
and protection from re-infection. These include:
1. RSV can still be neutralized at the cell surface even following attachment to 
the target cell, by antibodies during the first 60 minutes o f infection (Osiowy 
and Anderson 1995). Other studies also suggeste that some anti-F neutralizing 
antibodies decrease infectivity by inhibition of fusion at the plasma membrane 
(Beeler and van Wyke Coelingh 1989).
2. Local antibody response is induced by RSV (Both IgG, IgA, and IgM 
antibodies can be detected in the nasal washes during acute infection), this 
response is associated with viral clearance (McIntosh, Masters ct al. 1978).
3. In B cell defective mice or when B cells arc depleted, virus clearance 
following RSV infection is delayed and the animals show increased morbidity 
(Graham, Bunton et al. 1991).
1.6.3. Humoral immunity
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4. The relative protection from RSV infection in infants during the first weeks or 
months o f  life was associated with the level o f  passively transferred maternal 
antibody , while severe pneumonia was shown to be associated with low levels 
o f neutralizing antibodies (Glezen, Paredes et al. 1981; Englund 1994).
5. Following primary infection in young infants, the rate o f re-infection with 
RSV (LRI) at the time o f re-infection is correlated inversely with the level o f 
serum neutralizing antibody against RSV (Glezen, Taber et al. 1986).
6. Data from passive-transfer studies in rodents have demonstrated the protective 
effect o f  polyclonal immune sera and neutralizing RSV monoclonal antibodies 
(MAbs) in the LRT. The serum RSV-neutralizing-antibody titre following 
passive transfer is correlated with the level o f protection against virus 
replication in the LRT. While in contrast, the presence o f  serum neutralizing 
RSV antibodies usually has little effect on virus replication in the upper 
respiratory tract (URT) (Walsh, Schlesinger et al. 1984; Prince, Horswood et 
al. 1985; Prince, Hemming et al. 1987; Groothuis, Simoes et al. 1993; Sami, 
Piazza et al. 1995).
7. RSV neutralizing antibody also protects young infants as shown in a 
randomized study, where the titre o f RSV neutralizing antibody achieved in 
infants who received a dose o f  RSVIG in that was comparable to that 
previously demonstrated to protect the lungs o f  cotton rats against RSV 
infection (Groothuis, Simoes et al. 1993; The PREVENT Study Group 1997).
8. Following primary infection with RSV, serum antibody levels to the virus 
decline several months afier the infection to reach undetectable levels; this is 
normally also associated with primary infection occurring at a very young age. 
(Welliver, Kaul et al. 1980). However, these antibodies do provide a degree of
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protection against a second infection (Kreil, Burger et al. 1997). Serum 
antibodies are generally long-lived after a second or third infection 
(Domachowske and Rosenberg 1999) (Crowe 1999).
9. Secretory neutralizing antibody also plays a role in protection against RSV as 
shown in studies in adults and the presence o f secretory neutralizing antibody 
but not serum antibody is correlated with protection o f the upper respiratory 
tract against RSV (Mills, Van Kirk et al. 1971). The development of RSV- 
specific immunoglobulin A antibodies (IgA) in nasal secretions in infants is 
associated with virus clearance (McIntosh, Masters et al. 1978).
Specific Maternal antibody in the immunity against RSV
Epidemiological studies have shown protection against RSV in babies bom to mothers 
with high levels o f neutralizing RSV antibody. A correlation between IgG anti-fusion 
or F protein antibodies and its contribution to immunity from disease also has been 
demonstrated. Several studies have shown that pre-existing antibody could protect 
infants from RSV since babies bom to mothers with high levels o f IgG antibody to 
RSV were protected against infection during the first few months o f life. It has been 
demonstrated that in 575 randomly selected cord blood samples, protection against 
RSV infection in early days is correlated with the level o f  maternal antibody. 
Furthermore, the level o f antibody at birth directly correlated with the age at the time 
of infection. Kascl ct al. studied passively-transferred maternal antibody and naturally- 
induced scrum antibody to specific viral proteins in 34 children followed from birth 
up to 3 years o f age using immunoglobulin class-specific ELISA techniques. Levels o f 
IgG antibody to the F protein were correlated with immunity and children with less 
severe RSV disease had significantly higher anti-F antibody litres prior to infection. 
Other studies demonstrated that infants younger than 6 months do not produce
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antibody to RSV polypeptides following natural infection, which could explain the 
lack of specific RSV antibody and may account for high re-infection rates in young 
children (Englund 1994).
1.7 Developm ent o f a vaccine against RSV
There are serious difficulties to be faced in the development o f  an RSV vaccine 
including:
a) the need for the vaccine to be effective in seronegative children before six months 
of age, and in very young infants with maternally-derived RSV specific antibodies;
b) the vaccine needs to take into account the existence o f  two antigenically diverse 
RSV groups, A and B;
c) the vaccine should be designed to elicit neutralizing antibodies, since such 
antibodies have been shown to play a major role in resistance to RSV disease in 
humans, as well as in protection from infection in experimental animals; and
d) it is likely that it will be necessary that the vaccine be designed to induce CTL, the 
problem lies in the under role that CTls play in man. It is likely that more than one 
type o f vaccine will be needed in various human populations.
In the last 20 years, and since the FI-RSV trial in 1960s, several approaches have been 
used in the search o f  an effective RSV vaccine. These include the generation o f a 
genetically engineered (cDNA derived) RSV vaccine, synthetic peptides and viral 
protein subunits and live virus vaccines. Of these, only inactivated, subunit, and live 
attenuated RSV vaccines have been evaluated in human clinical trials to date. (These 
include the subunit vaccines PFP-I, PFP-2, BBGzNa and cold-passaged /temperature- 
sensitive mutants (Simocs 1999; Kneyber and Kimpen 2002).
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1.7.1. Formalin inactivated vaccine
In the 1960s, the potential o f a formalin-inactivated vaccine (FI-RSV) to protect 
against RSV disease was assessed. An alum-precipitated RSV vaccine (Lot 100) was 
developed by proliferation o f the Bemett strain of RSV in human embryonic kidney 
cells and passage in vervet monkey kidney cells and finally, inactivation o f the virus 
by formalin. The vaccine was tested in children between the ages o f  2 months to 7 
years.
Thirty-one children were immunized with 2 or 3 separate doses o f FIRSV and 
40 were given placebo. Unfortunately, the vaccine failed to protect against naturally- 
acquired RSV infection, and the use of this vaccine resulted in the development o f  an 
abnormal immune response to natural infection. As a result, 69% of the vaccine 
recipients developed pneumonia following subsequent infection with RSV and two o f  
the children died (Kapikian, Mitchell et al. 1969; Kim, Canchola et al. 1969).
Sera from vaccinated children contained high titres o f anti-F antibodies but 
these had low virus neutralization activity. Low levels o f  antibodies to F and G protein 
were observed following WT infection as compared to the placebo control group. 
Lymphocytes from vaccinated children showed far stronger proliferative responses to 
RSV Ag than those seen in lymphocytes from children naturally infected with WT- 
RSV. Subsequent analysis o f the sera from vaccinated children showed that anti-F 
antibodies had low fusion inhibitory activity, which may be a result o f  changes in the 
F protein function resulting from the treatment with formalin (Prince, Curtis et al. 
2001) .
In the lungs o f the children who died, a strong eosinophilic infiltrate was seen 
along with other strong cellular infiltrates composed o f  mainly lymphocytes, and the 
virus was also isolated at up to 104TCID50 per gram tissue from the lungs. One o f the
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children who died had Escherichia coli in the trachea, lungs, blood and spleen; the 
other had Klebsiella in the trachea, lungs, and nose (Kim, Canchola et al. 1969).
At the time o f this study it was proposed that the relatively low level of 
neutralizing antibodies induced to both F and G protein may have delayed the 
clearance o f  the virus or facilitated the enhancement o f disease along with the 
increased lymphocyte proliferative responses. The study was brief in its description of 
the histopathology and the details o f  the autopsies, and considered “ peri-bronchiolar 
monocytic infiltration “ with increasing eosinophils as the mark disease enhancement 
(Kim, Canchola et al. 1969). This study lead to the acceptance o f the view that 
eosinophils are the marker o f  the disease as suggested later by others (Prince, Curtis et 
al. 2001). In order to understand the mechanisms by which the vaccine contributed to 
disease enhancement and in order to develop a new safer vaccine, the availability of a 
good animal model that reflects the pathology seen in the lungs o f  the dead children is 
necessary.
A study that followed the trail pioneered by (Prince, Jenson et al. 1986) used 
the FI-RSV lot 100 to vaccinate cotton rats. Lungs from the vaccinated animals 
showed strong infiltration o f  lymphocytes, macrophages and neutrophils and the sera 
contained low levels o f  neutralizing antibodies. It was suggested that a protective 
epitope must have been changed as a result o f the formalin treatment and that another 
non-protective epitope induced high titres o f  antibodies that could have formed 
immune c omplexes. O ther s tudies s uggested p eri-bronchiolitis a s t he m arker o f t he 
disease caused by the vaccine (Opcnshaw, Culley et al. 2001; Prince, Curtis et al. 
2001). Again, a major criticism o f this study was the limitation o f  the lot 100 stock 
plus the fact that it was 20 years old, and the limited histopathology induced by its 
use.
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Recently, a batch of the vaccine 100 was re-produced by Wyeth-Lederle 
following the old protocol and to control for interference by any non-viral 
components, a mock infected (MFI-RSV) vaccine was produced along with the 
vaccine. Lungs o f cotton rats immunized with either the old or the new batch o f  the 
vaccine had enhanced lesions. Although the vaccine helped decrease viral replication, 
when animals were primed with the vaccine and exposed to WT infection, they 
developed marked lesions in the lungs, which were characteristic of those seen in 
animals with primary or secondary infections.
Comparative histological studies of lungs from the dead children with the 
animals vaccinated with either (FI-RSV or MI-FIRSV) revealed that peri-bronchiolitis 
consisting o f lymphocytes was a general finding while alveolitis consisting of 
neutrophils was associated mainly with the use FI-RSV vaccine (Figure 1.6 a, and b). 
The study involved 500 cotton rats and the authors considered alveolitis to be the main 
characteristic o f  enhanced disease caused by the virus. As a result of these studies, a 
case was made for the use of cotton rats as a reference model for the study o f  FI-RSV 
pathology along with other factors such as cytokines and chemokines.
The BALB/c mouse model has also been adopted for the study of immunity to 
human RSV and the development o f  immunopathology to RSV. Priming mice with 
FI-RSV resulted in a typical Th-2-type response with production o f  IL-4 and 5, strong 
cosinophilia and cytopathological changes in the lungs. In mice deficient in CD4+T 
cells or in mice following administration of blocking antibodies against IL-4 and IL- 
10, these responses were not observed (Connors, Kulkami et al. 1992).
Pathology similar to that seen in the lungs o f children who died in the FI-RSV 
vaccine trial was also seen when BALB/c mice were primed with either FI-RSV or 
vaccinia recombinant expressing the G-protein o f  RSV (vvG), followed by challenge 
with RSV. When immunized with vv expressing F or M2 proteins (vvF, vvM2) mice
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still showed the same inflammatory profile but without lung eosinophilia. The 
inflammation rather showed a typical memory T-cell response (Openshaw, Clarke et 
al. 1992). Earlier work by Alwan showed that transfer o f G-specific Th2 CD4*T-cell 
lines to naive animals induced lung eosinophilia following intranasal RSV challenge 
(Alwan, Record et al. 1992). More recently, Johnson, et al. 2003 investigated the 
involvement o f  IL-13 along with IL -4 in R S V  disease u sing m ice i mmunized w ith 
vaccinia recombinants expressing the G -protein (vvGs) and in FI-RSV immunized 
mice (Johnson TR 2003). In the vvGs immunized mice, inhibition o f  both IL-4 and 
IL-13 production was necessary to induce eosinophilia and a type 2 response. On the 
other hand, either IL-13 or IL-4 alone needed to be blocked in FI-RSV immunized 
mice in order to reduce the eosinophilia and type 2 cytokine production. This study 
further highlights the contribution o f  cytokines and other local environmental factors 
for the enhancement o f  the RSV disease (Johnson TR 2003).
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Figure 1.6
Photomicrographs of peribronchiolitis and alveolitis in Lot 100 autopsy (frames a and b) and FI- 
RSV immunized cotton rat autopsy (c and d ).
H&E stain zlOO (a and c, peribronchiolitis) and x400 (b and d, alveolitis). Neutrophilic 
alveolitis ( presence o f  n eutrophils i n t he a Iveoli), which i s t he k ey f  eature o f  vaccine- 
enhanced disease, is seen in both instances. Eosinophils, an infrequent finding in both Lot 
100 autopsies (highlighted by arrow , frame b), were not seen in cotton rats (Price et al. 
2001)
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1.7.2 Live attenuated vaccines
Considerable effort has been expended on the development o f  a live attenuated RSV 
vaccine since at the present time, this seems to be the best approach to develop an 
effective vaccine as soon as possible.
This approach has the following advantages:
1. A live attenuated RSV vaccine will induce an immune response that resembles 
the wild-type RSV; and
2. The immune response provoked by a live attenuated vaccine will be sufficient 
to protect young infants (< 1 year ) in the presence o f  maternal anti-RSV 
antibodies, since RSV infection can occur in the presence o f  maternal 
antibodies, as demonstrated by Crowe et al (Crowe, Firestone et al. 2001 ).
Several live attenuated viruses have been developed and tested over the last 20 years 
and the first attempt used an attenuated Bovine RSV hut this was shown to be poorly 
immunogenic in chimpanzees (Crowe 1995). Following this, two attenuated viruses 
have been produced: a) a cold passage mutant cp or (cpRSV)\ where the virus was 
attenuated hy decreasing temperature during culturing, b) temperature-sensitive Is 
mutants where virus replication was dependent on a specific temperature (RSV Is-/. 
RSV ts-2).These candidates failed in clinical trials because cither the mutant was 
genetically unstable and replication o f  the vaccine became temperature independent 
(RSV ts-2), or the mutant was weakly attenuated or over-attenuated. However children 
vaccinated with cither cpRSV, or RSV Is-1 had no enhanced disease-related effects 
(Crowe 1998).
Crowe et al. 1995 produced several live attenuated vaccine candidates, 
produced by a combination o f  chemical mutagenesis and cold passaging. All the 
candidates induced protective response against natural infection and retained their
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genetic stability when tested in chimpanzees. To test the efficacy o f  the vaccine in the 
presence o f  maternal antibodies, anti-RSV antibodies were administered intravenously 
to chimpanzees; all four mutants were genetically stable and induced neutralizing 
antibodies(Crowe, Bui et al. 1995).Two o f  the candidates (cpts248/404, and cpts- 
530/5009) were tested in infants and young children. Cpts-248/404 induced a 4-fold 
increase in virus neutralizing antibody titre in 68% of sero-negative children aged 6 to 
24 months; in 44% of sero-negative infants aged 3 to 5 months; and in 29% o f sero­
negative infants aged 1 to 2 months. Cpts-248/404 induced URTI in children younger 
than 6 months of age and a strong response to the G protein in younger infants. Both 
strains remained immunogenic and phenotypically stable. However, the cpts 248/955 
was shown to be genetically un-stable and the vaccine induced symptoms in very 
young infants and the children shed the virus (Crowe, Bui et al. 1995; Wright, Gruber 
et al. 2002).
Pringle et al.1988 had further investigated the possibility o f developing a ts vaccine 
using chemical mutagenesis and produced 4 mutants (tsl9A , tslA. tslB, and tsl9B). 
All four m utants r emained g enetically s table b ut a II i nduccd u pper r espiratory t ract 
symptoms in healthy adults which made the four candidates unsuitable for testing in 
infants. Another mutation was produced from ts /B  (tslC). This last candidate was also 
tested in healthy adults and did not cause any associated illness, but it still needs to be 
tested in infants (Mckay 1988 , pringle 1993).
1.7.3 Subunit vaccine
Purified F or G proteins o f RSV have been shown to induce protective immunity in 
the animal model o f  RSV. This protective immunity was limited to the lower airways 
in mice immunized with RSVF (Walsh, Brandriss et al. 1985). When purified F 
protein was used to immunize cotton rats, higher levels o f  anti-F antibodies were 
induced but the vaccine enhanced histopathological damage in the lung following 
challenge with wild-type RSV (Murphy, Sotnikov et al. 1990). Furthermore, when this 
vaccine was adminstrated to sero-negative chimpanzees, low titres o f neutralizing 
antibodies were induced (Crowe 1995).
Another subunit vaccine has been developed for use with the adjuvant Quillaja 
saponaria (QS-21) which may improve the immunogenicity o f  the subunit proteins. 
This vaccine was tested in mice and induced highe levels o f  virus neutralizing 
antibodies and cytotoxic T lymphocytes (Hancock, Speelman et al. 1995). Similar data 
were obtained by (Bastien and Trudel et al. 1999) who immunized mice with synthetic 
peptides representing the amino acid region 174 to 187 o f  the G protein from both 
human and bovine RSV together with cholera toxin as adjuvant. Both the peptides 
induced IgG responses in mice when immunized intranasally and higher titres were 
achieved when the peptides were combined with the adjuvant. Immunized m ice were 
protected from RSV infection after challenge but no secretory IgA was detected 
(Bastien, Trudel et al. 1999). Another subunit vaccine candidate is the BBG2Na 
peptide vaccine. This vaccine consists o f  an epitope from the G protein (130-230) 
expressed i n Escherichia c oli ( G2Na) a nd b ound t o t he C t crminus o f  an a Ibumin- 
binding region o f the streptococcal G protein (BB). BBG2Na induced high 
neutralizing antibody titres against RSV and did not induce a Th-2 type response, nor 
pathology in the lungs (Power, Plotnicky-Gilquin et al. 1997). BBG2Na is currently 
being evaluated in Phase III clinical trials (Kneyber and Kimpcn 2002).
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Other candidates which were tested in several clinical trails are the purified F 
protein (PEP) subunit vaccines (PEP-1 and PEP-2). PFP-1 consists of—90 to 95 % 
purified F protein, whereas PEP-2 consists o f  —98 % purified F protein. Tristram et al, 
tested the efficacy of PEP-1 in 26 children aged from 18 to 36 months (these children 
had previous RSV infections). The vaccine induced a 4-fold increase in neutralizing 
antibody titre in a majority of the immunized children, and all immunized children 
remained protected against subsequent natural RSV infection for 6 months (Tristram, 
Welliver et al. 1993). The efficacy o f PEP-2 has also been evaluated in children with 
cystic fibrosis and in pregnant women and has induced a 4-fold increase in 
neutralizing antibody titre in both populations. In summary, both PEP-1 and PEP-2 
induced high t itres o f anti-F and RSV neutralizing antibodies and the frequency o f  
RSV infection was lower in PEP vaccinated groups during the time o f the follow up. 
Although the PEP vaccines were immunogenic, they were tested either in sero­
positive children (under one year o f age with immune deficiencies) or in an elderly 
population. Thus, the efficacy of the vaccine is still to be evaluated in a healthy high- 
risk group suvh as young infants. Furthermore, the number o f individuals in the study 
was too small to effectively evaluate the outcome o f the use of the vaccine (Munoz 
FM 2003) (Kneyber and Kimpcn 2002).
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1.7.4 DNA vaccines
The use o f naked DNA as a vaccine is a promising approach to immunization against 
human disease that avoids disease-enhancement associated with some vaccines 
available on the market. There are several advantages in using DNA vaccines 
including:
•  the low economic cost o f  production, at a high level o f  purity and in large 
quantities;
• the vaccines are genetically and heat stable and can be genetically 
manipulated;
• the vaccines mimic natural viral infection which induces humoral as well as a 
cellular immune responses even in the presence o f maternal antibody;
•  the vaccines have a very low risk o f generating pathogenic infection;
• the vaccines provide the possibility o f  immunizing against different pathogens 
with a single vaccine; and
• the vaccines can induce long-lived immune responses, including persistent and 
protective antibody levels, which has important i mplications for vaccination 
strategies (Henke 2002).
However, some potential problems with DNA vaccines include:
■ possible random integration into the genome o f the vaccine
• the potential o f  induction o f  immunological tolerance
■ the induction o f  hyper-immunity
■ the potential o f  induction o f  anti-DNA antibodies
* the potential induction o f  autoimmune responses , and
■ the need to limit the persistence o f antigen
In RSV, the observation that DNA immunization induced protective immunity in mice 
in the presence o f  maternal antibodies makes this form o f immunization o f  particular
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interest for use in neonates and for developing an RSV vaccine to target this high risk 
group. Immunization of 1-week-old BALB/c mice with DNA encoding RSV protein F 
resulted in the induction of strong CTL responses and protective immunity (Martinez, 
Li et al. 1999).
A plasmid encoding 248-amino acids o f the G protein and not the full length (pND-G) 
was used to immunize Balb/c mice. The pND-G vaccine markedly inhibited the RSV- 
induced airway inflammation and decreased viral loads in the lungs o f immunized 
mice. Both IFN-y and IL-12 were induced by the vaccine and no airway eosinophilia 
was seen in the lungs o f the immunized animals. Sera from vaccinated animals 
contained higher levels o f anti-RSV antibodies than those induced following RSV 
infection (Miller, Cho et al. 2002).
In an attempt to develop an epitope based DNA vaccine, Hsu et al .1998 
constructed plasmid DNA vectors encoding a single cytotoxic T lymphocyte (CTL) 
epitope from either the M2 protein o f RSV or as a contol, from the nucleoprotein (NP) 
of measles virus (MV) with or without a signal sequence. Following intra-dermal 
immunization, p lasmids i n w hich t he C TL epitopes w ere expressed w ith t he s ignal 
sequence (pSecTag-M2/NP) were more effective at inducing peptide- and virus- 
specific CTL responses than plasmids expressing CTL epitopes without the signal 
sequence (pcDNA3-M2/NP). CBA mice immunized with pSecTag-NP showed greater 
peptide -  and MV-specific CTL responses than did mice immunized with PcDNA3- 
NP. Spleens from mice immunized with pSecTag-M2 induced both peptide and virus- 
specific CTL responses, while mice immunized with pcDNA3-M2 had neither 
demonstrable peptide nor RSV-specific CTL activity. DNA immunization induced 
protection against MV-induced encephalitis and a significant reduction in viral load 
following RSV challenge. The reduction o f  viral load following RSV challenge was 
abrogated by prior injection with anti-IFN-y antibodies again highlighting the
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importance o f IFN-y in CTL responses These results underline the ability o f epitope- 
based DNA immunization to induce protective immune responses to specific epitopes 
and point out the potential o f  this approach for the development o f  vaccines against 
infectious diseases (Hsu, Obeid et al. 1998).
A further study by the same group showed that the M2-RSV epitope 
expressing DNA plasmid formulated with chitosan and delivered intranasally to 
BALB/c mice induced both peptide- and virus-specific CTL responses that were 
comparable to those induced via intra-dermal immunization. Intranasal immunization 
with the free plasmid in the absence o f  chitosan failed to induce detectable CTL 
responses. A significant reduction in viral load following RSV challenge of chitosan 
/DNA immunized mice was observed in the lungs of immunized mice compared to 
that in the control group. The result highlights the potential o f  the intranasal route for 
the induction o f local and systematic CTL responses (Iqbal, Lin et al. 2003).
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Other approaches to the development o f a vaccine against RSV include:
• Vaccinia was used to express F or G protein and these constructs were 
immunogenic in rodents, and vaccinia expressing the M2 protein induced short 
lived protection in BALB/c mice.
However, recombinant adenovirus expressing RSV proteins failed to induce
demonstrable protection against RSV (Kneyber and Kimpen 2002).
• Genetically engineered vaccines have been developed to provoke a longer- 
lived cell-mediated response as well as humoral immunity. A combination of 
both DNA and live viral vectors has being used/ In this case, the DNA vaccine 
is used to prime a T-cell response and the recombinant viral vaccine is used to 
boost the response. In addition, a combination in which one recombinant viral 
vector is used for priming and a second viral vector for boosting has also being 
tested (Henke 2002; Robinson 2003).These heterologous “prime-boost” 
immunizations induce greater immune responses than can be achieved by 
priming and boosting w ith the same vector. The first immunogen initiates a 
memory cell response and, the second immunogen expands the memory 
response. The two vaccines do not induce responses against each other and 
therefore do not interfere with each other’s activity (Robinson 2003).
• ISCOMs have also been used for a vaccine against RSV. Trudel et al. were the 
first to show that subunit vaccines expressed in ISCOMs induced both 
neutralizing and CTL responses to RSV in BALB/c mice (Trudel, Nadon et al. 
1992). Hu et al.1999, immunized Balb/c mice with ISCOMs containing RSV 
F-protein and G protein (with lower expression o f  the latter) both intra-nasally 
and subcutaneously. Vims neutralizing antibodies were detected in serum and
1.7.5 Other RSV vaccine approaches
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in all mucosal organ extracts irrespective o f the immunization route used (Hu, 
Elvander et al. 1998).
1.7.6 Synthetic epitope-based vaccines
The antibody response to a protein antigen is predominantly focused to restricted parts 
of the molecule termed B-cell epitopes. These epitopes are mainly located on the 
surface o f  the molecule and thus it is essential that the antigen is in its native 
conformation for the interaction with antibodies to occur.
The complete surface o f  a protein molecule is now in general accepted as 
being antigenic and comprises many overlapping B-cell epitopes. B-cell epitopes are 
made up o f short linear sequences o f  amino accids along the polypeptide chain 
(continuous or linear B-cell epitopes), or consist o f  amino acid residues brought 
together by the folding o f  the polypeptide chains when the protein is in its native 
conformation (discontinuous or conformational B-cell epitopes) (Figure 1.7).However, 
some hidden residues in the protein structure seem to be directly involved in binding 
to the antibody. Such buried residues might be revealed following the binding of 
antibody to the surface exposed residues in the protein, and might induce side-chain 
adjustments in adjoining epitopes (Partidos and Steward 2002).
It is generally agreed that the majority o f  anti-protein antibodies recognize 
discontinuous or conformational B-cell epitopes, and only a small fraction have 
specificity for continuous B-cell epitopes. In the latter case, antibodies with specificity 
for continuous B-cell epitopes might be induced as a result o f  partial dénaturation of 
the antigen during the immunization procedure.
The demonstration that peptides can induce antibodies o f predetermined 
specificity that can interact with the native protein has prompted the examination of 
their potential as candidate vaccines. The cross-reactivity o f  the anti-peptide
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antibodies with the native protein might be explained by their inherent flexibility in 
solution and immunization with unconstrained peptides normally induces a diverse set 
of antibody specificities that bind several different conformations similar to that o f the 
native epitope (Partidos and Steward 2002).
The use o f synthetic peptides has contributed significantly to the understanding 
of the nature o f epitopes (Morris 1996). The synthesis o f  overlapping peptides 
covering the complete amino acid sequence o f  an antigen allows repeated screening 
with different monoclonal antibodies to assess their reactivity with specific linear 
sequences. Because o f cross-reactions, this technique also identifies a range o f  
sequences that are related to, but not 100% identical with the antigen sequence that 
induced the production o f  the specific monoclonal antibody.
A good deal of work has been focused on the problem o f identifying the 
structural characteristics o f linear B-cell epitopes and a number o f  empirical 
approaches have been used in attempts to predict such epitopes from the primary 
amino acid sequences o f protein. These include the identification o f regions o f  
hydrophilicity, solvent accessibility, protrusion, atomic mobility and secondary 
structure (e.g. /Mums).
The value o f  these methods for potential vaccine use is limited as they only identify 
linear B-cell epitopes. As mentioned above, it is very likely that induce virus­
neutralizing antibodies will often be conformational in nature and therefore, these 
epitopes cannot be predicted from the primary amino acid sequence.
The development of combinatorial peptide libraries where random peptide 
sequences serve as a pool of diverse molecular shapes has provided important means 
for analyzing the specificity of immune responses to an antigen (Muller, Plauc et al. 
1990). Combinatorial peptide libraries can be constructed with bacterio-phages 
expressing random peptide sequences and also by solid-phase peptide synthesis o f
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random sequences on a solid support such as (resin beads) (Partidos and Steward 
2002). In the latter instance, following interaction o f  a target molecule (antibody or 
other ligand) with the peptide-bead, and using a simplified detection system based on 
ELISA, resin beads carrying novel peptide sequences recognized by the antibody or 
ligand can be selected and the peptide sequence identified by micro-sequencing.
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In the case o f  the F-protein o f  RSV, several linear B-cell epitopes have been identified 
using synthetic peptides and conformational epitopes have been identified following 
the use o f  Mabs or polyclonal antisera to screen solid phase combinatorial peptide or 
bacteriophage libraries. These epitopes from the F-protein o f  RSV are listed in Table 
1.1, and are matched with the corresponding linear overlapping peptides used in the 
present study.
The concept o f a mimotope was first defined by Geysen in 1985 as: “ a 
molecule able to bind to the antigen-binding site o f an antibody molecule, not 
necessarily identical with the epitope inducing the antibody, but an acceptable mimic 
of the essential features o f  the epitope (Figure. 1.8)(Partidos and Steward 2002). 
Although atomic identity might explain the same antigenicity displayed by an epitope 
and a mimotope, this molecular mimicry might result from the fact that the epitope 
and the mimotope bind to different subsites within the same paratope o f  the antibody. 
As a result, a mimotope may react with an antibody directed to the native epitope 
without actually binding to the same paratope as the native epitope. In this case, anti- 
mimotope antibodies are unlikely to cross-react with the native epitope (Figure. 1.8). 
For a mimotope to be considered as a candidate for vaccine development, it should:
(i) mimic the antigenicity o f  the epitope by binding to the antibody that 
recognizes the native epitope, preferably with high affinity; and
(ii) mimic the immunogenicity o f  the epitope by inducing antibodies 
cross-reactive with the native epitope. In spite o f  the potential 
difficulties with this approach, it has proved successful in a number 
ofinfections.
68
I Mimotope
| Epitope
| Mimotope
| Epitope
Figure 1.8
The difference between an ep itope and a mimotope (Partidos 2002). 
A) is the top d iag ram  and b) is the bottom diagram
A) The epitope and the mimotopc bind to 
different subsite« within the paratope
-The mi mo lope is not a true mimic o f  the native epitope 
-The mimotopc is antigenic since is recognised by the 
antibody directed to the native epitope 
-The anti-mimotopc antibodies will not cross-rcact with 
the native epitope
-The mimotopc is of no use for vaccine development
B) T h e epitope aad the mimotope bind to the 
same sabsite withia the paratope
-The mimotope is a true mimic of the native cptlopc 
•The mimotopc is antigenic since it is recognised by 
the antibody directed to the native epitope 
- The anti-mimotopc antibodies will cross-rcact with 
the native epitope
•The mimotopc can be a candidate for vaccine development
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Amino acids 
mimic shape of 
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(“ mimotope” )
tective, 
eutralising 
.ab
Screen peptide library
Figure 1.9
Concept o f "mimotopes” o f  conformational B-cell epitopes.
A monoclonal antibody with specificity for a protective, neutralizing epitope on the viral 
protein is allowed to react with the combinatorial peptide library. Strong binding to a 
particular bacteriophage or resin bead carrying a specific peptide implies a “good fit” of 
the antibody binding site with that peptide sequence. This peptide is thus a mimic of the 
conformationally-determined epitope in the protein i.e. a “mimotope”. The sequence of 
the mimotope can be determined and the peptide can be synthesized and used as a 
vaccine to Induce an antibody response hopefully with specificity similar to that of the 
original protective monoclonal antibody.
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Several mimotopes have been characterized and have been shown to produce antigen 
-specific neutralizing and protective antibodies when used as immunogens. For 
example, a protective neutralizing murine monoclonal anti-RSV antibody (mAb 19) 
was used to screen an 8 mer solid phase combinatorial peptide library. Five resin 
beads were selected and the peptide sequence obtained by micro sequencing. In an 
attempt t o i mprove t he binding o f  m Ab 1 9 w ith t he m imotopes, s ingle a mino a cid 
substitutions at each position o f two o f the peptides (SI and S2) were performed. 
Three sequences were derived from the SI peptide (SIS, S1K, and SIP) that showed 
enhanced binding to the antibody. The three mimotopes were synthesized as multiple 
antigenic peptides on a polylysine backbone (MAPs) and were used co-immunize 
BALB/c mice together with a peptide representing a promiscuous T-helper epitope 
from measles virus fusion protein to induce T-cell help. This resulted in the induction 
of specific anti-peptide antibody. The anti peptide antibodies inhibited the binding o f  
mAbl9 to RSV antigen and neutralized the virus in vitro with similar titres to those 
found in sera from RSV-infected animals. Considerably higher titres o f antibody were 
induced following immunization with a MAP construct with mimotope SIS to which 
the Th peptide was covalently synthesized. However, immunization with the 
mimotope S2-MAP complex induced antibodies that failed to neutralize RSV in vitro. 
Following RSV challenge o f  SIS-MAP-immunised mice, a 98-7% reduction in the 
litre o f  virus was observed and a markedly reduced cellular infiltration in the lungs o f  
immunized mice compared to that in controls was observed. Although the covalent 
synthesis of the Th epitope to the S1S-MAP construct resulted in higher in vitro 
reactivity of the anti-peptide antibodies for RSV, immunization with this construct did 
not result in a detectable increase in the clearance o f RSV in vivo (Chargelcguc, Obeid 
ctal. 1998).
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It is likely that the ability to induce virus-specific cytotoxic T-lymphocyte 
responses will also be a necessary property o f  an effective vaccine against RSV. 
Immunization o f  BALB/c mice with a synthetic peptide or recombinant vaccinia virus 
expressing a single CTL epitope from the M2 protein o f the virus (M2-9) induces 
virus-specific CTL and results in a reduction in virus titre following challenge with 
virus (Hsu, Chargelegue et al. 1998). The work o f  Chargelegue et al. cited above 
shows that immunization with a synthetic peptide vaccine induces virus-specific 
antibodies and is also protective. Taken together, these results indicate that responses 
directed to either the antibody-or cell-mediated arm o f the immune response are 
effective in the absence o f a response in the alternative arm o f  the response (Hsu, 
Chargelegue et al. 1999).
To determine whether peptide-induced humoral or cell-mediated responses 
would act synergistically to enhance virus clearance to an extent greater than the 
individual antibody- or cellular responses alone, peptides representing B-cell, Th-cell 
and CTL epitopes were injected together in a peptide cocktail. This resulted in a more 
effective clearance o f  RSV in the peptide cocktail-immunized, challenged mice them 
in mice immunized with peptides inducing B-cell or CTL responses alone. While the 
mechanisms underlying the synergistic effect on protection following immunization 
with the peptide cocktail were not investigated, i t is possible that protection results 
from the production o f appropriate cytokines or from other unknown co-operative 
mechanisms between humoral and cellular immune response.
In a study by Ji ang, et al., 2002 a 1 5-mer peptide ( aa92-aal06) from the F 
protein of RSV was shown to act as an MHC class I-restrictcd (H-2Kd) epitope for 
RSV-specific CD8+ CTL. This was the first report o f murine CTL epitope in the F 
protein. When this peptide P8 was used to immunize BALB/c mice, peptide and RSV- 
specific CTL responses as well as peptide-specific proliferative responses were
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induced. Following intranasal challenge with RSV, lungs from immunized mice 
showed a significant reduction in viral load compared to that seen in the control non- 
immunized group. Even though both peptide specific CD4* and CD8+T cells were 
isolated from the lungs o f  immunized mice, a decrease in CTL activity was shown 
following treatment with anti-CD4 antibody which suggests that the CTL activity was 
controlled mainly by the CD8+ population o f cells. Furthermore, passive transfer of 
purified peptide specific CD8+ lymphocytes into BALB/c scid  mice prior to challenge 
with RSV also resulted in a reduction in the virus load in lungs o f  challenged mice 
(Jiang, Borthwick et al. 2002).
This last result and previous results from the same group indicate the potential 
of synthetic peptide epitopes for the induction of protective immune responses against 
RSV infection. However, this approach involves the identification o f the critical 
epitopes able o f  inducing both the appropriate antibody (B cell epitopes) and cellular 
(T-cell) immune responses, and that is by no means a straightforward task. 
Furthermore, careful consideration needs to be given to the question of MHC 
restriction o f CD4 and CD8 T-cell responses. Although there is evidence that there are 
promiscuous CD4 and CD8 T-cell epitopes, much work will need to be done for each 
vaccine to ensure adequate coverage o f  genetically diverse human populations.
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Reference Amino acid residue Type of epitope Linear-
conformational
Corresponding 
peptide in this 
study
(Trudel, Nadon et al. 2I6-236/F1 Mab /neutralizing C P 20-21
1987)
(Bourgeois, Corvalsler 200-225 L P 18-25
et al. 1991)
(Trudel, Stott et al. 216-232 Mab L P 20-21
1991) 221-237 P 20-21-22
275-288 P 26-27
(Levely, Bannow et al. FI(328-355) Human Th P 31-32-33
1991) neutralizing site
(Partldos, Stanley et 283-327 Mab /neutralizing C P 27-28-29
al. 1991)
(Lopez, Andreu et al. 215-275 Mab /neutralizing C P 20™25
1993) 255-275 P 24-25
(Lounsbach, 265-272 (12mer) Mab C P 25
Bourgeois et al. 1993)
(Lopez, Bustos et al. F255-275 CD, and NMR C P 23-24-25
199«) Helli-Ioop spectroscopy
(Corvalsler, Guillemin 205-225 T-cell P-18-21
et al. 1993)
(l.angcdljk, Meloen et N—FI(I73-182) Mab /Neutralizing L
al. 1998) site
(Chargelegue, Obeld SI (HWYISKPQ) Mab / Neutralizing C none
et al. 1998) And S2
(HWYDAEVL)
Table 1.1
U near B-cell epitopes Identified from the F-protein of RSV.
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1.8 Aims and objectives o f the thesis:
❖  To identify linear human B-cell epitopes o f the fusion protein o f  RSV using 
the reactivity o f  human sera with 55 overlapping peptides covering the whole 
of the fusion protein o f  RSV.
❖  To identify peptide mimics (mimotopes) o f a conformational human B-cell 
epitope using a human monoclonal antibody (RF2) that recognizes a 
conformational epitope in the fusion protein.
❖  To test the reactivity o f human sera with previously identified mimotopes: 
SIS, and SdS (2 mimotopes that mimic a conformational shape in the fusion 
protein).
❖  To attempt to identify any differences in the profile o f peptide recognition by 
sera taken at different stages o f  exposure to the virus
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CHAPTER 2
M ATERIALS AND METHODS
2.1 Selection and synthesis o f peptides
Conventional (solid phase peptide synthesis) using Fmoc chemistry was used to 
synthesize 55 overlapping peptides o f RSV A2 strain fusion protein covering the 
whole protein. Each peptide was 15 amino acids long and overlapped by 5 residues 
with the following peptide (except for peptide 55 which was 13 amino acid long).
The peptides were synthesized by Dr Shisong Jiang, Immunology unit, LSHTM.
The amino acid sequence o f the fusion protein used for the synthesis o f  these peptides 
is shown in Figure (2.1).
2.1.1 Solid phase peptide synthesis
The c oncept o f  s olid p hase p eptide s ynthesis i s to r etain c hemical reactivity o f  t he 
peptide seen in solution when the peptide is on a solid phase by adding a covalent 
attachment step that links the peptide to an insoluble polymeric support (resin). The 
resin must contain appropriate functional groups onto which the first amino acid can 
be anchored. The next step is the systematic elaboration o f the growing peptide chain. 
Even when a residue has been incorporated effectively into the growing resin-bound 
polypeptide chain, it may still undergo irreversible structural modification or 
rearrangement during subsequent synthetic steps.
Temporary protecting groups are therefore used that can be removed with 
minimal level of side reactions that can affect the desired product e.g. the N" 9-amino 
flourcnyl methoxy carbonyl (Fmoc) group (Grant 2002). The 55 peptides were 
synthesized in two batches of 25. 0.3g resin was distributed equally into 25 cartridges 
of the RAMPS multiple peptide synthesis system (Dupont), washed with DMF and 
allowed to swell. Each peptide bond was built from the carboxyl to the amino-
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terminus, adding one amino acid at a time. Fmoc protected amino acids (at 5-fold 
excess) previously converted to the hydroxyl-benzotriazol-activated esters by 
treatment with 1.5mmol HOBT and 1.2 mmol DIPICI/mmol o f amino acid for 20 
minutes in DMF/DCM were used to elongate the peptide chain. The coupling 
reactions were carried out in DMF, and the cartridges were rocked for 2 x 60 minutes. 
At the time of coupling the first residue, dimethyl-amino-pyridine was added to 
catalyse incorporation. The resin was then washed in DMF, Fmoc groups were 
removed with 20% piperidine in DMF for 20 minutes, and followed by 10 washes in 
DMF. After the final de-protection of the last amino acid, the peptide-resin was 
washed in DMF, shrunk in DCM and diethyl ether and dried. The coupling and de­
protection reactions were monitored by the addition of 3, 4-dihydro-3-hydroxy-4-oxo- 
1, 2, 3-benzotriazine (10 mg/ml in DMF) which turns bright yellow in the presence o f  
free a mino groups. S ide c hain p rotection w as p rovided b y the following p rotecting 
groups: Mtr(4, methoxy, 2, 3, 6, trimethyl) for arginine, TRT (trityl)for histidine, 
Boc1 (tertiary butoxycarbonyl) for lysine and tryptophan for serine, threonine and 
tyrosine, Obu1 (tertiary butyl ester) for aspartic acid and glutamic acid, except for, 
(Asn and Qln), where the Opfp (pentafluorophenol ester) was used .
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MELLILKANA ITTILTAVTF CFASGONITE EFYOSTCSAV SKGYLSALRTI 2 3
GWYTSVIT1E LSN1KENKCN GTDAKVKLIK QELDKYKNAV TELQLLMQST 
PPTNNRARRE LPRFMNYTLN NAKKTNVTLS KKRKRRFLGF LLQVQSAIAS
9 10 II 12 13
GVAVSKVLHL EGEVNK1KSA LLSTNKAVVS LSNGVSVLTS KVLDLKNY1D
U  15 Tft 17 18
KOLLP1VNKO SCSISNIETV IEFOOKNNRL LEITREFSVN AGVTTPVSTY
19 20 21 22 23
MLTNSELLSL INDMPITNDQ KKLMSNNVQI VRQQSYSIM SIIKEEVLAYV
24 25 26 27 28
VOLPLYGVI DTPCWKLHTSP LCTTNTKEGS NICLTRTDRG WYCPNAGSVS
29 Jli 3 1 T 1 3:
FFPQAETCKV OSNRVFCDTM NSLTLPSEIN LCNVDIFNPK YDCKIMTSKT
----------------------- 53--------------------  35 T S  37 ?8
DVSSSV1TSL GA1VSCYGKT KCTASNKNRG IIKTFSNGCD YVSNKGMDTV
------------------  39 -----------------------TO--------------------- 41 ------------------------ 32-------------------  43
SVONTLYYVN KOEGKSLYVK GEPIINFYDP LVFPSDEFDA SISOVNEKIN
-------------------375----------------------45 47 48
OSLAFIRKSD ELLHNVNAGK STTNIMITTI HVIIVILLS LIAVGLLLYC
---------------  49 ------------------------- 50---------------------  51------------------- 32------------------- S3
KARSTPVTLS KDQLSGINNI AFSN
--------------------34--------------------  3S(l3m cri)
Figure 2.1
Am ino acid sequence of the K protein of RSV (Collin* el aL 1984).
The numbered and underlined sequence* represent the overlapping peptides used in this 
study.
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2.1.2 Peptide-resin cleavage
For peptide cleavage and side chain deprotection, peptides were rocked in 95% TFA 
and 5% scavengers for approximately 3 hours at room temperature. Longer cleavage 
times were allowed for sequences that contained any arginine residues due to the 
lower acid lability o f  the mtr group. Water was used as a general scavenger, but for 
peptides containing methionine, 1, 2 ethanedithiol was used and for arginine, phenol 
was used. If the peptide contained both methionine and arginine, a combination o f 
both phenol and ethanedithiol was used.
The resin was then filtered, washed with the cleaving solution and dried to an oily 
residue in a rotary evaporator. The peptides were precipitated by the addition o f  cold 
diethyl ether (50-60 ml). Finally, after a couple o f washes and trituration with diethyl 
ether, the peptides were then desiccated and the white flaky powder was collected and 
stored-20°C.
2.1.3 Peptide Characterization
The peptides were characterized by:
(i) H igh performance 1 iquid c hromatography ( HPLC) t o e xclude any contamination 
with deletion products and to ensure the presence of a single peak of the major 
product.
(ii) Mass spectrometry to determine the molecular weight of the synthetic peptides 
(analysis performance by Eurogentec UK Ltd).
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2 .2  Human monoclonal antibody (RF2)
2.2.1 RF2 Production
A  human monoclonal antibody (RF2) specific for a conformational epitope on human 
RSV was kindly provided by Dr.P.Brams, IDEC Pharmaceuticals, San Diego 
California. The antibody was isolated from a spontaneous abdominal tumour in a 
severe combined immunodeficient mouse (SCID) reconstituted with human spleen 
cells from one human donor with idiopathic thrombocytopenic purpura. The 
reconstituted mouse was immunized with the F protein o f  RSV. The tumour was 
shown to have developed spontaneously as EBK-transformed human B cells. The 
tumour cells expanded rapidly in culture, were stable more than 18 months and 
secreted high levels o f  specific human anti-RSV monoclonal antibody. Antibodies 
were purified from supernatants by adsorption to a protein A Sepharose 4B column 
and Protein A-bound human monoclonal IgG was eluted with citrate buffer, pH 3.5 
RF2 had human yi heavy chain and k  light chain and was shown to recognize a 
conformational epitope, since it required both 48K and 23K disulphide-linked 
fragments o f  the F protein for binding by immuno-blotting (Chamat, Walsh et al. 
1999).
2.2.2 Synthesis of the solid-phase combinatorial peptide library
The 8 mer peptide library was synthesized on Novasyn TG resin, (a polystyrene-poly 
oxythylene resin functionalized with amino groups) so that each resin bead bears a 
different 8 amino-acid peptide. The resin allows the de-protection o f  the peptide 
without its cleavage from the resin. There are 2.8x106 beads /g  o f resin with a capacity 
of 0.24 mol/g. Nineteen reaction vessels containing the resin were used for the 
synthesis by Fmoc chemistry with all natural amino acids except cysteine. After each 
synthesis step the resin in each vessel was pooled, thoroughly mixed and re-dispensed
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into the 19 vessels for the next synthesis step (Hsu, Crowe et al. 1995). The library 
was synthesized by C.Stanley, and M. Long in the Immunology unit, LSHTM.
2.2.3 Bead selection
0.05g o f resin was blocked with blocking buffer (10% BSA 1% Tween 20 in PBS) for 
2 hours at room temperature with continuous shaking, centrifuged and excess buffer 
removed. The resin was divided into ten equal parts in microfuge tubes. The human 
monoclonal antibody to t he RSV F protein ( RF2) was diluted with blocking buffer 
into half log|0 dilutions at 10 mg/ml, and 200pl of each dilution w  as added to  the 
resin. This was left overnight at 4°C with continuous shaking. It was then washed five 
times with washing buffer (PBS with 0.05% Tween 20). Goat anti-human IgG 
peroxidase was added and left for 2 hours at 37°C. The substrate, consisting o f  lOmg 
of 3, 3’, 4, 4 ’ diaminobenzidine-HCl in 5ml methanol, 30mg 4-chloro-l-naphthol in 
5ml methanol, and 30mg 4-chloro-l-napthol in 5 ml methanol was added to 40 ml 
PBS with 10 pi o f hydrogen peroxide added just before use. 200 pi o f  substrate was 
added to each tube and the color was allowed to develop for 5 minutes, after which the 
reaction was stopped with 100 pi o f  2 M of sulphuric acid. The resin was placed in a 
24-well microtitre plate (NUNC) and dark brown stained beads were selected with a 
capillary tube. The antibody was stripped from the peptide on the beads by incubating 
in TFA for 1 hour. Excess TFA was washed away with distilled water. Dr Herve 
Drobecq (Pasteur Institute of Lille) generously determined the sequence of the 8-mer 
peptide attached to the beads by micro-sequencing.
2.2.4 SPOTs Synthesis
Combinatorial peptide synthesis is a new development in work with peptides which 
allows the synthesis and screening of several peptides in parallel. SPOTs synthesis is 
one example of this procedure. That has the advantage o f being relatively inexpensive 
and requiring only simple apparatus. It is straightforward to perform and can be
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carried out on the open bench, except for the de-protection steps. It is also relatively 
quick to perform and provides a rapid system for analyzing antibody responses and for 
epitope mapping. The disadvantage o f  the SPOTs synthesis is that the peptide length 
is usually limited to around 10 residues. The solid phase support used in the spot 
technique is a cellulose membrane that can be bought commercially or prepared in- 
house, and materials for the whole assay can be purchased commercially. The first 
step o f the synthesis involves derivatizing the hydroxyl functions on commercially 
available filter paper or introducing a modifying group upon which the peptide can be 
synthesized. The commercial membrane normally has 96 spots, but when the 
membrane is synthesized manually, the number o f individual peptides on the 
membrane can be controlled.
2.2.4.1 Synthesis of peptides by the SPOTs technique 
The first stage o f  synthesis is to prepare the paper by introducing a modifying group 
onto which the peptide can be built. The method uses conventional reagents: 
diisopropylcarbodiimide (DIC), hydroxy-benztriazole (HOBt), FMOC-gly with 
addition of a catalyst (2-dimethylaminopyridine (DMAP)) to couple glycine to sugar 
hydroxyls by an ester linkage (Suchankova, Ritter et al. 1990):
Fmoc-NH-CH2-C 02H + HO-R => FMOC-NH-CH2COO-R + H20  Fmoc-glycine 
paper ester
(In presence o f  DIC, HOBt, and catalyst)
The water finishes up reacting with the DIC, which is a dehydrating agent. 
Following removal o f  the Fmoc group, a second amino acid active ester is spotted on 
the paper in a poorly volatile solvent to create the spots on which the individual 
peptides will be constructed. The unreactcd amino groups covering the rest o f the
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paper must then be acetylated, and the Fmoc group on the second linking amino acid 
removed to provide paper with spots which contain available amino groups for peptide 
synthesis, and the rest o f the paper where amino groups are now absent.These spots 
can be visualized by adding a small amount o f the dye bromophenol blue in a non- 
aqueous solvent. Bromophenol blue is yellow in solvent where it cannot ionize or 
donate a proton to a suitable acceptor-like an amino group, but when it ionizes it turns 
the familiar blue colour. Treatment of the paper reveals spots where the presence of 
amino groups both bind bromo-phenol blue and turn it blue, and show that such amino 
groups are not available over the rest o f the paper (Figure 2.2, and 2.3). These spots 
also provide a convenient aid for spotting amino acid derivatives for synthesis.
Synthesis consists o f cycles of addition of appropriate amino acid active esters 
to each spot (Figure 2.3), allowing reaction to proceed, capping o f any un-reacted 
amino groups by acetylation, de-protection o f  the N-terminal Fmoc and re-treatment 
with bromophenol blue ready for the next cycle of addition. Where peptides of 
different lengths are to be synthesized, peptides are acetylated as they are finished. At 
the e nd o f  sy nthesis, t he N -terminal F mocs a re r emoved a nd t he N -terminal a mino 
groups acetylated, and the side-chain protecting groups, which have remained intact 
during synthesis, are removed by treatment with trifluoroacetic acid (TFA). Following 
washing the paper is ready for use. This work was preformed under the expert 
supervision o f Dr P.Corran, Immunology unit, LSHTM.
In order to improve the antigenic properties of the three mimotopes, the same SPOTs 
technique was used to systematically substitute each amino acid the in the 8mer 
peptide sequence with all possible naturally occurring amino acids.
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Figure 2.1
Treatment o f  the paper reveals spots where the presence of amino groups both bind bromophenol 
blue and turn it blue.
Figure 2.2
Treatment of the paper reveals spots where the presence of amino groups both bind bromo­
phenol blue and turn it blue, and show that such amino groups are not available over the rest of 
the paper.
These spots also provide a convenient aid for spotting amino acid derivatives for 
synthesis.
S4
!Figure 2 3
Synthesis of SPO Ts consists o f cycles of addition of appropriate amino acid active esters to each
spot.
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2.2.4.2 Synthesis of mimotopes by solid phase synthesis
Peptides representing the identified mimotope sequences were synthesized as 
described in the solid phase peptide synthesis section (2.1.2) by Ms. M.Long in 
Immunology unit, LSHTM.
2.2.4.3 Coupling mimotopes to KLH
Sephadex PD-10 G25 was soaked overnight in an excess o f phosphate buffered saline 
(PBS). A disc of 3MM filter paper to fit the syringe barrel was inserted as a bed 
support. T he c olumn w as a Mowed to ru n d ry a n d a  s econd d isc o f  filter p aper w as 
place on the column top. A solution 1 % of BSA was prepared and. 0.5 ml was added 
to the Sephadex column and the eluate was collected. The column was washed with
0.5 ml PBS, and collected into the same fraction. The column was then eluted with 1 
ml aliquots o f  PBS, and the eluate collected into 20 separate fractions. An aliquot of 
each fraction was assayed for protein using Bradford’s reagent
Sulfo-MBS (m-Maleimidobenzoyl-N-hydoxysuccinimide ester) was allowed to warm 
to room temperature, and was washed into the KLH solution with a pipette and rotated 
until dissolved ( at room temperature for 1 h ). The column was allowed to dry and 
KLH coupling mixture carefully pipetted into the middle o f  the filter paper disc and 
allowed to run into the column top. 1 ml aliquots o f  PBS were added to the column, 
and allowed to drain into the column each time before adding the next aliqoate. 20 ml 
fractions were collected. 5pl o f each fraction was transferred into the wells of a flat- 
bottomed titre plate and 200 pi of Bradford reagent diluted 1:1 with water was added 
to each well. Protein-containing fractions turned bright blue and protein emerged in 
fractions 6-7 (Figure 2.4). An appropriate aliquot o f the KLH solution was added to 
each o f  the peptides (pH between 7.2 and 7.3) and rotated at 4°C overnight (or for a 
minimum o f 2h at ambient temperature) and excess peptide removed by dialysis 
against PBS.
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The avidin-biotin interaction is the strongest known non-covalent biological 
recognition between protein and ligand. The bond formation between biotin and 
avidin is very rapid and once formed is unaffected by most extremes of pH, organic 
solvents and other denaturing agents. Optimal antigen binding capabilities can be 
realized by using a biotin derivative that has an extended spacer arm, thus reducing 
steric hindrance. The spacer arm also improves the complex formation of biotin with 
the deep biotin binding site o f avidin. This affords an increase in sensitivity o f  
detection. EZ link-NHS-LC-LC-Biotin was used as a biotin analogue with extended 
spacer arms o f  approximately 22.4 A and 30.5 A in length, the chemistry o f  EZ link- 
NHS-LC-LC-Biotin is similar to that o f Sulfo-NHS-LC-LC-Biotin reaction and to that 
of other NHS esters. The biotinylation reaction was carried out in the absence of 
organic solvents such as DMSO or DMF. The reaction was carried out at 4°C, reaction 
mixture pH values o f 7-9. The mimotopes were still on the resins and therefore, 
biotinylation was carried out manually in the cartridge. The resins were weighed and 
soaked in DMF for 10 minutes and left to drain. 20% DMF/pip was added twice for 3, 
and 7 minutes allowing the liquid drain between each addition. This was followed 
with a wash in DMF for 10 minutes. The Biotin analogue was weighed (4 fold more 
than the weight o f  each mimotope), dissolved and DMF and stirred in DMF for 10 
minutes. Then it was added to the cartridge for 1 hour and drained. A wash with DMF 
was p reformed 1 0 1 imes, t hen 4 washes w ith p ropan-2. T he c artrdridges t hen w ere 
dried in the desiccator over night and the final mimotopes were weighed and cleaved 
as described previously.
2.2.4.4 Coupling mimotopes to Biotin
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Figure 2.4
Detection o f KLH Protein-containing fractions using Bradford reagent.
K1H was collected in 20 fractions and was detected in fraction 5-7. The OD shown is the 
maen of 2 OD readings.
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All procedures involving manipulation o f human serum was carried out in a class I 
microbiological safety cabinet (Envair, UK).
The human sera used in the work described in this thesis were from two sources;
1. Serum from healthy adults working in the Department o f Infectious and 
Tropical Diseases, and 5 other serum samples obtained from individuals 
working elsewhere in LSHTM.
2. Sera were received from Prof. Peter Aaby from babies from Guinea-Bissau, 
taken as part o f  an ongoing programme o f research on RSV. Two or three 
samples were obtained from each child. The first serum sample was taken at 6 
months o f  a ge b efore a ny o bserved i nfection w ith R SV a nd i s c onsidered a 
pre-infection sample; post-infection samples were taken at 9 or 18 months or 
both for some children. Serum samples from 49 children were received of 
which 20 have so far been analyzed (12 o f  these had RSV before six months of 
age). Samples were analyzed coded, but no information about the detailed 
clinical status o f  these children was obtained.
2.3.1 Animals and immunization 
Animals
Groups o f four week old inbred female BALB/c (H-2d) mice were purchased from the 
Medical Research Council, Mill Hill, London, United Kingdom.
Animals were housed for one week before use in a pathogen-free animal facility at the 
Biological Services Unit at LSHTM. The animals were kept throughout the 
experiment in the same unit and were checked for the appearance o f  any disorder. Any 
animal showing sign o f  disease was excluded from the experiment.
2 .3  H a n d l i n g  o f  h u m a n  s e r a
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Immunization of mice:
Previous studies in the laboratory had shown that the optimal route to produce the best 
serum anti-peptide antibody response was found to be the sub-cutaneous route. 
Immunization with linear peptides
All mice were sub-cutaneously co-immunized with 50pg o f  the linear peptide and 
50|ig o f  TTB -peptide (T-cell helper epitope from measles fusion protein) in complete 
Freund’s adjuvant (CFA). The animals were boosted by the same route with the same 
dose o f  the peptide alone in_incomplete Freund’s adjuvant (IFA) three weeks later. 
Sera from the animals were collected from each mouse from the retroorbital venous 
plexus under halothane anesthesia before boosting and then 20 days after the boost. 
The ability o f each peptide to induce serum antibody was assessed by direct peptide 
ELISA as described previously. Sera from the animals from each group were obtained 
before the start o f  the experiment and used as a negative control for reactivity with 
both RSV Ag and the tested peptide in every assay.
Immunization with mimotopes:
Mice were sub-cutaneously immunized with 50pg o f  the peptide in CFA, and boosted 
three weeks later by the same route with the same dose o f  the same peptide in IFA. 
Sera from individual animals were collected prior to the boost and then 20 days after 
the post the boost. The ability o f each peptide to induce a serum antibody response 
was assessed by direct peptide ELISA.
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2.4 Enzyme Linked Im m unosorbent Assay (E L ISA )
2.4.1 Production of negative human sera
Sera from a healthy working adults working in Immunology unit, LSHTM were 
selected to produce the anti- RSV negative control serum. Immunolon 2 HB 96-well 
microtitre plates (Dynex) were coated overnight at 4°C with RSV Ag at a 
concentration o f  5pg/ml in carbonate bicarbonate.
Then sera was added and incubated for 3 hrs at 37°C, antigen and antibody complex 
was allowed to form. Supernatant was then removed and spun down to remove any 
Ab/Ag complex that was not absorbed stuck to the plate. Then reactivity o f  the normal 
sera plus the absorbed sera was measured and reduction in the antibody reactivity was 
observed in the absorbed sera compared to the normal serum.
2.4.2 ELISA for human anti- peptide IgG antibodies
Immunolon 2 HB 96-well microtitre plates (Dynex) were coated overnight at 4°C with 
synthetic peptide at a concentration o f  5pg/ml in carbonate bicarbonate buffer 0.1M 
(pH 9.6) at 50(pl/well). Plates were then washed four times with the washing buffer: 
PBS, 0.1% Tween 20 pH 7.2 (PBS-Tw). Any remaining binding sites were blocked 
with blocking buffer (PBS, 0.1 %  Tween 20, 1% BSA at 37°C for 2 hours. Samples 
were tested in duplicate at a starting dilution of 1/200 for the children’s samples and at 
1/100 for adult sera. After incubation at 37°C for 45minutes, plates were washed and 
goat anti-human IgG peroxidase conjugate was added. After a further 45 minutes at 
37°C, the plates were washed and 50pl /well substrate was added to each well. This 
consisted o f  a freshly made solution o f  0.004% hydrogen peroxide and 0.5mg/ml o- 
phenylenediamine in phosphate-citrate buffer (0.2M sodium orthophosphate and 0.1M 
citric acid, pH 5.5). The reaction was stopped after by the addition o f  50pl/of 2M 
sulphuric acid. Plates were then read in the ELISA reader (Dynatech MR500) at 490
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nm the reactivity o f  serum with each peptide was expressed for each sample as the 
optical density value A4W
2.4.3 ELISA for human IgG anti- RSV antibodies
Immunolon 2 HB 96-well microtitre plates (Dynex) were coated overnight at 4°C with 
RSV antigen obtained from Biogenesis Ltd, UK at a concentration o f  5pg/ml in 
carbonate bicarbonate buffer 0.1M (pH 9.6) at 50pl/well. The RSV antigen was 
prepared from the RSV long strain on a monolyer of MA cells. The virus was purified 
from cells by low speed centrifugation then collected by high speed centrifugation. 
The ELISA was performed as described in 2.5.1.
2.4.4 ELISA for human anti- RSV SIS (Ml) - SDS (M2) mimotopes.
ELISA plates were coated with two mimotope peptides representing a conformational 
epitope from RSV F protein (SIS and SdS) identified by screening the solid phase 
peptide library with anti-RSV Mabl9 (Chargelegue, Obeid et al. 1998). Mimotopes 
were coated at 5pg/ml in carbonate bicarbonate buffer 0.1M (pH 9.6) at 50pl/ well. 
The ELISA was performed as described in 2.5.1.
2.4.5 Standardizing ELISA for human samples
The optimal conditions for the ELISA assay to screen human sera for reactivity with 
the overlapping peptides o f  the F protein o f  RSV was determined by the use o f  
different ELISA plates (Nunc, Immunolon 2, and 4) , as well as by varying the 
percentage o f  Tween 20 in both the blocking buffer and the diluents. Also, the use o f  
the gelatin was compared to the use o f  BSA as a blocking agent in the blocking buffer 
or the diluents. The optimal conditions for the analysis o f  human sera by ELISA as a 
result o f these experiments were as follows: Immunolon 2 HB 96-well microtitrc 
plates (Dynex), 1% BSA in the blocking buffer with 0.1% Tween 20, 0.25% BSA in 
the diluents with 0.1% Tween 20.Thc reactivity o f the optimal dilution o f the human
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sera for use in ELISA was determined by checkerboard titration ELISA with RSV Ag 
on the plate.
2.4.6 Controlling the assay
A pool from all the nine adult anti-RSV positive human sera was used to produce a 
positive control. This pool was checked for its reactivity with RSV antigen. Amongst 
the nine adult human sera titrated against RSV Ag, one with the lowest reactivity with 
the RSV antigen was chosen for use negative control by absorption of the antibody 
with RSV antigen. The Ag-Ab complexes were allowed to form and the spun down at 
3000 rpm. The reactivity o f  this negative control was compared to that o f  the original 
serum sample. Total IgG also was determined for the sample before and after 
absorption.
2.5 Cell cu lture
2.5.1 Growing RSV
RSV (A2 strain) stock was grown in HEp-2 cells in MEM-10 FCS + 0.2 p/s. The titre o f  
RSV stock was estimated by a plaque assay and expressed as the log 10 o f  the reciprocal 
of the dilution giving 1 PFU as follows :When the cells reached about 25% confluence 
(or up to 50%), then were washed in serum-free MEM. Virus stock was diluted to 0.1 
PFU /cell or less in final volume o f 3.5 ml (approx lx l0 6 pfu/ flask) and incubated at 
37°C for 90 min. The medium was redistributed every 10 minutes by rotating the flask 
through 90°. Fresh MEM 10% was added and the flask incubated for 48 hours. Medium 
was then removed and spun down. The pellet was re-suspended in 10 ml o f spent 
medium and returned to the flask. 40 ml o f  MEM (with 2% FCS was added and the flask 
incubated for 24 hours. When the cells were at least 75% confluent (if not, they were 
incubated for another day). The medium was then collected and remaining cells rinsed 
with a few ml PBS, poured o ff and added to the supernatant. Adherent cells were then re­
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suspended with trypisin/ EDTA and mixed with the supernatant. Cell debris was removed 
by spinning at 3000rpm for 15 mins and aliquots o f  2ml were immediately prepared and 
put into cryoutubes on ice and stored in liquid N2 .
2.5.2 RSV titration assay
HEP-2 cells were grown overnight in 96-well flat-bottom culture plates (Nunc) having 
5x l04 cells in each well. The medium in each well was removed and serial dilutions (10 
fold) o f the virus in maintenance medium (mm) containing 2% FCS were added 
(50pl/well). The plates were incubated at 37 °C for 2 hours in 5 % C O2 1 o allow the 
adsorption o f  virus to the cells. The inoculum was replaced with 0.75% 
carboxymethylcellulose (CMC Sigma) in growth medium containing 10% FCS and 
plates were incubated at 37°C for four days. Plates were observed daily for the 
appearance o f  cytopathic effect (plaque formation). The infected and mock infected 
monolayers were fixed in formaldehyde in phosphate-buffered saline (lml/well) at 
room temperature for one hour. The fixed monolayer was washed with distilled water 
and stained with 0.1% crystal violet for 30 minutes. The plates were washed with 
distilled water again and dried in a hot room and the titre was calculated.
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CHAPTER 3
THE IDENTIFICATION OF LINEAR B-CELL EPITOPES  
FROM THE F PROTEIN OF RSV USING ADULT SERA.
3.1 Introduction
Re-infection with RSV can occur in both adults and children, but adults re-infected with 
RSV are rarely symptomatic and usually display symptoms on ly  as severe and long- 
lasting as a common cold (Hall, Geiman et al. 1976; Hall, Hall et al. 1978; Hall, Walsh 
et al. 1991). Although RSV is being recognized as a crucial pathogen in young children 
and in the elderly population, there are few published studies that document immunity 
to RSV in the largest risk population (healthy adults and young children). RSV infection 
in adults was first reported more than 40 years ago by Hamry and Procknow, they 
reported the recovery o f RSV isolates from 1 5 m  edical students; the infections were 
described as causing only upper respiratory tract illness with an average duration o f  10.3 
days (Hamre D 1966). Subsequent descriptions o f  RSV infection in adults have focused 
mainly on high risk populations, such as elderly individuals and those with underlying 
diseases (Hall, Long et al. 2001). The early work on RSV adult infection was confirmed 
by a more recent study from Hall etal.2000, 2960  healthy adults were evaluated for 
having RSV infection. The surveillance was carried out over 20 years and included 
epidemiological and clinical observations when RSV was active in the community. The 
study included families o f hospitalized children living in the city, students, medical 
personnel and residents. 7% o f  the2960 adults evaluated acquired RSV infections which 
suggest that RSV is relatively a common infection among adults. The mean duration of 
illness was 9.5 days (Hall, Long et al. 2001).The widespread nature o f  RSV infections 
and the consistent, sizeable number o f  yearly outbreaks o f  RSV, suggest that RSV 
infections also may be frequent in healthy employed adults (Falsey and Walsh 2000).
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Nevertheless, it appears that the immune response to RSV does play a role in 
mediating the severity o f the clinical symptoms o f  the infection and therefore it is 
possible the quality o f  the antibody and cellular responses to the infection may play a 
role in determining whether or not there is a repeat infection.
3.1.1 Adult humoral response to RSV
Following primary infection, anti-RSV antibodies decline to low or undetectable 
levels within a year (Welliver, Kaul et al. 1980). Higher titres o f antibody are 
produced and persist longer after a second infection. Thus, there is a pattern o f  
increasing levels o f  serum antibody with successive infections which parallels the 
accumulative acquisition o f resistance to severe illness (Stott and Taylor 1985).
There are few published studies that document immunity to RSV in the elderly. It is 
not clear if  all older adults or only specific groups such as elderly with underlying 
disease have reduced humoral immunity. Neutralizing anti-RSV antibody titres in 20 
healthy older adults were significantly lower and demonstrated greater diversity than 
those in younger subjects (Falsey and Walsh 1998). Several reports indicate that all 
older adults have measurable RSV-speciflc IgG in their serum and that most infected 
individuals will develop a fourfold or greater increase in IgG (Falsey and Walsh 
1992). Results from this study suggest that the increased morbidity and mortality 
observed in older persons with RSV infection is not due to a key defect in the humoral 
immune system. No decrease in quantitative or q ualitative measures o f  RSV serum 
antibody was observed among these subjects. In addition, no differences in 
complement -  enhanced neutralizing t itres w ere seen, s uggesting t hat t here w ere n o 
age-related differences in IgG isotypes (Falsey, Walsh et al. 1999).
A possible role o f  serum anti-RSV IgE in  pathogenesis w as s uggested. The 
study analyzed anti-RSV IgE in the blood o f  220 RSV cases among adults with 
different various complications o f  bronchitis. A correlation between high levels of
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anti- RSV IgE and the presence o f bronchospasm in patients was revealed in this study 
(Falsey and Walsh 1992). In a study by Noah and Becker 2000, 10 healthy non­
smoking adults were inoculated nasally with RSV and a daily nasal lavage was taken 
to assess viral load and chemokine profile. Only 3 out o f  the 10 subjects developed 
RSV (Noah and Becker 2000). In a more recent study, RSV was nasally inoculated to 
32 healthy adult volunteers. The subjects were followed for 21 days with daily 
monitoring o f  their health. In addiation a nasal lavage sample was taken daily and 
used for viral detection. 18 o f  the 32 adults became infected as detected by both viral 
shedding and A g detection. The 18 adults showed URTI symptoms and disruption of 
normal middle ear function (Buchman, Doyle et al. 2002).
All these studies and observations from adult infection with RSV highlight the 
importance o f  investigating the immune response to RSV in adults. Thus, it is possible 
that some adults either develop: Full immunity to RSV in adulthood which could 
explain why infection with RSV happens only in half o f any adult population 
following intranasal challenge with RSV (Noah and Becker 2000; Buchman, Doyle et 
al. 2002) and the development o f  milder disease following re-infection with RSV in 
adulthood. Consequently, the identification o f  antigenic regions in the F protein o f  
RSV that induce antibody responses in adults could contribute to our understanding o f  
this so-called partial immunity. In addition, identifying such regions could provide 
information that could help in the design o f  a vaccine that protect against RSV 
therefore, in this chapter, sera from 10 healthy adults working at the London School o f  
Hygiene and Tropical Medicine were used to screen for both linear and 
conformational B-cell epitopes on the fusion protein o f  HRSV.
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3.2 Results
3.2.1 Reactivity of the pooled human sera and the absorbed human 
negative serum
For all the experiments presented in this chapter, the availability of an anti-RSV 
negative control serum was crucial. It was decided to produce this negative control 
serum in-house. Plates were coated with RSV Ag (Biogenesis) at 5 pi /ml and used to 
screen the anti-RSV reactivity o f  human pooled sera, human absorbed serum and 
human normal serum before absorption (see section 2.4.1) (Figure 3.1).Results 
showed that as expected, there was a significant reduction in the reactivity o f  the 
absorbed serum compared to that seen in the serum before absorption. And 
accordingly, a cut off value o f O.D. 0.2 was used for all human sera
3.2.2 Identification of antigenic epitopes of F protein using overlapping 
synthetic peptides
55 overlapping peptides covering the whole of F protein were used as solid-phase 
antigens on ELISA plates, to screen for linear epitopes recognized by adult polyclonal 
human sera. The reactivity o f pooled polyclonal sera to RSV Ag was used a positive 
control, and the human serum absorbed with RSV Ag was used as negative control. 
Following an initial screening o f  the 55 peptides with one serum sample, all o f  the 
nine healthy adult serum samples were screened for reactivity with the 55 peptides for 
reactivity at a dilution o f 1/100 (Appendix 1-3). Peptide six was excluded from the 
study since in preliminary experiments, it showed cross-reactivity with the secondary 
antibody used (goat anti-human IgG peroxidase conjugate). The 9 human sera reacted 
positively with several peptides at 1/100. A number o f  peptides were recognized by all 
the nine adult sera with high levels o f reactivity (greater than 2x the cut off).Thcse 
were peptides: 4, 8, 11, 14,18,24,36, and 41 (Figure 3.3). Other peptides were 
recognized at a lower level o f binding by the majority o f  the nine human samples (e.g.
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p28). Peptides that were recognized by only some o f  the sera, or had a binding of less 
than 2 x the cut off, were not included in the final analysis o f the data (See appendix). 
A summary o f  reactivity o f  the sera with the peptides is given in Table 3.1.The 
frequency o f  peptide recognition by the 9 healthy human sera o f  the 55 peptides is 
shown in Figure 3.2.
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□  pooled sera ■  normal serum □  absorbed serum
1.7 2 2.3 2.6
S e ra  dilutions in logio
Figure 3.1
Reactivity o f  the pooled human sera and the absorbed human negative sera.
T he human pooled sera was found to bind strongly to the RSV Ag, the absorbed anti­
serum to RSV was shown to have a very significantly reduced reactivity with RSV Ag compared  
to the normal pooled serum. The OD shown is the maen o f 2 OD readings.
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Figure 3.2
Reactivity o f  the adult human sera with the 8 peptides, with the highest OD readings. Sera 
samples were run at 1/100 dilution. Sera were from 9  healthy individuals and are indicated as A- 
H. * Cut/off w as at 0.2 OD reading at 490 nm. The O D  shown is the maen of 2 OD readings.
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T a b le  3 .1
Reactivity of sera with peptides (OD at 1:100 dilution)
Peptide number
Sera
sample P4 P8 P ll P14 P18 P24 P36 P41
A
0.764 0.907 0.692 0.537 1.28 1.389 0.653 0.668
B
0.674 0.876 0.831 0.637 1.03 1.28 0.761 0.41
C
0.855 0.75 0.969 0.596 1.055 1.37 0.8 0.74
D
0.875 0.89 1.158 0.695 0.883 0.987 0.921 0.653
E
0.936 0.829 1.527 1.23 1.811 1.62 1.304 1.209
F
0.532 0.604 0.956 0.748 0.462 1.324 0.67 0.703
G
0.593 0.6 1.053 1.075 0.423 1.643 0.64 0.682
H
1.073 0.809 1.114 1.689 0.552 0.956 0.8 1.133
I
0.522 0.607 1.09 0.748 0.323 0.876 0.665 0.682
1.5 A490nm p 4
1.2
A B O D E  F G H
Figure 3.3.a
Reactivity o f the nine human adult sera with peptide 4 The OD show n is the maen o f 2 OD 
readings
1 -5 A490nm
1.2 i
0.9
0.6 
0.3 
0
A B C  D E  F G H  I 
Iog10 Dilution
□ 2 ■  2.3 □ 2.6 □ 2.9
Figure 3 J .b
Reactivity of the nine human adult sera with peptide 8 The OD shown is the maen of 2 OD
readings
log 10 Dilution
Figure 3.3.C
Reactivity of the nine human adult sera with peptide 11 The OD shown is the maen o f  2 OD 
readings
Iog10 Dilution
(9 2 ■  2.3 0  2.6 □ 2.9
Figure 3 J .d
Reactivity of the nine human adult sera with peptide 14. The OD shown is the maen of 2 OD
readings
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Figure 3 .3 .e
Reactivity o f  the nine human adult sera with peptide 18. The OD show n is the maen of 2 OD 
readings
A B C D E F G H  I 
□  2 ■ 2.3 □  2.6 □  2.9 
Iog10 Dilution
Figure 3 .3 .f
Reactivity of the nine human adult sera with peptide 24. The OD shown Is the maen of 2 OD
readings
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Figure 3.3.g
Reactivity o f the nine human adult sera with peptide 36. The OD shown is the maen o f  2 OD 
readings
A B C D E F G H  I 
Iog10 Dilution
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Figure 3.3.h
Reactivity of the nine human adult sera with peptide 41. The OD shown is the maen of 2 OD
readings
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Figure 3.4
Frequency of peptide recognition by th e  9 healthy human sera with the 55 peptidei
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3.2.3 Discussion
The immune response to RSV plays a role in mediating the severity o f  the clinical 
symptoms o f the infection and therefore it is possible that the quality o f  the antibody 
and cellular responses to the infection may play a role in determining whether or not 
there is a repeat infection. But adults re-infected with RSV are rarely symptomatic and 
usually display symptoms only as severe and long-lasting as those for a common cold. 
Little information about the role of immunity to RSV exists in the major part o f the 
population; t he r ate o f  RSV i nfection i n p ersons w ith n o u nderlying c  ompromising 
conditions (healthy working adults) is difficult to determine, considering the 
variability o f  exposure among adults at work and home. Both the significant gaps in 
our understanding o f RSV infection in adults, and the difficulty o f diagnosing RSV in 
adults, highlights the importance o f  studying RSV immunology in this group o f  
individuals.
The role o f  antibodies in immunity to RSV remains not fully understood and in this 
context, screening o f the reactivity o f  the human sera with the 55 RSV-F protein 
peptides as linear B-cell epitopes plus their reactivity with the mimotopes identified 
from the F protein o f RSV could be useful in identifying immune dominant epitopes 
involved in inducing protective antibody responces against RSV. The results obtained 
from screening the sera o f  laboratory personnal working on RSV showed a clear 
profile for peptide recognition. Eight o f the 55 peptides were strongly bound by all 
adult sera: peptides 4, 8, 11, 14, 18, 24, 36, and 41 (Figure 3.2). All nine (100%) sera 
recognized the following peptides in the order o f  decreasing OD values; 
11>24>14>36>18>41>4>8. 77% o f  the sera recognized peptide 10. 66% of the sera 
recognized peptide 28. Peptides 1/5/7/19 were recognized by 22% o f the sera. It is 
possible that these 8 peptides most frequently recognized by the sera may represent 
linear epitopes o f the F protein that could be important in the development o f a
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protective antibody response. Accordingly it was decided to test their immunogenicity 
in animal studies (see chapter 6). I f  these linear epitopes could produce protective 
antibody in animals this would suggest that they could be candidates for vaccine 
development.
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CHAPTER 4
REACTIVITY OF SERA FROM GUINEA BISSAU  
CHILDREN W ITH LINEAR PEPTIDES FROM RSV F- 
PROTEIN
4.1 Introduction
Infectious diseases are considered to be the major reason for morbidity and 
mortality in very young infants in developing countries. RSV is certainly the most 
important cause o f  viral acute LRI in both developed and developing countries 
(Simoes 1999). It also accounts for 20-25% hospitalization o f infants in developing 
countries (Wright 1996). Children with a cough or difficult breathing and fast 
breathing would meet the current world health organization definition of pneumonia 
used by health workers at health care facilities in developing countries. Weber et al. 
showed that RSV LRI led to 8-fold and 4-fold increases in subsequent wheezing and 
non-wheezing LRI in the following 2 years compared with control subjects (Simoes 
1999). In a more recent study, Openshaw et al tested the effect o f age at first infection 
on re-infection in mice. Mice were infected at day 1, 4, or 8 weeks of age then 
challenged at 12 weeks. Neonatal mice challenged with RSV showed increased 
inflammatory cell infiltration (Th2 cells and eosinophilia) plus increased weight loss. 
The delay in priming the led to enhanced IFNy production and the clinical profile of 
the disease was also less severe. (Culley, Pollott et al. 2002)
In developing countries, health care workers often do not use a stethoscope to 
distinguish between wheezing and non-wheezing LRI, and perceptible wheeze is the 
only criterion used in some o f  these situations. However, wheeze that is easy to hear
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present only in the more severely ill children with wheezing LR1, and its recognition 
by health care workers is often poor (Simoes 1999).
There tire three main trategies for controlling RSV infections (Weber MW
1999).
i) Case management
ii) Prevention through vaccination
iii) Identification o f  risk factors which might be altered through 
interventions.
4.1.1 The influence of maternal antibody on immunity to RSV in African 
children
In a study carried out in the Gambia, designed to determine the influence o f placental 
malaria infection and maternal hyper-gamma-globulinemia on trans-placental 
antibody transfer, 213 mother-baby pairs were recruited at delivery in the labour ward. 
Only 51.1% o f the study population had placental malaria infection 24.7% had active 
infection, whereas 49 (45%) and 33 (30.3%) had active chronic infection and chronic 
infections, respectively. Mothers with placental malaria infection transferred 
significantly lower levels o f  IgG l, IgG2 to their newborns than did mothers without 
placental malaria infection. Placental transfer o f  antibodies against HSV-1, RSV, and 
VZV was a lot lower in the placental malaria-positive mothers/baby pairs than in the 
placental malaria negative pairs. Results from this study confirm data from similar 
studies in Brazil and Malawi (Okoko, Wesumperuma et al. 2001).
In a study carried out in rural Mozambique during the 20 months o f  hospital- 
based surveillance (October 1, 1998, to May 15, 2000), 4589 children were admitted, 
all children <5 years old admitted to the ward fulfilling the WHO criteria for LRTI, a 
nasopharyngeal aspirate (NPA) was collected. Serum samples were collected also 
from infants with RSV infection < 1 year o f  age and from uninfected controls to
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assess the effect o f  serum antibodies on the incidence o f  RSV infection in. Anti-RSV 
antibodies were assessed by a membrane fluorescent antibody test (MFAT) for (IgG) 
antibodies and by a neutralizing antibody test. IgG anti-RSV antibodies were of higher 
prevalence and at higher levels in the control group compared to the infected case 
group, indicating an important role for IgG antibodies in protection. IgA RSV 
antibodies were also measured by MFAT. IgA anti-RSV antibody prevalence was 
very low in patients and controls, signifying that the detected IgG RSV antibody in 
both groups was o f  maternal origin. The results emphasize the theory o f maternal 
vaccination in the control o f RSV in very young children that represent the highest 
risk group (Roca, Abacassamo et al. 2002).
Evidence from laboratory studies and clinical trials strongly suggests a 
dominant role for antibodies in protection against re-infection. The relative protection 
of infants from virus-associated lower respiratory tract (LRT) disease in the first 
weeks or months of life is related to the level o f  passively-acquired maternal 
antibodies to RSV (Crowe 1996). Data from passive-transfer studies in rodents have 
demonstrated the protective effect o f  polyclonal immune sera and neutralizing RSV 
monoclonal antibodies (MAbs) in the LRT (Crowe 1996). Virus replication in the 
LRT was inversely correlated with the serum RSV-neutralizing-antibody titre 
following passive transfer. While in contrast, the presence o f  serum neutralizing RSV 
antibodies usually has little effect on virus replication in the upper respiratory tract 
(URT) (Crowe 1996). However, high titres o f serum neutralizing antibody against 
RSV do protect the LRT against RSV infection, as shown in animal studies, 
epidemiological observations, and most recently, in clinical trails o f RSV hyper 
immune globulin (RSVIG) passively transferred to high-risk infants (Dudas and 
Karron 1998). High titres o f  maternally-derived RSV antibody (as measured by IgG 
enzyme-linked immunosorbent assay [ELISA] or virus neutralization), in maternal
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blood or cord blood have been shown to  correlate inversely with the incidence o f  RSV 
infection (Dudas and Karron 1998) and with the severity o f  RSV pneumonia in the 
first 6 months o f  life (Dudas and Karron 1998). The rate o f  re-infection with RSV and 
the rate ofLRI at the time o f re-infection also correlate inversely with the level of 
serum neutralizing antibody against R SV  following primary infection in young infants 
(Dudas and Karron 1998). The effect o f the administration of RSVIG in high-risk 
infants was measured in a randomized study, and it was shown that those who 
received monthly doses o f 750mg/kg had significant reductions in the rate and 
severity o f LRI as measured by the need for hospitalization, days spent in hospital,and 
days spent in intensive care (Dudas and Karron 1998).
Primary infection with RSV does not always evoke an immune response that 
will protect the lower respiratory tract, since RSV-associated LRI can occur in young 
children experiencing their second episode o f RSV (Dudas and Karron 1998). The 
lack of protection may be explained in part by group specificity, since children with 
primary RSV infection develop a neutralizing antibody response in serum more 
frequently and o f greater magnitude to the infecting strain than to the heterologous 
RSV strain. The identification o f  an ideal response o f  young infants to primary 
infection with RSV has i mportant implications for vaccine development, because it 
suggests that more than one dose o f  vaccine will probably be needed to induce 
sufficient levels o f RSV neutralizing antibody in this age group (Dudas and Karron 
1998).
A prospective community cohort was set up in several districts in the capital o f  
Guinea Bissau. More than 2000 houses were included in the study. Around 1300 
children were followed with w eekly morbidity reports and NPA (nasopharyngeal 
aspirate) when they have WHO criteria for LRI.
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The WHO definition o f  LRTI was defined as children who presented with 
cough, nasal secretion or difficulty in breathing and who had one or more of the 
following: chest indrawing, crackles, wheezing, or increased respiratory r ate (WHO 
1991)
The outpatient clinic at the hospital and the health centre is screened for severe 
cases. Blood samples have been taken from cases (and controls as well as mothers o f  
cases and controls) at time o f  infection but the diagnosis was based on NPA. Most o f  
these children were included in a community study of a two-dose measles 
immunization schedule (6+9 months) and have had blood samples taken at 6, 9 and 18 
months.
The following samples were selected for the work discussed in this chapter:
- Children with a pre-primary infection sample (6 months) and a post-infection 
sample (at 9 or 18 months or both). I n all cases, the RSV was diagnosed by antigen 
detection.
- Children with two episodes of RSV and two post-infection samples: 11 had the first 
episode before 6 months and one or two further episodes after 6 months but before 18 
months. 6 children had episodes between both 6-9 and 9-18 months (Figure 4.1).
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Diagram showing the num ber of children samples used in the study and how the samples were 
divided.
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The hypothesis to be tested in the work described in this chapter is that during the first 
infection with RSV, incomplete immunity is developed as a measure of the production 
o f an antibody response that is not directed to the protective epitope or epitopes. 
Furthermore, in order to attempt to answer the question o f why individuals can be re­
infected with RSV, the panel o f  synthetic 55 overlapping peptides covering the whole 
of the fusion protein was screened with sera from children with sequential infections 
with RSV to determine whether or not there were differences in the pattern of peptide 
recognition in sera at different stages o f exposure to RSV.
4.2 Results
4.2.1 Recognition of the F peptides by sera from Guinea Bissau
In order to answer the question o f  why individuals can be re-infected with RSV, an 
attempt was made to determine whether or not there were differences in the pattern of 
peptide recognition by human sera at different stages o f  exposure to RSV. ELISA 
plates were coated with the 55 peptides representing the whole of the fusion protein. 
Since the sera were from infants, very limited volumes were available and thus the 
samples were used at 1/200 dilution. The reactivity o f each serum was determined as 
the mean of the optical density o f  the wells containing the specified peptide minus the 
OD value obtained with empty, blocked wells with the samples from each child. An 
adult human serum pool was used as a positive control, an RSV absorbed human 
serum was used as a negative control.
Analysis o f the binding o f peptides by sera from the children at various stages of 
infection showed that in children with pre and first infection samples only, peptide 4 
was recognized by 45% of the pre-infection sera. Binding of peptide 4 was seen in 
18% in the primary sera after exposure to RSV infection. Peptide 48 on the other 
hand, was recognized by 46% o f  the post infection sera and peptide 14 was recognized 
by 72% of both pre -infection and first infection samples (Figure 4.2).
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In samples from children with both primary and secondary infection, peptides 19, 20, 
32 and 48 were recognized by 50-54 % of the secondary infection sera. Peptide 14 in 
was recognized by 66% o f  the pre-infection serum samples, 81 % o f the sera obtained 
following the primary infection with the virus, and 73% o f  the sera following the 
secondary infection with the virus. Peptide 4  was recognized by approximately 40% 
o f the sera at all stages o f  exposure to RSV (Figure 4.3).
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Percentage of the binding of peptides recognized by sera from RSV infected infants. Data shown are from sera taken from children prior to exposure and following 
primary RSV infection. Sera were run at 1/200 dilution.The OD shown is the maen of 2 OD readings.
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Figure 4 J
Percentage of the binding of peptides recognized by sera from RSV infected infants.Data shown are from sera taken from children prior to exposure and 
following primary and secondary RSV infection. Sera were run at 1/200 dilution. The OD shown is the maen of 2 OD readings.
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4.2.2 Recognition of peptides 4 and 14 by sera from children
Peptides 4 and 14 were the most frequently recognized peptides among all the serum 
samples tested. Therefore, the reactivity o f  the sera to these two peptides was analyzed 
in details and related to the child’s state o f exposure to the virus. The reactivity o f  sera 
from children with pre-and first infection samples was not high and only two samples 
had demonstrable reactivity to peptide 4 as shown in Figure 4.4. However, in sera 
from children with 2 repeated infections with RSV, peptide 4 was recognized by 16 
(42%) o f the samples.
In an attempt to determine if the presence of antibodies to peptide 4 was associated 
with prevention o f a repeated infection, the reactivity o f  sera with peptide 4 at various 
stages o f  exposure to the virus was analyzed. Sera from children 1, 23, and 32 reacted 
with peptide 4 in the pre-infection samples but serum taken following the first 
infection and the second infection did not recognize the peptide. Sera from child 1 had 
no detectable anti-RSV antibodies which again suggest that the child was not actually 
infected. In the case o f  child 23, the post-first infection sample had high antibody 
reactivity against RSV but the second post-infection sample was not available.
Sera from both child number 5 and 25 had reactivity with peptide 4 following the first 
infection. No anti-RSV Ag reactivity was detectable, again suggesting that these 
children were not infected. Sera from children number 26, 40, and 44 had anti-peptide 
antibodies in both pre-infection, and post-first infection samples but no reactivity to 
the peptide in the second post infection samples. However the sera did havedetectable 
anti-RSV antibodies.
Peptide 14 was recognized by the pre, first and second- infection samples from most 
individuals, and in most o f the sera, OD values for binding o f peptide 14 were high at 
all stages of exposure to the virus. Approximately 78% of the sera taken from post- 
first infection bound significantly to the peptide. However, highest values o f binding
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were shown in sera taken post-second infection (Figure 4.6, and 4.7).
The question o f  whether the presence of antibodies to peptide 14 was associated with 
prevention o f  a repeated RSV infection was also addressed. It was noticed that only 
child number 34 had reactivity to peptide 14 in the pre-infection samples but not in the 
post-first infection sample, while the reactivity o f  this serum to RSV Ag was high. 
Among children from whom samples from two repeated infection were available, 
child 1, 28, and 40 had reactivity to peptide 14 in their pre- and first infection samples 
but not in the sera from the second post-infection samples. Furthermore, none o f  the 
second post-infection samples had anti-RSV antibodies.
4.2.3 Recognition of peptide 19
In children sera with only pre- and first infection samples, peptide 19 was recognized 
by 27% o f  the sera both prior to and when exposed to the virus for the first time.
In infected children sera from which 2 samples were available, peptide 19 was 
recognized by 21% o f the sera in pre-infection samples and by 27% o f the sera 
following their first exposure to the virus. The reactivity o f  the sera with peptide 19 
increased to 51% following the second infection with RSV.
4.2.4 Recognition of peptide 20
It was noticed that only in the pre-infection samples and not in the post-first infection 
samples was peptide 20 recognized. However, in children with two episodes o f  RSV 
infection, 2 1 % o f t he p re-infection s amples 3 0% o f  the p ost-first i nfection s amples 
and 51% o f  the samples following second exposure to RSV were reactive to with 
peptide 20
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4.2.5 Recognition of peptide 32
In pre-infection sera, 9% were reactive with peptide 32 and 27% of post-first infection 
sera were reactive with the peptide. While in sera from children both first and second 
infection samples, reactivity with peptide 32 was 13% in pre-infection samples, 24% 
in first infection samples and 54% following second infection.
4.2.6 Recognition of peptides 48
In pre-and first infection samples, the proportion of sera reactive with peptide 48 was 
9%, and 45%, respectively while in both first, and second infection sample reactivity 
of the sera with peptide 48 was 16% o f  pre-infection samples, 13% o f  first infection 
samples and 50% in sera with second post infection samples.
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Figure 4.4
Recognition of peptide 4 by sera from children with pre-and first infection samples only.
OD values shown are the OD at 490 nm of a 1:200 dilution. T he OD shown is the maen o f 2 OD 
readings
123
0.9 A490 nm
0.8 
0.7 - 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
0 J
□ pre- 
infection
■ first- 
infection
□ second- 
infection
lllli III
2 4 5 7 11 12 14 15 17 18 19 20 22 23 24 25 26 27 28 29 31 32 33 35 36 38 39 40 41 43 44 45 47 48 49
CHILD ID
Figure 4.5
Recognition of peptide 4 by sera from children with 2 repeated infections. OD values shown are the OD at 490 nm of a 1:200 dilution. The OD shown is the maen of 2
OD readings
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Figure 4.6
Reactivity of peptide 14 by sera from children. With pre-and first infection samples only. OD values shown are the OD at 440 nm of a 1:200 dilution. The OD shown is 
the maen of 2 OD readings
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Figure 4.7
Recognition of peptide 14 by sera from children with 2 repeated infections. OD values shown are the OD at 490 nm of a 1:200 dilution. The OD shown is the maen of 2 
OD readings
126
The reactivity o f sera with RSV antigen was also tested at the same time using the 
commercially available RSV antigen (Biogenesis). The reactivity of each serum with 
RSV Ag was determined as the mean o f  the optical density o f  the wells containing the 
RSV antigen minus the OD recorded with empty, blocked wells with samples from 
each child (Table 4.1). Twelve of the children’s sera that were taken prior to exposure 
to RSV infection had reactivity with RSV antigen. This could mean that an active 
RSV infection had started around the time the sample w as taken. Therefore, these 
samples were screened to determine whether or not IgM anti-RSV antibodies could be 
detected (Figure 4.8). 4 children (8, 10, 11, and 30) out o f  the 12 that were suspected 
to have an active RSV infection had detectable I gM a nti-RSV binding (OD ranged 
from 0.14-0.22) in the pre-infection serum sample (6 months of age) (Figure 4.8). 
Other observations can be drawn out here:
•  Child 3: Sera were obtained after only one episode of RSV. There was no 
recognition o f  any o f  the peptides either in the pre-infection sample or in the 
sample following primary infection. Furthermore, these sera had no detectable 
reactivity with the RSV antigen in the ELISA.
•  Child 9: No peptides were recognized by the pre, or post first-infection serum 
samples from this child. However, serum from the post second-infection 
strongly recognized peptide 48. These results are consistent with those from 
the RSV ELISA, which showed the absence o f  reactivity with RSV in pre­
infection and post first infection sera. Post second infection serum showed 
reactivity with RSV at twice the background level.
• Child 19, and child 29: Sera from these children at the pre-infection and post 
first infection stage did not have reactivity to either RSV antigen or to any of 
the peptides, but sera taken post-second infection did react with peptide 14 and
4.2.7 Reactivity of  sera from children with the RSV antigen
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4.2.8 Sequence analysis of the identified peptides:
A comparative study using the computer program Swiss-Prot/protein blast p was 
performed in order to confirm the identified peptides (Table 4.2). The program 
uses (Swiss-Prot/protein database on the web) search sequence databases, to 
evaluate similarity scores, and identify periodic structures based on local sequence 
similarity. The peptides had 100% identity with their native protein which 
confirms their origin. Some o f the first matched sequences are shown in (Table 
4.3), and all the rest are shown in the appendix section (Appendix 4-15). None of 
the peptides had similarity with any human proteins, with the exeption of peptide 
41 which had similarity with Cytochrome c, which is a small, highly conserved 
protein involved in mitochondrial electron transport. This may suggest that the 
peptide could not be of use as a vaccine and this needs further invistigation 
However, a few peptides had sequence similarity with other unrelated proteins, the 
most significant ones are listed in (Table 4.4).
with the RSV antigen.
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Child
number
Pre-infection Post-first-
infection
Post-second-
infection
1
2
3 N.A
4 ++++
5
6
7 +
8 + +++ N.A
9 ++
10 + + N.A
11 ++ ++
12
13 N.A
14 N.A +
15
16 N.A
17
18
19
20
21 N.A N.A N.A
22 +++ +++
23 + ++++++ N.A
24 ++++++
25
26 + +++++++ +++
27 +++ ++++
28 N.A
29 ++++
30 ++ + N.A
31 +++ ++ ++
32
33 +++ ++ +++++++++
34 +++++ N.A
35 ++
36 + ++++
37 ++ N.A
38 +++++++++
39 Lost ++++++++
40
41 ++++++++
42 +++ N.A
43
44 ++++++
45 ++++++
46 N.A
47 N.A ++++++
48 ++++++++
49 N.A ++++++
Table 4.1
Reactivity with RSV antigen of sera from children.
Each sample was tested at 1/200. The reactivity with RSV A g was determined as the 
optical density o f the background (cut off) subtracted from the O D  in wells with the RSV 
antigen. Results are illustrated in the table as + -  cut off and N .A -  sample not available.
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Figure 4.8
IgM level in pre-infection serum samples.
Samples were tested at 1/200 dilution. IgM anti-RSV reactivity with RSV was expressed 
as the OD of the sera in the well containing the RSV Ag minus the OD obtained after 
addition of the secondary antibody to an em pty blocked well. The cut off in this assay 
was the OD of the secondary antibody to an empty blocked well. The OD shown is the 
maen of 2 OD readings.
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Peptide Sequence
4 WYTSVWYTSVITIE LSNIKE aaS2-66
8 ELQLLMQST PPTNNR aa92-106
11 AKKTNVTLS KKRKRR aa 122-136
14 VAVSKVLHL EGEVNK aa 152-166
18 VLDLKNYID KQLLPI aa 192-206
19 QLLPIVNICQ SCSISN aa202-216
20 CSISNIETV IEFQQK aa212-226
24 LTNSELLSL INDMPI 252-266
32 ICLTRTDRG WYCDNA aa332-346
36 SLTLPSEIN LCNVDI 372-386
41 CTASNKNRG IIKTFS aa422-436
48 ISQVNEKIN QSLAFI aa492-506
Table 4.2
Sequences and am ino acid position for the mapped peptides.
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Peptide Identities Accession
num ber
Definition Isolate
4 15/15- 100% AAM68160 fusion glycoprotein [Human respiratory 
syncytial virusl
HRSV
8 15/15-100% P03420 Fusion glycoprotein precursor [Contains: 
Fusion glycoprotein F2;
Fusion glycoprotein FI 1
HRSVA2
VGNZA2 cell fusion glycoprotein precursor - human 
respiratory syncytial 
virus (strain A2).
HRSVA2
AAB59858 fusion glycoprotein [Human respiratory 
syncytial virus
HRSVA2
II 15/15- 100% B28929 cell fusion glycoprotein - human respiratory 
syncytial virus (type A).
HRSVA
14 15/15- 100% P23728 Fusion glycoprotein precursor [Contains: 
Fusion glycoprotein F2;
Fusion glycoprotein FI].
BRSV RB94
VGNZBS cell fusion glycoprotein precursor - bovine 
respiratory syncytial 
virus (strain RB94).
BRSV RB94
BAA00798 fusion protein [Bovine respiratory syncytial 
virus].
BRSV
18 15/15 - 100% AAM68I60 fusion glycoprotein [Human respiratory 
syncytial virus
HRSVA
19 15/15 - 100% AAM68160 fusion glycoprotein [Human respiratory 
syncytial virus
HRSVA
20 15/15 - 100% AAM68I60 fusion glycoprotein [Human respiratory 
syncytial virus
HRSVA
24 15/15 - 100% P23728 Fusion glycoprotein precursor [Contains: 
Fusion glycoprotein F2;
Fusion glycoprotein FI ].
BRSV RB94
VGNZBS cell fusion glycoprotein precursor - bovine 
respiratory syncytial 
virus (strain RB94).
BRSV RB94
BAA00798 fusion protein [Bovine respiratory syncytial 
virus].
BRSV
32 15/15- 100% P23728 Fusion glycoprotein precursor [Contains: 
Fusion glycoprotein F2;
Fusion glycoprotein FI],
BRSV RB94
VGNZBS cell fusion glycoprotein precursor - bovine 
respiratory syncytial 
virus (strain RB94).
BRSV RB94
BAA00798 fusion protein [Bovine respiratory syncytial 
virus].
BRSV
36 15/15 - 100% B28929 cell fusion glycoprotein - human respiratory 
syncytial virus (type A).
41 15/15 - 100% P23728 Fusion glycoprotein precursor [Contains: 
Fusion glycoprotein F2;
Fusion glycoprotein FI 1-
BRSV RB94
VGNZBS cell fusion glycoprotein precursor - bovine 
respiratory syncytial 
virus (strain RB94).
BRSV RB94
BAA00798 fusion protein [Bovine respiratory syncytial 
virus].
BRSV
48 15/15 - 100% AAM68160 fusion glycoprotein [Human respiratory 
syncytial virus
HRSVA
Table 4.3
KSV aequences producing significant alignment« with the identified peptide«.
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Peptide Identities Accession number Definition Isolate
4 9/14 -64% NP_716069 aconitate hydratase 2- Shewanella oneidensis 
MR-1
9/13 -69% PI 9584 
A31389 
AAA23204
Beta-amylase, 
thermophilic precursor 
(1,4-alpha-D-gl ucan 
maltohydrolase
Thermoanaerobacterium
thermosulfurigenes
8/14 -57% NP 454772 
CAD01317.1 
NP 804047 
AE0522 
AA067896.1
aconitate hydratase 2 Salmonella enterica 
CT18 and Ty2
8/14-57% NP 285814.1 
NP 308149.1 
B90644 
B85495 
AAG54422.1 
BAB33545.1
aconitate hydrase B/ 
Escherichia coli
0157:H7 EDL933 and 
0157:H7
8 7/7-100% CAF89628 unnamed protein 
product
Tetraodon nigroviridis. 
taxon:99883
8/10-80% NP 985668 
AAS53492.1
AFR12I Wp. Eremothecium gossypii 
-ATCC 10895
7/7-100% AAL88727 similar to Homo 
sapiens (Human). 
HERC2 protein 
[Dictyostelium 
discoideuml.
Dictyostelium
discoideum
45-100% Multiple hypothetical protein Multiple organisms
11 9/11-81%
8/9-88%
8/10-80%
EAA61925
NP 705854 
NP 588327.1
hypothetical protein 
AN9092.2
hypothetical protein
hypothetical protein
Aspergillus nidulans 
FGSC A4
Plasmodium falciparum 
3D7
Schizosaccharomyces
pombe
8/10-80% CAE01390 tuber borchii white 
collar
Tuber borchii (whitish 
truffle)
8/9-88% EAA17525 AT hook motif, 
putative
Plasmodium yoelii 
voelii
8/9-88% CAA29838.I pyrG product Aspergillus nigcr
8/9-88% DCASON orotidine-5'-phosphatc
decarboxylase
Aspergillus niger
41 8/9-100% EAA20535 hypothetical protein Plasmodium yoelii 
yoelii
8/10-80% Multiple cytochrome c Multiple human and 
chimpanzee
Table 4.4
Non-RSV sequences producing significant alignments with the identified peptides
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4.3 Discussion
Evidence from laboratory studies and clinical trials strongly suggests a dominant 
role for antibodies in protection against re-infection. The relative protection of 
infants from virus-associated lower respiratory tract (LRT) disease in the first 
weeks or months o f  life is related to the level o f passively-acquired maternal 
antibodies to RSV. Since the presence of specific anti-F antibodies plays a major 
role in immunity against RSV, the identification o f  the immunogenic epitopes 
recognized by sera from infected individuals could be very useful in vaccine 
development against RSV, and this study was performed to identify these epitopes 
using a panel o f  peptides representing the F protein. The pattern of peptide 
recognition varied according to the state o f exposure to the virus. When the data 
were analyzed with the sera treated as 3 different groups that had different 
exposure to RSV infection regardless o f  them being from the same children, no 
clear pattern could be observed. Nevertheless, the following points can be drawn 
from an analysis o f  the results:
•  In all children, sera obtained following the second infection were likely to 
show peptide binding activity.
•  Peptides 4 and 14 were recognized strongly by sera from both adults and 
children.
•  Peptide 4 was recognized by 45% o f the pre-infection samples. This value 
drops to 18% in sera o f  children that had been exposed to RSV infection. In 
addition, sera from adults also had reactivity to this peptide. Taken together, 
these observations indicate that reactivity with this peptide in the children is 
maternally-derived antibody and suggest that the peptidesis not likely to 
represent a protective epitope.
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• As discussed in section 4.2, peptides 19, 20, 32, and 48 were recognized by 
50-54% of the post-second infection serum samples but antibodies were also 
present in both pre- and post- first infection samples. This could again suggest 
that these peptides may not represent protective epitopes.
Several factors complicated the analysis o f the data:
•  The negative controls available were the so-called pre-primary infection samples 
which are from children who did not have clinical RSV before 18 months o f  age 
- but they may well have had sub-clinical infection which could explain the 
presence o f antibodies to RSV in these sera.
•  The reactivity o f some o f the sera either negatively or positively with RSV Ag 
was not related to the presence of antibodies to peptides, this caused a 
confusion in interpreting the data.
•  The presence o f  maternally-derived antibodies could have also interfered with 
the results obtained since maternal antibody has been shown to interfere with 
how babies respond to RSV. In a study carried out in a rural area o f  the 
Gambia, mothers with placental malaria infection transferred significantly 
lower levels o f IgGl and IgG2 to their newborns than did mothers without 
placental malaria infection. Placental transfer o f  antibodies against HSV-1, 
RSV, and VZV was a lot lower in the placental malaria-positive mother/baby 
pairs than in the placental malaria negative pairs. Only 51.1% of the study 
population had placental malaria infection (Okoko, Wesumperuma et al. 
2001) .
To exclude the possibility o f  the presence o f cross-reacting antibodies from other 
infections, a comparative study using the computer program Swiss-Prot/protein blast p 
was also performed in order to identify any similarity between our reactive peptides 
with any other human proteins. No homology was detected with any human protein.
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Nevertheless, analysis o f the location o f the identified peptides from both the children 
and the adult sera on the F protein reveals some interesting points for discussion as 
shown in Table 4.16, and Figure4.9. Both peptide 4 and 8 are located in the F2 region 
of the fusion protein which is the most divergent fragment o f  the F molecule among 
all the antigenic groups o f  HRSV. The F2 has the bulk o f the potential sites for N 
glycosylation in the F protein (Lopez, Bustos et al. 1998) which makes it very difficult 
to map epitopes within this region. Therefore it is quite interesting that sera from both 
adult and children did have reactivity towards peptide 4 and 8, and especially since a 
protective CTL epitope has been identified in peptide 8.
Peptide 11 shares the sequence KKRKRR at the C-terminal end o f  F2, the most likely 
the site o f proteolytic processing o f the Fo precursor. Most interestingly, peptide 11 
contains 15 amino acids o f the pep27 fragment which has been shown to be released 
between the two cleavage sites as a separate peptide (Zimmer G 2001), (Calder, 
Gonzalez-Reyes et al. 2000). However, its function is still unknown.
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Peptide no Location on the F protein aa position
4 F2 52-66
8 F2 92-106
11 F2 (cleavage-peptide)- 
Pep 27
122-136
14 S-S bridge/ FI 152-166
18 FI 192-206
19 Fl/Fusion peptide 202-216
20 FI 212-226
24 FI 252-266
32 FI 332-346
36 FI 372-386
41 FI 412-426
48 492-506
Table 4.9
Location of peptides in the F-protein that are recognized by sera from  both children and adult
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CHAPTER 5
THE ANTIGENICITY AND IM M UNOGENICITY OF 
MIMOTOPES FROM  THE F PROTEIN O F  HRSV
5.1. Introduction
5.1.1 Concept of mimicry.
Antibodies can be directed to both linear and conformational epitopes. Linear epitopes 
of an immunogenic region o f the protein are represented b y  c ontinuous amino acid 
sequences. Conformational epitopes on the other hand, are made up o f  amino acid 
sequences brought together by the folding of the protein and are thus discontinuous in 
nature (Partidos and Steward 2002).
It is likely that the majority o f  antibody responses to viral proteins are directed 
towards conformational rather than to linear B-cell epitopes (Steward 1997; 
Olszewska, Obeid et al. 2000). Since conformational epitopes are very difficult to 
predict from the primary amino acid sequence and are perhaps impossible to produce 
by conventional peptide synthesis, peptide vaccines developed thus far have been 
restricted to amino acid sequences representing linear B-cell epitopes. However, the 
development of phage display libraries and solid phase combinatorial peptide libraries 
has provided a means for mimicking conformational epitopes. These libraries can be 
screened with monoclonal antibodies, polyclonal sera or receptor molecules on 
various cell types that are specific for conformational structures. In this way, 
bacteriophage or resin beads expressing peptide sequences that mimic the shape o f  the 
epitope that induced its production in vivo can be identified.
Library- derived peptides that have been isolated by affinity selection and those that 
mimic these complex epitopes are therefore called mimotopes. It was the pioneering 
work on the specificity o f antibody-antigen interaction b y  M. Geysen that led to the
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introduction o f the term mimotope. He defined the term to mean a “molecule able to 
bind to the antigen combining site o f  an antibody molecule, not necessarily identical 
with the epitope inducing the antibody, but an acceptable mimic o f the essential 
features of the epitope” (Geysen, Rodda et al. 1986). Although atomic identity might 
explain the same antigenicity displayed by an epitope and mimotope, this molecular 
mimicry may also arise because both mimotope and epitope bind to different subsites 
within the same paratope. It follows therefore, that a mimotope may react with an 
antibody directed to the native epitope without actually binding to the same paratope 
as the native epitope. In this case, anti-mimotope antibodies will not cross-react with 
the native epitope (El Kasmi, Fillon et al. 2000).
Mimotopes have to be antigen- specific and at the same time immunogenic in 
order to qualify as potential vaccine candidates. The ability o f  a mimotope to induce 
antibody responses against the native epitope that it mimics is also challenging in that, 
in addition to the structural features o f the mimotope, host factors such as antigen 
presentation, genetic background and MHC haplotype influence the induction of 
immune responses and control antibody affinity and specificity. Mimotopes can be 
used to induce a defined antibody response towards a specific epitope where 
immunization with the antigen is either not possible or induces an inappropriate 
antibody response. If as seems likely, epitopes that induce virus neutralizing 
antibodies are o f  a discontinuous nature, the use o f mimotopes could be considered as 
a new generation o f  specific sub-unit vaccines against viruses.
Several mimotopes have been characterized and have been shown to generate 
antigen-specific neutralizing and protective antibodies when used as immunogens 
(e.g. against RSV fusion protein). A protective neutralizing murine monoclonal anti- 
RSV antibody (mAb 19) was used to screen a solid phase combinatorial peptide 
library (Taylor, Stott et al. 1992). Five peptides were selected but none reacted with
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mAb 19 when used as free peptide, nor in a peptide ELISA, and none were able to 
inhibit the binding o f mAb 19 to the RSV antigen in a fluid phase assay. The five 
peptides were re-synthesized as peptide-TG resin complexes. Two o f the mimotopes, 
SI and S2, reacted strongly with mAb 19 when presented as resin-bound peptides and 
SI, but not S2, reacted strongly with the monoclonal antibody when synthesized as 
SPOTs peptides. In an attempt to improve the binding o f  mAb 19 with the two 
mimotopes, single amino acid substitutions at each position o f  the 8-mer were 
performed. 3 sequences were derived in this way from mimotope SI that showed 
increased binding with the monoclonal (SIS, S1K, and SIP). These three mimotopes 
were synthesized as multiple antigenic peptides (mAPs) and when BALB/c mice were 
co-immunized with the mAPs together with the promiscuous T-helper epitope from 
measles virus fusion protein, (aa 288-302) specific anti-peptide antibody was induced. 
These anti- peptide antibodies inhibited the binding o f  m Abl9 to RSV antigen and 
neutralized the virus with similar titres to those found in sera from RSV-infected 
animals (Chargelegue, Obeid et al. 1998).
In a similar approach using molecular mimicry, a phage display library was 
used to select mimotopes for HBsAg using human sera. Four mimotopes (0 13, 0 14, 0 
17 a nd 0 3 0) w ere s elected b y screening t he p hage 1 ibrary w ith s era from s elected 
patients and the 0 35 mimotope was identified using a monoclonal antibody (Meola, 
Delmastro et al. 1995). Sera from C57BL/6 and BALB/c mice, two groups o f  rabbits 
immunized with these mimotopes and sera from patients reacted with the mimotope. 
Sera from healthy control individuals did not react. Furthermore, the anti-mimotope 
sera reacted with HBsAg.
Similar protective mimotopcs have been identified in the F protein of measles virus 
(MV). A panel o f  six mimotopes o f  an epitope recognized by a monoclonal antibody 
to the F protein o f MV was identified using a solid-phase 8-mer random combinatorial
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peptide 1 ibrary. T he 8 -mer m imotopes s elected from t he 1 ibrary w ere b ound b y t he 
monoclonal antibody with different relative affinities using an inhibition 
immunoassay. Affinity o f  the binding ranged from 1.1 x 102 to 1.26 x 106 M '.T he six 
peptides were not immunogenic on their own, but following co-immunization o f  
BALB/c m ice with the individual mimotopes and a T-helper epitope peptide from the 
fusion protein (F) o f  MV, anti-mimotope antibodies were induced with affinities for 
their homologous peptides ranging from 8.9 x 10s to 4.5 x 107 M'1. However, only one 
o f  the anti-mimotope antibodies (to mimotope 2) cross-reacted with MV in an ELISA 
and inhibited MV plaque formation (Shaw, Stanley et al. 1993; Obeid, Partidos et al. 
1995) (Partidos and Steward 1992; Olszewska, Obeid et al. 2000) (Steward 1997).
A p anel o f f  our m imotopes o f  a n e pitope r ecognized b y a h ighly p rotective 
monoclonal antibody against Schistosoma mansoni (152-66-9B) was obtained by 
screening the solid-phase 8mer random peptide library (Amon, Tarrab-Hazdai et al. 
2000). Three of the four mimotopes (p28, p29 and p30) were efficiently recognized in 
an in vitro radioimmunoassay by the monoclonal antibody and by sera from infected 
mice. One mimotope, (p30) induced in vitro proliferation o f  primed lymphocytes. 
When the mimotopes were conjugated to bovine serum albumin (BSA) and the 
conjugates used to immunize C57B1/6J mice, only the p30-BSA induced antibodies 
that were effective at complement-mediated killing o f  schistosomula (Amon, Tarrab- 
Hazdai et al. 2000).
The potential for the use o f  the mimotopes extends to fields other than 
synthetic vaccines. The approach h as b een used to  identify and mimic receptors or  
binding sites such as TNF-a and chemokine receptor CCR5 which works as a co 
receptor for macrophage (m)-tropic (or R5) strains o f  HIV-1.Two mAbs to CCR5 , 
were used to screen a cysteine constrained phage library in a search for mimotopes o f  
CCR5.Two mimotopes were identified. Both mimotopes and synthetic peptides
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reacted with the corresponding antibody, synthetic peptides inhibited antibody binding 
to the phagotope. The synthetic peptides corresponding to the phagotopes also showed 
a CD4-dependent reactivity with gp 120 of a primary-m-tropic HIV-1 isolate (Konigs, 
Rowley et al. 2000).
In an attempt to mimic the conformational characteristics o f  the TNF-a 
receptor binding site, a phage library displaying 15-mer random peptide sequences as 
fusions a 11 he a mino t erminus o f  t he c oat p rotein p III was t ested w ith r ecombinant 
human TNF-a bound onto polystyrene beads. 40 randomly selected phage clones were 
amplified and tested for their ability to inhibit mouseTNF- a. Only 5 clones inhibited 
the apoptotic effect o f  TNF-a. in vitro. Sequencing o f  their peptide inserts yielded 2 
sequences which did not exhibit any homology with the primary structures o f  the 
human or the mouse TNF-q 55 kDa and 75 kDa receptors. The two mimotopes were 
then synthesized and tested for their ability to inhibit the cytotoxic activity o f  TNF-a 
onto L929 cells. The mimotope corresponding to clone DEF was effective in 
inhibiting both the mouse of TNF-a, and the human TNF-a. The mimotope 
corresponding to the phage clone B13 had lost its activity (Chirinos-Rojas, Steward et 
al. 1998).
BSW17 is a mouse anti-human IgE monoclonal antibody, which recognizes a 
receptor bound-IgE without inducing inflammatory mediator release (Rudolf, Vogel 
et al. 1998). Immune complexes o f  IgE and BSW17 did not bind to the IgE receptor 
(Fc€RI). Isolation o f  a mimotope for BSW17 was achieved only when a random nona- 
peptide library in which the peptides were displayed as circular loops held together by 
a disulphide bond was used. The amino acid sequence o f  the BSW17 mimotope was 
not present within the primary sequence o f  the IgE molecule. Furthermore, reduction 
of the disulphide bonds destroyed the reactivity o f BSW17 with the mimotope, which 
confirms its conformational nature. Binding inhibition studies carried out using
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synthetic peptides and phage-displayed mimotope confirmed the specificity o f the 
mimotope as an epitope for BSW17. Immunizing rabbits with mimotope induced anti- 
IgE antibodies which were inhibited by BSW17 (Rudolf, Vogel et al. 1998).
The identification o f mimotopes can also provide reagents that can be used for 
diagnostic assays.
To identify a candidate diagnostic for Lyme disease (LD),biotinylated IgG 
samples from ten positive and ten negative sera were used to probe a a 12-mer random 
phage display library and 17 peptides were selected. Four o f  the peptides reacted well 
with all the ten positive sera and very weakly, or not at all, with the negative sera. 
These four peptides therefore may well be of value as diagnostic antigens 
(Kouzmitcheva, Petrenko et al. 2001).
In systemic lupus erythematosus (SLE), a peptide mimic was selected using 
patients’ sera to screen a phage display library. The peptide identified was bound by 
both anti-dsDNA and anti-ssDNA antibodies from SLE sera, suggesting that the 
mimotope shares an antigenic structure with both ssDNA and dsDNA and that, SLE 
anti-DNA antibodies are cross-reactive. Therefore, the SLE mimotope has potential 
for use as a diagnostic candidate and/ or therapeutic agent (Sun, Fong et al. 2001).
Because o f  the complexity and low abundance o f  epitopes presented on 
tumours, the identification o f  these epitopes is very difficult, particularly since the 
proteins concerned are unknown. Therefore, mimotopes may have therapeutic 
potential in cancer immunotherapy. A combinatorial peptide library has been used to 
identify two CTL mimotopes specific for the EL4 mouse lymphoma. Two peptides 
were identified that mimic an H-2Db and an H-2Kb restricted CTL epitope. 
Immunization o f  mice with the mimotopes mixed with incomplete Freund’s adjuvant 
elicited CTLs that lysed EL4 cells, but immunization with the mimotopes had no 
therapeutic effect on tumors that existed already. Both o f  the mimotopes needed a T-
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helper epitope to be included in the immunization to induce a CTL response and 
immunization o f H-2Db mice resulted in the induction o f  a protective immune 
response against challenge with EL4 cells (Tirosh, el-Shami et al. 1999).
PS (Polysaccharide) conjugates are now being used to induce anti­
polysaccharide antibodies a nd t his a pproach i s the b asis o f  t he s ome v ery e ffective 
anti-bacterial vaccines (Valadon, Nussbaum et al. 1998). Conjugating PS to a carrier 
protein converts the antigen from a thymus independent antigen (Tl) to a thymus 
dependent antigen (TD). A major limitation to the use o f  carbohydrate -based 
vaccines is the difficulty o f designing the oligosaccharides that are known to induce 
protective antibodies. A s a  result, research has been focused on identifying peptide 
mimics of carbohydrate antigens and to use these as surrogate antigens for use as 
vaccines (Valadon, Nussbaum et al. 1998).
Mab 2E9 is a human monoclonal antibody to GXM (Cryptococcus neoformans 
capsular polysaccharide glucuronoxylomannan). 2E9 has shown to be protective in 
animal models o f cryptococcosis and shares an idiotype (Id) with antibodies to GXM 
found in human sera. 2E9 was used to screen a peptide library and this resulted in the 
identification a peptide mimic o f  the GXM epitope it recognized (PI 3). Immunization 
of BALB/c mice with P13 presented as three different conjugates (coupled to BSA, 
tetanus toxoid (TT), or to BSA2) resulted in the production o f  three populations o f  
protective antibodies:anti~GXM antibodies; anti-P13 antibodies and antibodies 
reactive with both PI 3 and GXM (Valadon, Nussbaum et al. 1998).
There are several more mimotopes that have been shown to be useful as 
potential vaccine candidates and these are listed in Table 5.1.
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5.1.2 RSV Human monoclonal antibody (RF2)
Problems with the use o f  murine Mabs in humans derive from their short circulating 
half-life when used therapeutically and the association with serious_serum sickness or 
type III h ypersensitivity,_particularly in situations where a second administration o f  
the antibody is needed. Murine Mabs also have limited functional activity in humans, 
which reduces their effectiveness in viral clearance. By comparison, human Mabs 
function optimally in man since they are predominantly non-immunogenic, and they 
have longer serum half- lives than their murine counterparts. Thus, producing MAbs 
from B cells from individuals who have appropriate anti-viral immunity could provide 
a potentially valuable source o f  therapeutic antibodies (Chamat, Walsh et al. 1999).
For the experiments described in this chapter, a human monoclonal antibody 
(RF2) specific for a conformational epitope on human RSV was kindly provided by  
Dr.P.Brams, IDEC Pharmaceuticals, San Diego California. The antibody was isolated 
from a spontaneous abdominal tumour in a severe combined immunodeficient mouse 
(SCID) that had been reconstituted with human spleen cells from a single donor with 
idiopathic thrombocytopanic purpura and then boosted with F protein o f RSV. The 
tumour was shown to have developed spontaneously as EB  F-transformed human B  
cells. The tumor cells expanded rapidly in culture were stable for more than 18 
months and secreted high levels o f  specific human anti-RSV monoclonal antibody. 
Antibodies were purified from supernatants by adsorption to a protein A Sepharose 4B  
column and the protein A-bound IgG was eluted with citrate buffer, pH 3.5. RF2 w as  
of the human (yi,/r) isotype subclass and recognizes a conformational epitope as it 
requires both 48K and 23K disulphide-linked fragments o f the F protein for 
recognition when immunoblotted (Chamat, Walsh et al. 1999).
In the work described here, Mab RF2 was used to screen a solid phase 
combinatorial peptide library in an attempt to identify mimotopes o f the
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conformational epitope recognized by the antibody. The library was synthesized using 
the Novasyn TG resin and consisted o f  2.8x106 8-mer peptides (containing all natural 
amino acids except cysteine) per gram of resin (Hsu, Shaw et al. 1995) as described in 
Chapter 2.
5.1.4 The biological significance of antibody affinity
Affinity is the term that defines the quality o f the binding between an Ag and its 
paratope (a single binding site on the antibody molecule) and it determines the ability 
of the antibodies to form a stable complex with the antigen. When a B cell encounters 
antigen, it starts a clonal expansion process producing cells that share the same B-cell 
receptor (BCR) and subsequently plasma cells that produce antibodies with the same 
antigen-binding site. Affinity maturation occurs during the development o f  the 
antibody response as a result o f mutation o f  the genes o f the variable region in the 
DNA encoding the hyper variable regions that result in the production o f  cell 
receptors o f  better or increasing affinity for selection by antigens to produce a higher 
affinity antibody response.
It was Heidelberger and Kendall in 1935 who first demonstrated the 
progressive change in the quality o f the antibody response to albumin which occurs 
with time after immunization. They observed the rapid production o f high affinity 
antibody in secondary responses. There is now a substantial body of literature that 
demonstrates the superiority o f  high affinity antibody compared to low affinity 
antibody in a number of biological reactions and indicates the importance and 
biological significance of affinity maturation. It is very clear that the affinity markedly 
influences the biological function and effectiveness o f antibodies. Therefore, the 
production o f high affinity antibody is an advantage to the host, since immunity 
provided b y s uch a  ntibody i s m ore e ffective t han t hat p rovided b y a 1 ower a ffinity 
response.
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As the production o f  antibody responses o f high affinity is likely to be more 
effective in vivo than antibodies o f low affinity, certain diseases may be associated 
with the production o f  antibody o f a particular affinity. Early work that supported this 
view was the observation that low affinity antibody production was associated with 
susceptibility to chronic immune complex disease in mice (Steward 1976) (Steward 
1979) (Steward 1979) (Steward 2001) (Partidos and Steward 2002).
Evidence obtained subsequently from several laboratories as demonstrated the 
association o f  the production o f  an antibody response o f a particular affinity with the 
susceptibility to disease.
5.1.5 Affinity maturation
The observed rapid production o f high affinity antibody in secondary responses to the 
antigen and the greater biological effectiveness o f the high affinity antibodies 
compared to low affinity antibodies suggests that a mechanism o f selection does exist.
Two theories to account for affinity maturation have been proposed:
The first theory was that early after immunization, a large amount o f  free antigen is 
present in the circulation which binds to high affinity antibodies resulting in their 
removal from the circulation, leaving only low affinity antibodies will be able for 
binding . As antigen becomes limiting, free high affinity antibody becomes available 
in the circulation. According to this theory, the affinity characteristic is the same 
throughout the period o f  response to the antigen and the observed differences in 
affinity following immunization arise simply from the selective adsorption, by  
antigen, o f  the highest affinity antibody.
The second theory for affinity maturation is that early in the response to 
antigen when there is a lot o f antigen present, all antigen-specific antibody cell 
receptors can bind antigen irrespective o f  their affinity. Thus, the average affinity o f  
the antibody produced by these cells will be low. As antigen becomes limiting, the
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higher affinity receptors have an advantage over those of lower affinity to bind the 
limited antigen and are thus stimulated. Low affinity receptor-bearing cells are not 
triggered to produce antibody and the result is that the affinity o f  the antibody 
response increases. Thus in the early response, antibody producing cells produce low 
affinity antibody and later, predominantly high affinity antibody is produced. This 
later theory was supported by results derived from experiments measuring the affinity 
of antibodies produced by lymphoid cells from immunized animals in vitro in the 
absence of antigen. Cells obtained early after immunization produced lower affinity 
antibodies than the antibodies produced by cells obtained from animals later after the 
immunization. It was also demonstrated that rabbits immunized with low doses of 
antigen produced higher affinity antibody in vitro than did cells from animals 
immunized with higher antigen doses.
The process of B-cell affinity maturation takes place in the germinal centers. 
After a B cell encounters antigen, it migrates t o  the primary follicles and begins a 
rapid mitosis producing clones of cells synthesizing the same B-cell receptor BCR 
and, eventually, secreting antibodies with the same binding site. This is associated 
with somatic or /  and point mutations o f the I g  genes, those occurring in the DNA 
encoding the hypervariable regions may generate a binding site with increased affinity 
for its epitope. The result is affinity maturation, the production o f antibodies of 
progressively increasing affinity for the antigen.
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M im otope identified R eference
Hepatitis B virus envelope protein (Meola, Delmastro et al. 1995)
Measles fusion protein (Steward, Stanley et al. 1995)
P la sm o d iu m  fa lc ip a r u m (Stoute, Ballou et al. 1995)
circumsporozite surface protein
Hepatitis A virus capsid protein (Mattioli, Imberti et al. 1995)
Hepatitis C virus (Prezzi, Nuzzo et al. 1996)
Respiratory Syncytial Virus (Chargelegue, Obeid et al. 1998)
fusion protein
Binding site o f the TNF-alpha (Chimos-Rojas et a l , 1997)
receptor
Measles virus haemagglutinin (HI Kasmi, Deroo et al. 1999)
CTL mimotope o f  Lymphoma E4 (Tirosh, el-Shami et al. 1999)
anti- IgE (Rudolf, Vogel et al. 1998)
Chemokine receptor CCR5
binding site o f gp 120 (Konigs, Rowley et al. 2000)
S c h is to so m a  m o n so n i (Anton, Tarrab-Hazdai et al. 2000)
dsDNA of ( S L E ) (Sun, Fong et al. 2001)
Diagnostic mimotope o f LD (Kouzmitcheva, Petrenko et al. 2001)
Surrogate Ag o f carbohydrates in (Monzavi-Karbassi, Cunto-Amesty et
vaccine al. 2002)
Table 5.1
Summary of som e o f the published research on mimotopes
5.2 Results
5.2.1 Reactivity of Human monoclonal anti-RSV (RF2) with RSV antigen
(RSV/Ag)
Before using the antibody RF2, its reactivity with RSV antigen was confirmed using 
an ELISA. RF2 was titrated against the RSV antigen (Biogenesis) starting at a 1:100 
dilution o f 64 mg/pl antibody. The results showed that RF2 gives a consistent OD 
reading o f  between 1.6-1.8 at A 490 nm at dilutions o f 1/100-1/10000 and the titre of 
this sample dilution was logi0 7.7 (Figure 5.1)
5.2.2 Reactivity of human monoclonal antibody RT-2 with a panel of 55 
overlapping peptides of the F protein of RSV.
The ability o f  RF2 to bind to linear peptides from RSV F was assessed b y  ELISA 
using a panel o f  55 overlapping peptides representing the F protein o f  RSV. The 
antibodies were used at a starting dilution o f  1/100 and a human serum that had been 
absorbed with the RSV/ Ag was used as a negative control. The results obtained show 
that RF2 did not recognize any o f the 55 linear peptides, (OD values < 0.2 at dilutions 
of 1:100) which appear to confirm that it recognizes a conformationally determined 
epitope on the protein (data not shown).
151
5.2.3 The sequence of the mimotopes selected from screening the peptide 
library with RF2
Following the screening o f  the combinatorial peptide library with antibody RF2, three 
strongly-stained beads were obtained and the amino acid sequence was determined by 
micro-sequencing. The sequences obtained were as follows:
M imotope R H 1 YPKRKHAD 
Mimotope RH  2  IHRAKRKW 
M im otope RH 3  VKPKFVYM
5.2.4 Reactivity of RF2 with the mimotopes RH 1, RH2, RH3 in ELISA
Mimotopes RH1, RH2, RH3 were synthesized as described in Chapter 2 and RF2 was 
tested against the three mimotopes in an ELISA (Figure 5.2) at the same dilution as 
was used for the screening o f  the peptide library. RF2 was used at a starting dilution 
o f 1/100 and ELISA plates were coated with the three mimotopes at 5mg/ml in 
carbonate/bicarbonate buffer. None o f  the mimotopes showed binding by the antibody 
that was significantly above background levels when they were bound to the solid 
phase in ELISA.
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Figure 5.1
Binding of human monoclonal anti-RSV RF2 to RSV antigen in ELISA. The OD shown is the 
maen o f 2 OD readings
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Figure 5.2
Binding of the three mimotopes RH1, 2, and 3 by RF2 in ELISA.
RF2 was used at a starting dilution o f  1/100 and ELISA plates were coated with the three 
mimotopes at 5mg/ml in carbonate /bicarbonate buffer. The OD shown is the maen o f  2 
OD readings.
154
5.2.5 Reactivity of adult human sera with mimotopes of conformational 
epitopes of the F protein
In the studies described here, two monoclonal antibodies were used to screen a 
random solid phase peptide library to identify mimotopes of the conformational 
epitopes:
1. The murine monoclonal anti-RSV F antibody (Mab 19) and
2. The human anti-RSV F antibody (RF2).
Two mimotopes recognized by Mab 19 (M l and M2 originally called SI /S2 
(Chargelegue, Obeid et al. 1998) and three mimotopes recognized by Mab RF2 (RH1, 
RH2, and RH3) identified in this study.
5.2.5.1 Reactivity of human anti-RSV sera with mimotopes of Mab 19 
(M l, M2)
The panel of nine adult human sera, were used in ELISA assays to determine their 
ability to recognize the mimotopes Ml and M2. The sequence o f mimotope Ml was 
HWS1SKPQ and that o f mimotope M2 was HdWSISKPQ. They thus differ only in 
that M2 has a D-amino acid at position 2 (Chargelegue et al, personal communication) 
Sera were used at 1/100 dilution and samples were run in duplicate. The results 
(Figure 5.3) show that all the sera bound to both Ml and M2 but the binding to M2 
was slightly higher.
5.2.5.2 Reactivity of human anti-RSV sera with mimotopes recognized by 
the human Mob RF2 (RH1, 2,3)
The nine adult human sera were used in ELISA assays to determine their ability to 
recognize the mimotopes o f the conformational RSV F epitope recognized by the 
human monoclonal anti-RSV antibody RF2 (RH1, RH2, and RH3). Doubling 
dilutions of the sera were used, starting at 1/100 dilution and samples were run in 
duplicate. Two o f the human adult sera (D and I) bound mimotope RH2 with an OD
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that was twice the cut o ff  and one adult serum (I) bound to the mimotope RH1 with a 
value higher than cut o ff  at 1/200 dilution. None o f the adult human sera bound to 
mimotope RH3 with OD values that were greater than 2 times the cut off (Figure 5.4).
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Figure 5.3.
Reactivity o f human anti-RSV sera with mimotopes of Mab 19. The OD ihown if the maen of 2 
O D readings. Sera were used at a dllutionl/100
Figure SJ.a. Binding of M l mimotope o f  RSV by 9 o f the human adult sera 
Figure S 3 , b. Binding of M2 mimotope o f  RSV by 9 o f  the human adult sera
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Figure 5.4.a
Binding of RH1 mimotope of RSV by 9 of the human adult sera. The OD shown is the maen of 2 
OD readings.
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Figure.5.4. b
Binding o f RH2 mimotope o f RSV by 4 o f the human adult sera The OD shown is the maen of 2 
OD readings.
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Figure 5.4.c
Reactivity of human anti-RSV sera with mimotope RH3 with the nine adult human sera The OD 
shown is the maen of 2 OD readings.
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In an attempt to enhance the binding o f  RF2 to the 3 mimotopes selected by the 
combinatorial library the three mimotope sequences were re-synthesized using the 
SPOTs system in which each amino acid in the mimotope sequences was replaced by 
glycine. 8 peptides were generated for each mimotope and their reactivity with RF2 at 
a dilution o f  1/10,000 was assessed. The OD data were analyzed with the (image J) 
software.
Substitution of the amino acids in mimotope RH1 with glycine did not 
negatively affect binding o f RF2 to any o f  the generated peptides. However, the 
results in Figure 5.5 and 5.6 suggest that replacement o f  amino acids in peptides 5, 6, 
7 (arginine 4, lysine 5, histidine 6) with glycine actually enhances the binding o f  RF2 
toRH l.
Substitution o f the amino acids in mimotope RH2 with glycine shows that 
arginine 3, alanine 4, and lysine7 are important contact amino acids for the binding of 
RF2 to RH2, since replacement of these amino acids inhibited or reduced binding 
activity o f  RF2 to peptides 13, 14, and 17.
When valine 6, tyrosine7, and methionine 8 were replaced with glycine in 
mimotope RH3, binding o f RF2 to peptides 25, and 26 was lost and the binding of 
RF2 to RH3 to peptide 27 was reduced.
5.2.6 SPOTs synthesis of mimotopes RH1, RH2, RH3
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9 8 7 6 5 4 3 2 1
RH1 
RH2 
RH3
27 26 25 24 23 22 21 20 19
Figure 5.5
RHI, RH2, RH3-mimotopes synthesized as Spots peptides screened with RF2 Mab
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Spot(peptide number)
t T t
Original Original Original
Figure 5.6
Reactivity o f RF2 to spots expressed as area-
The histogram was generated from data shown in Figure 5.5.
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Spot
number
Sequence
1 IHRAKRKW
2 G H R A K R K W
3 IG RAKR KW
4 IH G A K R K W
5 IH R G K R K W
6 IH R A G R K W
7 1H R A K G K W
8 IH R AKRG W
9 IH R AKRKG
10 YPKRKHAD
11 G PKR KH A D
12 Y P G R K H A D
13 YPKGKH AD
14 YPKRGH AD
IS Y P K R K G A D
16 Y P K R K H G D
17 YPKRK H AG
18 Y P K R K H A D
19 VKPKFVYM
20 G K P K FV Y M
21 V G P K FV Y M
22 V K G K F V Y M
23 V K P G FV Y M
24 V K P K G V Y M
25 VKPKFG YM
26 VK PKFV G M
27 VK PKFV YG
Table S.2
T he amino acid sequences of each spot (peptide).
The original mimotopc sequences are highlighted. Sequences o f the peptides that 
affected by the amino acid substitution are in bold and italic font.
Preliminary results (Figures 5.5 and 5.6) from glycine substitutions in the RSVF 
mimotopes highlighted how a single amino acid replacement in the peptide sequence 
could influence the binding o f  Mab RF2 either by enhancing, reducing, or even 
inhibiting the binding. Therefore, in order to identify the contact residues in 
mimotopes RH1/2/3, a series o f  peptides was generated from each o f  the RH1/2/3 
mimotope sequences in which each amino acid was systematically replaced by all the 
possible amino acids at each amino acid position. The original mimotope was 
repeatedly included among the substituted peptides as a positive control. A human 
monoclonal antibody to HIV-1 gpl20 (GP68) was used to screen all the SPOTs assays 
as a negative control. Results were first analyzed visually as shown in Figures 5.7, 5.9, 
and 5.11, w here t he results a re r epresented i n t he f  orm o f  graded grey scale b oxes 
n z n z m m m m . The black box represents the strongest binding and the 
white box represents the lowest binding achieved between the Mab and the 
synthesized mimotope according to visual analysis. The sequences o f  the original and 
the substituted peptides are listed in Figures 5.8, 5.10, and 5.12. Results in parallel 
were analyzed using Total Lab Array, a software product that was developed 
specifically for analyzing microtitre plate images, grided arrays, dots and slot blots. 
The software defines the area o f  each spot, calibrates their quantity o f material and 
produces measurement data. It reads each individual digital pixel within the area of 
the tested defined spot and then expresses the data as a total volume o f the individual 
spot according to the density o f  the staining and also as a total volume. The spot 
representing the negative control was defined and this volume was subtracted from the 
total volume o f  the tested spots. The cut-off value was considered to be the highest 
volume achieved among the spots representing the original mimotope sequence. 
Accordingly, any value below this cut o ff  represents a reduction o f  the binding, and
5.2.7 Systematic substitutions of amino acids in RH1, 2, and 3.
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values twice the cut off represent enhancement of the binding. This analysis o f the 
data was dependent on both the visual assessment and the use o f the total array 
software.
RH1
Results from the systematic substitution in each position were not consistent with the 
results obtained with the glycine substitutions o f RH1 shown previously (Figure 5.5, 
and 5.6). In the experiments here, a negative effect on binding o f RF2 to RH1 was 
only observed when arginine 4 was substituted with glycine (peptide 66) whereas in 
the previous experiments, this showed enhancement o f the binding. However, earlier 
results were confirmed with the enhancement o f binding seen when histidine 6 was 
replaced with glycine in peptide 107 (volume reading was equal to the volume o f the 
average positive peptide tested). This confirms the data shown in Section 5.2.4. The 
substitution o f  tyrosine 1 showed an increase in the binding o f  RF2 to RH1 when it 
was replaced with cysteine (peptide 2), lysine (peptide 10), tyrosine (peptide 17), 
valine (peptide 18).
A reduction o f  RF2 binding to RH2 was seen when tyrosine 1 it was replaced with 
glutamic acid (peptide 4), methionine (peptide 11), and asparagine (peptide 12). An 
enhancement of the binding was observed when proline 2 was substituted with 
phenylalanine (peptide 25), arginine (peptide 35), serine (peptide 36), tryptophan 
(peptide 39) and tyrosine (peptide 40).Whilst the binding was inhibited when proline 2 
was replaced with either aspartic acid (peptide 23), glutamic acid (peptide 24), or 
aspargine (peptide 32). Substitutions o f leucine 3 did not result in enhancement o f  
binding. In fact, when leucine 3 was replaced with alanine (peptide 41) or cysteine 
(peptide 42). A further 7 out o f  the 20 peptides showed a decrease in the level o f  
binding by RF2 (47, 48, 50, 53, 54, 57, and 58) in which leucine 3 was substituted. 
Similar results were obtained for substitutions o f arginine 4 where 10 out o f  20
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Figure 5.7
Systematic substitution in RH1.
Circles In yellow Indicate the original sequence of the mimotope; red circles represent the 
negative control (unrelated sequence)
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82 YPKRAHAD residue 1 122 YPKRKHAD
83 YPKRCHAD u 123 YPKRKHCD
84 YPKKCHAD 124 y p k r k h d
85 YPKREHAD 125 m a r n i  -
86 YPKRFHAD 126 YPKRKHFD
87 YPKRCHAD 127 YPKRKHCD
88 YPKRHHAD 128 YPKRKHHD
89 YPKRIHAD 129 YFKRKHZD
90 YPKRKHAD 130 YPKRKHKD
91 YPKRIHAD 131 YPKRKHLD
92 Y F W H D 132 YPKRKFfO
93 YPKKNHAD 133 YPKRKHM3
94 YPKRPHAD 134 YPKRKHFD
95 YPKRÜHAD 135 YPKRKHJJ
9b YPKRKHAD 136 YPKRKHRD
97 YPKRSHAD 137 YPKRKHSD
98 YPKKTHAD 138 YI’KRK} flT)
99 YPKRVHAD 139 YPKRKHVD
100 YPKFWHAD 140 m a r n e
M YPKRYHAD 141 YPKRKHYD
102 YPKRKAAD residue 2 142 YPKRKHAA
103 Yl ’KPKf 'AI V 143 YFKRKHAC’
104 YPKRKFflD 144 YPKRKHAD
105 YPKRKEAD 145 YPKRKHAE
106 YPKRKFAD 146 YPKRKHAF
107 YPKRKGAD 147 YPKRKHAG
108 YPKRKHAD 148 YPKRKHAH
KW YI’KRK 1 Al 149 YPKRKHAI
110 YPKKKKAD 150 YPKRKHAK
III r a m a *  ■ 151 YPKRKHAL
112 YPKRKMAD 152 YPKRKHAM
113 YPKRKNAD 153 YPKRKHAN
114 YPKRKPAD 154 YPKRKHAP
115 YPKRKQAD 155 YFKRKHAO
116 YPKKKRAI - 156 YPKRKHAK
117 YPKRKHAD 157 YPKRKHAH
118 YI’KPKTAI 158 YPKRKHKT
119 YPKRKVAD 159 YPKRKHAV
120 YPKRKWAD 160 YPKRKHAW
121 YPKRKYAD 161 YPKKKHAY
162 MYVFKFKV
toAHudnimr
nsudue 3
u
HesoMdnpiu
The wquencaa of the original and Ih« lubitltutcd pepili!r> In mlmotopc KHI
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RH2
Earlier data (Section 5.2.4) indicated that arginine 3, alanine 4 and lysine 7 are 
important contact residues for the binding of RF2 to RH2. Results shown in this 
section confirm that lysine 7 is an important contact residue for RH2 as the 
replacement of this amino acid inhibited the binding o f  RF2 to the substituted peptides 
(123,125,133, and 136). The binding by RF2 was also inhibited in the following 
peptides (83,104,105,106,113,142,149,153,156) which may indicate that lysine 5; 
arginine 6, lysine 7, and tryptophan 8 are contact residues for RH2 although by visual 
inspection, an improvement o f the binding by RF2 to several newly generated 
peptides can be observed. However, when total array software analysis was carried 
out, the cut off was quite high, and subsequently only peptides 9, 102, and 103 were 
considered to have improvement in the binding to RF2 where isoleucine 1 was 
replaced with lysine or arginine 6 was replaced with either alanine or cysteine 
(Peptide 9,102,103). It was very difficult to determine which peptides showed a 
reduction in the binding by RF2, again because o f  the high cut off value.
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Figure  34 F i gu re  33
K i l l  i  R N 3  b
Figure 5.9
Systematic substitution in RH2.
Circles in yellow indicate the original sequence of the mimotope; red circles represent the 
negative control (unrelated sequence)
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88 IHRAHRKW
89 IHRAIRKW
90 IHRAKRKW
91 IHRAIRKW
92 IHRAM^KW
93 IHRANRKW
94 IHRAFRKW
95 IHRACRKW
96 IHRARRKW
97 IHRASRKW
98 IHRATRKW
99 IHRAVRKW 
UK) IHRAWRKW
K)l IHRAYRKW ______
102 IHRAKAKW reidu:2
103 IHRAKCKW U 
KM IHRAKDKW
105 IHRAKKKW 
K)6 IHRAKFKW 
KT7 IHRAKGKW
108 IHRAKHKW
109 IHRAKIKW
110 IHRAKKKW
111 IHRAKIRW
112 IHRAKMKW
113 IHRAKNKW
114 IHRAKFKW
115 IHRAKUKW
116 IHRAKRKW
117 IHRAKSKW
118 IHRAKTKW
119 IHRAKVKW
120 IHRAKWKW
121 IHRAKYKW
122 IHRAKRAW
123 IHRAKRCW
124 IHRAKRDW
125 IHRAKREW
126 IHRAKRFW
127 IHRAKRGW
128 IHRAKRHW
129 IHRAKRIW
130 IHRAKRKW
131 IHRAKRLW
132 IHRAKFJ4W
133 IHRAKKNW
1.34 IHRAKRFW
135 IHRAKRCW
¡36 IHRAKRFW
137 IHRAKRSW
138 IHRAKRIW
139 IHRAKRVW
140 IHRAKRW
Ml IHRAKKYW
142 IHRAKRKA
143 IHRAKRKC
144 IHRAKRKD
145 IHRAKRKE
146 IHRAKRKF
147 IHRAKRW3
148 IHRAKRKH
149 IHRAKRKI
ISO IHRAKRKK
151 IHRAKRKI,
1S2 IHRAKRKM
153 IHRAKRKN
154 IHRAKRKI1
155 IHRAKRKO
156 IHRAKRKR
157 IHRAKRKS
158 IHRAKRKT
159 IHRAKRKV
160 IHRAKRKW
161 IHRAKRKY
162 WKRKARHI
residue 3
u
Rcvcnul sojjcikc
Figure 5.10
The sequences of the original and the substituted peptides in mimotope RH2
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RH3
Replacement o f valinel by histidine (peptide 7), asparagine (peptide 12), serine 
(peptide 16) resulted in the enhancement o f the binding o f  RF2 to the newly RH3 
generated peptides. It should be noted, however, that when valinel was substituted by 
any other amino acid, the binding to RF2 was inhibited. Substitutions o f  lysine2 in 
RH3 resulted in enhancement o f the binding only when it was replaced with 
phenylalanine (peptide 25), or tryptophan (peptide 39). All other substitutions in 
position 2 either reduced or blocked the binding o f RF2 to mimotope RH3.
At position 3 (proline), substitution with either aspartic acid (peptide 43), 
methionine (peptide 51) or asparagine (peptide 52) resulted in an increased binding by 
RF2. All other substitutions at that position either blocked or decreased the binding. 
Any amino acid substitutions at lysine4 reduced the binding o f  RF2 to RH3 with the 
exception that replacement o f  lysine4 with threonine (peptide 77) enhanced the 
binding between RF2 and the generated peptide. Peptides generated from substitutions 
made between positions 5 to position 8 were excluded from the Final analysis because 
a possible technical fault in the synthesis process.
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Figure.S.11
Systematic substitution in RH3.
Circles In yellow indicate the original sequence of the mlmotope; red circles represent the 
negative control (unrelated sequence)
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Figurc S.12
The sequences of the original and the substituted peptides In mlmotope KH3
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Original sequence Substituted peptide sequence
RH1-Original sequence 
YPKRKHAD
R H  1 (Substituted peptide sequence)
R H la  YWKRKHAD
R H lb  YYKRKHAD
R H lc  YPK.RKSAD
RH2-Original sequence IHRAKRKW R H 2 -Substituted peptide sequence)
R H 2a KHRAKRKW
R H 2b IHRAKAKW
R H 2c IHRAK.CKW
RH3-Original sequence VKPKFVYM RH 3 (Substituted peptide sequence)
R H 3a VKDKFVYM
R H 3b VKNKFVYM
R H 3c VKPKFWYM
Table 53
The sequence o f  the mimotopes that showed increased reactivity with RF2 as a result o f amino 
acids substitutions.
175
5.2.9 Discussion
The reactivity o f  the panel of nine adult human sera with the two mimotopes (M 1, and 
M2) recognized by murine (Mab 19) was assessed by ELISA. The results showed that 
5 o f the 9 sera bound to Ml with OD value that was 2 times the cut off (0.2). Sera 
from all the 9 adult sera recognized M2 with significantly higher OD values than that 
seen with the binding to M l. The reactivity o f all the 9 human sera with M2 ranged 
between 3 times the cut o ff and 5 times the cut off (0.6-1 OD Aiwnm)- Suggesting that 
mimotope M2 may represent a potential candidate epitope for inclusion in a vaccine. 
This possibility was investigated by experiments described in Chapter 6.
The nine adult human sera were also used in ELISA assays to determine their 
ability to react with mimotopes RH1, RH2, and RH3 recognized by the human 
monoclonal anti-RSV antibody (RF2). Two o f the human adult sera bound mimotope 
RH2 with an OD 2 times the cut o ff  and one adult serum bound to the mimotope RH 1 
with a value higher than cut o ff at 1/200 dilution. None o f  the adult human sera bound 
to mimotope RH3 at a value 2 times the cut off. Work described in Chapter 6 tests the 
immunogenicity o f  the three mimotopes.
Analysis o f  the binding the adult sera to the mimotopes showed that 
mimotopes M l, M2, RH1, and RH2 could represent epitopes that may have 
importance in generating a protective antibody response. However, when the 
reactivity o f RF2 to the detected mimotopes was tested in ELISA no binding was 
detectable. This is possibly due to the conformation they adopt on binding to the solid 
phase in the ELISA plates. In order to improve the binding o f  RF2 to the identified 
mimotopes by presenting them in a more appropriate conformation to RF2, they were 
synthesized in the SPOTs system.
The substitution o f amino acids in the sequences o f  the detected mimotopes 
was performed in two stages. In the first stage, each amino acid in the 8-mer peptide
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sequence was replaced with glycine. In the second stage, every amino acid in the 8- 
mer sequence was systematically replaced by all 20 possible amino acid substitutions. 
In RH1 the results showed that proline 2 is potentially an important contact residue in 
the RH1 sequence for the binding by RF2, since replacing proline 2 with either 
aspartic acid (peptide 23), glutamic acid (peptide 24), or asparagine (peptide 32) 
resulted in inhibition o f  binding. Replacement of histidine 6 with glycine (peptide 
107) resulted in an enhancement o f the binding of RF2 to the peptide. The substitution 
of tyrosine 1 also resulted in an increase in the binding by RF2 when it was replaced 
with cysteine (peptide 2), lysine (peptide 10), tyrosine (peptide 17), and valine 
(peptide 18).
Data from the amino acid substitution in RH2 indicated that that lysine 7 is a potential 
contact residue for RH2 as the replacement o f this amino acid inhibited the binding of 
RF2 to peptides (123,125,133, and 136). The binding o f  RF2 was also blocked in the 
following peptides (83, 104, 105, 106, 113, 142, 149, 153, 156) which highlight that 
lysine 5; arginine 6, lysine 7, and tryptophan 8 m ay be contact residues for RH2 
although the visual inspection could falsely show improvement o f  the binding of RF2 
to several newly generated peptides (data summarized in Table 5.3).
Data obtained from substituting amino acids in the RH3 mimotope sequence 
indicated that residues 1-4 may be important contact residues where only in few 
peptides there was an increase in the binding. Unfortunately due to a technical mistake 
during the synthesis, all the substitutions made from position 5-8 were excluded from 
the analysis o f  the data and therefore nothing can be concluded here about these 
substitutions.
Although the results from the experiments described here support the 
suggestion that amino acid substitution in the mimotopes could enhance their potential 
as vaccine candidates, difficulties exist in assessing the data. The observation that the
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binding results with certain peptides were not consistent is a particular problem. These 
inconsistencies could have arisen from the relative insensitivity of the assay. 
However, the synthesis o f  so many peptides is very labour-intensive and the 
possibility o f  e rrors i n t he p rocedure c annot b e ruled o ut. T he d ata g enerated from 
these studies are summarized in Tables 5.4; 5.5 and 5.6.
Following the successful identification o f mimotopes bound by the human 
monoclonal anti-RSV antibody RF2, it was planned to make substitution o f each of 
the amino acids in their 8-mer sequence to look for enhancement binding by RF2. 
Amino acid substitutions o f  the mimotopes in the SPOTs system indicated that such 
changes a ffected b inding b y t he m onoclonal antibody a nd t his w as o bserved b y a n 
increase in density o f  the colour. (As measured by increased colour in the SPOTs 
system) (Table 5.3). It is important to know whether this increase in binding is a 
reflection o f  a n i ncrease i n a ntibody a ffinity. S everal m ethods a re available f  or t he 
measurement o f antibody affinity. In each method, a system is set in which antigen 
and antibody are allowed to come to equilibrium. Data from these systems are 
analyzed by applying the Law o f Mass Action to give the equilibrium (affinity) 
constant K. For this work, it was proposed to use the technique o f surface plasmon 
resonance (SPR) to determine the kinetics and affinity constant o f  the interaction o f  
Mab RF with peptide mimotopes using the Biacore. The mimotopes were to be mono- 
biotinylated, and w ill b e  bound to  streptavidin (Sigma) immobilized onto the CM5 
sensor chip on which the legends would be coupled by streptavidin -biotin coupling.
However, although preliminary experiments were preformed, time did not 
allow sufficient work to be performed to merit inclusion in this chapter.
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Mimotope Peptide number (Amino acid + 
original position
New amino acid 
substituted
RH2 83 Lysine 5 Cysteine
104 arginine 6 aspartic acid
105 ~ glutamic acid
106 ~ Phenylalanine
113 ~ Asparagine
123 Lysine 7 Cysteine
125 ~ glutamic acid
133 ~ Asparagine
136 ~ arginine
142 Tryptophan 8 Alanine
149 Isoleucine
153 Asparagine
156 Arginine
Table 5.3
Summary of amino acids substitutions in RH2
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Mimotopc sequence
Y P K R K H A D
A 1 1
C 1 A A A
D A A A A
E A A
F A A
G 1 A A
H i A A A
I A A A
K A A
L A A A A
M A A A A
N A A A A
P A A A
Q 1 A A
R A TH A
S TH
T t i X
V A A A
W A
Y
9
i  1.5 3
B <
Table 5.4
Summary o f the effects of amino add substitutions in mimotope RH1 using the total array 
software.
( t )  means enhancement in the binding by RF2. ( i )  is reduced binding compared to the 
original m im otope.. X -indicate a total block o f the binding .No sign means that the 
volume was equal to the average volume calculated. H is high.
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Mimotope sequence
I H R A K R K W
A A A A
C A A
D A A
E A A
F A
G A
H
I A
K A A
L
M A
N A A A A
P A A
Q A A
R A A
S A
T
V A
W A
Y
Table 5.5
Summary o f the effects o f  amino acid substitutions in mimotopc RH2 using the total array 
software.
( t )  means enhancement in the binding by RF2. (1) is reduced binding compared to the 
original m im otope.. X -indicate a total block of the binding .No sign means that the 
volume was equal to the average volume calculated.
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A
m
in
o 
ac
id
s
V K p K F V Y M
A 4 4
C X X t t
D X X t 4
E X X X t
F X t X 4
G X X 4
H T 4
I t 4 X 4
K X 4
L X 4 X 4
M X X T t
N t  V H X T 4
P X 4 4
Q X 4 1 4
R X 4 4 4
S T X 4 T
T t ; 4
V X 4 4
W X t 4 4
Y X T 4
Table 5.6
Summary or the effects o f amino add substitutions in mimotope RH3 using the total array 
software.
( | )  means enhancement in the binding by RF2. (j)  is reduced binding compared to the 
original mimotope. X -indicate a total block of the binding .No sign means that the 
volume was equal to the average volume calculated.
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CHAPTER 6
ASSESSMENT OF THE IMMUNOGENICITY OF  
LINEAR AND CONFORM ATIONAL EPITOPES FROM  
THE F PROTEIN O F  RSV 
6.1 Introduction
Although the severity o f  RSV disease declines with repeated infection, previous 
infection with the virus does not prevent disease and immunity remains incomplete. 
Virus- specific neutralizing antibodies, when administered prophylactically have been 
shown to protect against infection and disease in the mouse model o f RSV and in 
infants (Prince, Horswood et al. 1985). In animal models, a vaccine inducing 
neutralizing antibodies provided long term immunity (Prince, Horswood et al. 1985). 
Also in early infancy, levels of maternally-derived antibodies correlated with 
protection from RSV infection (Englund 1994). Therefore, developing an epitope- 
based synthetic peptide vaccine that includes appropriate epitopes to induce virus­
neutralizing antibodies against RSV would be a valid approach to developing a 
potential vaccine for human use. The conserved F protein is one o f the two major 
protective antigens o f  RSV (the other is the G protein) and induces protective 
antibody responses (Wertz, Stott et al. 1987). Therefore identification o f  epitopes 
defined by such protective antibodies would provide important information for the 
design of an effective epitope-based vaccine.
The potential o f  synthetic peptides as vaccines has been recognized for over 30 
years. Anderer (1967) was the first to show that synthetic peptides can induce 
antibodies with virus-neutralizing properties. Most synthetic peptides are good 
immunogens when presented appropriately to the immune system, and there is usually
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no difficulty in raising antibodies against them by standard immunization procedures. 
For example, work by Muller (Muller, Plaue et al. 1990) showed that immunization 
with free peptides o f a length o f 14-25 residues could lead to moderate antibody 
response after 2-3 injections. However in order to obtain anti-sera o f adequate titre, 4- 
5 injections were usually necessary.
Synthetic peptide vaccines have several potential advantages including:
■ They are inexpensive to produce;
■ They are easy to manufacture and purify;
■ They are stable and thus there is no need for cold chain maintenance;
■ They are not o f  a biological nature and are thus non -infectious;
■ They are o f  a chemical nature and thus have genetic and structural stability. 
Experimental peptide-based vaccines have been widely studied in the past. The 
effectiveness o f  linear peptides to induce humoral immune response and significant 
protection against infection in animals has been documented in measles. Partidos et al. 
showed that a chimeric peptide representing two copies o f  a T-cell epitope from the F 
fusion protein o f  measles virus (aa 288-304) coupled via a glycine-glycine spacer to a 
B-cell epitope also from F protein (aa 404-414) was immunogenic in several inbred 
strains o f mice. This peptide (TTB) induced high titres o f  peptide-and virus-specific 
antibodies (Partidos, Stanley et al. 1991).
Obeid et al.1995 tested the ability o f  immunization with TTB to induce a 
protective immune response against intra-cerebral challenge with neuro-adapted 
strains o f MV and canine distemper virus (CDV) in mice and showed that TTB 
induced a protective response against challenge with both MV and CDV. A significant 
reduction in mortality was demonstrated together with the absence o f  acute clinical 
encephalitis and histological absence o f  acute encephalitis. In TTB-immune mice, 
challenged with MV, a significant reduction in viral load in the brains was seen in
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comparison to that in the non-immunized but challenged control mice. In a subsequent 
study, a chimeric peptide composed o f one copy of the T-cell epitope and one copy of 
the B-cell epitope (TB), failed to induce a protective response. It was suggested that 
the differences in protective efficacy observed following immunization could be due 
to higher affinity o f the antibody being induced by the TTB peptide than that produced 
following immunity with the TB peptide. Also, differences in the immunoglobulin G 
subclass o f  the anti-peptide antibody responses were observed, which could also have 
contributed to the differences in protection seen (Obeid, Partidos et al. 1995).
In a later study by the sam e group Partidos et al. 1997, passive transfer o f  anti- 
TTB antibody to naive animals protected against MV-induced encephalitis. 
Immunization with the TTB peptide was shown to induce high affinity antibodies 
against the B-cell epitope 404-414. Immunization with the TT peptide covalently 
linked to a CTL epitope (aa52-aa60) from the MV nucleo-protein, induced strong 
CTL responses in mice (Partidos et al., 1997). Further work from the same group 
using sera from humans containing anti-MV antibodies (Atabani et al, 1997) identified 
an antigenic region from the F protein representing peptide aa 388-aa 402 (p32) that 
was located within the highly conserved, cysteine-rich domain o f the F protein of 
paramyxoviruses. T he e ntire 1 5-amino-acid s equence was r equired for high-affinity 
interaction with anti-MV antibodies. The peptide p32 was shown to be immunogenic 
in two strains o f  mice and induced anti-peptide antibodies that cross-reacted with MV 
and neutralized the virus in  vitro. In addition, antibodies to p32 conferred significant 
protection against MV-induced encephalitis when passively transferred to naive mice. 
Data from Obied et al. and those from other groups highlight that synthetic peptide 
vaccines have potential for use in young infants to overcome the suppressive effect o f  
maternally-transmitted anti-RSV antibodies. A cocktail o f peptides from the H protein
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of (MV) was able to induce anti-MV responses in neonates even in the presence o f  
maternally-derived anti-MV antibodies (Obeid and Steward 1994).
These studies, using defined peptides, whether linked to a carrier or used 
together with an adjuvant, highlight the ability o f  small linear peptides to be 
immunogenic. However, it is generally accepted that B-cell epitopes that induce 
protective antibody responses are usually conformational rather than linear in nature 
and thus in the work described in this chapter, an attempt will be made to mimic such 
a structure in the F protein o f  RSV. The immunogenicity o f these mimotopes will be 
assessed together with the immunogenicity o f linear B-cells epitopes were identified 
using human sera.
In Chapters 3 and 4, several linear B-cell epitopes were identified using the 
sera from 9 adults and 49 infants. Peptides 4, 8, 11, 14, 18, 24, 36, 41 were strongly 
recognized by the 9 adult sera. Analysis, o f the binding o f peptides by sera from the 
babies at various stages o f  infection showed that in sera from children with pre- and 
first infection samples only, peptide 4 was recognized by 45% o f the pre -infection 
sera and this value dropped to 18% in the primary sera after infection. Peptide 48 was 
also recognized by 46% o f  the sera and peptide 14 was recognized by 72% in both pre 
-infection and first infection. In samples from children with both primary and 
secondary infection. Peptides 19, 20, 32 and 48 were recognized by 50-60% o f the 
secondary infection sera. In children with samples o f  2 post infection sera with RSV 
Peptide 14 was recognized by 66% o f the pre-infection serum samples, by 81.4% of 
the sera following the primary infection with the virus and by 73% of the sera 
following the secondary infection with the virus. The pattern o f  peptide recognition 
varied according to the state of exposure to the virus but in all children, sera obtained 
following the second infection showed the highest levels o f peptide binding and 
peptides 4 and 14 were recognized strongly by sera from both adults and children.
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In the work described in Chapter 5, a human monoclonal antibody (RF2) that 
recognizes a conformational epitope on the fusion protein of HRSV was used to 
screen a combinatorial peptide library to identify mimotopes of this conformational 
epitope. These mimoptopes were identified (RH1, RH2, RH3). On the basis o f these 
results, both the linear B-cell epitopes and the mimotopes identified were used in vivo 
experiments to assess their ability to induce anti-peptide antibodies and to determine if 
these antibodies cross-react with RSV.
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6.2 Results
6.2.1 Antibody response following immunization with linear peptides
The immunogenicity o f the linear peptides: 4, 8, 11, 14, 19, 20, 24, 32, 36, 41, and 48 
was tested individually in groups of four o f  BALB/c mice. In all experiments, mice 
were sub-cutaneously co-immunised with 50pg of the linear peptide and 50pg o f TTB 
-peptide (to provide T-cell help) in complete Freund’s adjuvant (CFA).
Previously, Partidos et al. had shown that simple co-immunization o f  a non- 
immunogenic B-cell epitope with a peptide representing a Th epitope can induce 
antibody to the B-cell epitope. The co-immunization did not require covalent linkage 
of the two peptides and this approach has being used frequently in the lab therefore 
was adopted in this study (Partidos, Obeid et al. 1992). The animals were boosted by 
the same route with the same dose o f  the peptide alone inincomplete Freund’s 
adjuvant (1FA) three weeks later. Sera from the animals were collected from each 
mouse before boosting and then 20 days after the boost. The ability o f each peptide to 
induce antibody was assessed by direct peptide ELISA as described previously. Sera 
from the animals from each group were obtained before the start o f the experiment 
and used as a negative control for reactivity with both RSV Ag and the tested peptide 
in every assay. In addition, two positive controls were included: 1) sera from mice that 
had been intranasally immunised and challenged with RSV, and 2) RF2, the human 
monoclonal anti -RSV F antibody (see Chapter 2).
In preliminary studies, mice were immunised with peptides 11, 24, and 36, 
without including TTB as a source o f  T-cell help. Peptide 11 induced an antibody 
response (Figure 6.1) with titre of 2.2 for sera from mouse 1 and 2, and 1.9 for serum 
from mouse 3. No response was detected in any mouse even following boosting with 
the peptides 24, and 36 (data not shown). Therefore, in all subsequent immunisations,
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the individual peptides were co-immunised with peptide TTB for the induction of T- 
cell help.
Antibody response following immunization with peptide 4
IgG antibodies to peptide 4 were not detectable in the sera of the mice either after the 
first immunisation or after the boost, nor was there detectable reactivity with the RSV 
antigen either before or after the boost (data not shown).
Antibody response following immunization with peptide 8
Detectable levels o f  anti-peptide antibody were observed against peptide 8 at a 
dilution o f  1/10 in all mice and sera from two mice 1, and 4, had titres o f log i01.6 and
2.2, respectively (Figure 6.2). However, none of the sera from the four animals 
immunised with peptide 8 reacted with RSV Ag on the plate.
Antibody response following immunization with peptide 11
Sera from three o f the four immunized animals (2, 3, 4 ) showed antibody binding that 
was greater than the negative control at a dilution o f  1/10, and two of the sera had 
titres o f  2.5 and 2.8, respectively (Figure 6.3.a). However, none o f the peptide- 
immunized mice produced antibodies that cross-reacted with RSV (Figure 6.3.b).
Antibody response following immunization with peptides 14/19/ 20/ and
32
None o f  the sera from immunized with the peptides 14, 19, 20, and 32 had detectable 
anti-peptide or anti-RSV responses even after boosting (data not shown).
Antibody response following immunisation with peptide 24
Mice immunised with peptide 24 did not produce detectable anti-peptide antibodies. 
Interestingly, sera from animals 2 and 4 showed cross reactivity with the RSV antigen 
with an OD value at a dilution o f  1/10 that was twice that of the control negative 
serum (Figure 6.4).
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Antibody response following immunisation with peptide 36
Sera from mice immunised with peptide 36 did not show reactivity against the 
immunising peptide either from the second bleed (data not shown) or in the final 
bleed. However, as with sera from peptide 24 immunised mice, sera from 3 mice 
immunised and boosted with peptide 36 (animals 1, 2,4) cross -reacted with the RSV 
antigen with an OD value at a dilution o f 1/10 that was twice that o f  the control 
negative serum (Figure 6.5).
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1.2 A  490 nm pi 1/ Final bleed
1 □  serum 1 ■ serum 2 D serum 3 □ serum4 ■  (+ ) m (-)  S H m a b
0.6
0.8
0.4
0.2
0 In  2 d m  no
i 1.3 1.6 1.9 2.2
Log 10 dilution
RSV
Figure 6.1a
Immunoreactivity o f sera from mice immunized with peptide 11 following immunization in the 
absence o f TTB as source of T-cell help. The OD shown is the maen of 2 OO readings.
Antibody binding is shown as OD values at A <90. At various log |CI dilutions o f  sera from 
individual mice. Data shown are from the final bleed following boosting with the peptide 
only.(+) is the positive control used which is sera from mice challenged three times with 
RSV intranasally/(-) negative sera
Represents the HM ab RF2 which is used as a control for the assay for binding to
RSV
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1.2 A 490 nm pi 1/ Final bleed
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□ serum4
0.«
m(-)
0.4 QHmab
0.2
0
RSV
Figure 6.1 b
Reactivity o f  sera at 1:10 dilution with RSV antigen in the plate. The OD shown is the maen o f 2 
OD readings.
Data shown are from  the final bleed following boosting with the peptide only.
(+) is  the positive control pooled serum from mice challenged three times with RSV 
intranasally/. (-) is the negative control serum
Represents the HMab RF2 which is used as a control for the assay for binding to
RSV
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1.2 A 490 nm Peptide 8
1
Figure 6.2
Reactivity of sera from mice immunized w ith  peptide 8 against peptide 8 in ELISA. The OD  
shown is the maen o f  2 OD readings.
Antibody binding is shown as OD values at A 490 at various log 10 dilutions o f  sera from 
individual mice. (+) is the positive control used which is sera from mice challenged three 
times with RSV intranasally/(-) negative sera
Represents the HMab RF2 which is used as a control for the assay for binding to
RSV
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1.2 A 490 nm Peptide 11
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□ serum 1 ■  serum2 □ serum3 □ serum4 ■ (♦) m (-) n  Hmab
[I Ol
Figure 6.3.a
Reactivity o f  sera from mice immunized with peptide 11 against peptide 11. The OD shown is the 
maen of 2 O D  readings.
Anti peptide antibody binding is shown as OD values at A 4m, At various loglu dilutions of  
sera from individual mice. (+) is the positive control used which is sera from mice 
challenged three times with RSV intranasally/ (-) negative sera
B  Represents the HMab RF2 which is used as a control for the assay for binding to
RSV
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1.2 A  490 nm Peptide 11
0.8 
0.6 
0.4 
0.2
Q I _ _____ I
RSV(k>g1.7)
□ seruml ■ serum2 □ serum3 □  serum4 ■ (+) ID (-) 0  Hmab
Figure 6.3.b
Reactivity o f  sera at 1:10 dilution with RSV antigen in the plate. The OD shown is the maen of 2 
O D readings.
(+) is the positive control used which is sera from mice challenged three tim es with RSV 
intranasally/ (-) negative sera
Represents the HMab RK2 which is used as a control for the assay for binding to
RSV
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1.2 A 490 nm Peptide 24
1
0.8
0.6
0.4
0.2
0
□  seruml ■  serum2 □  serum3 □  serum4 ■  (+) ID (-) E3 Hmab
R S V  ( l o g  1 .7 )
Figure 6.4
Reactivity o f  sera from mice immunized with peptide 24 against RSV antigen. The O D shown is 
the maen o f  2 OD readings.
A ntibody binding is shown as OD values at A 4W At a serum dilution of 1:10. (+) is the 
positive control used which is sera from mice challenged three times with RSV  
intranasally/ (-) negative sera
I I  Represents the HMab RF2 which is used as a control for the assay for binding to
RSV
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1 . 2 A  490 nm Peptide 36
1 □ serum l ■  serum2 □  serum3 □  serum4 ■  (+) OD (-) 0  Hmab
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Figure 6.5
Reactivity o f sera from mice immunized with peptide 36 against RSV antigen. The O D  shown is 
the maen o f 2 OD readings.
Antibody bindings shown as OD values at A 4W at a 1:10 dilution of the sera. (+) is the 
positive control used which is sera from  mice challenged three times with R SV  
intranasally/ (-) negative sera
Represents the HMab RF2 which is used as a control for the assay for binding to
RSV
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Antibody response following immunization with peptide 41
Mice immunized with peptide 41 did not produce detectable anti-peptide antibodies 
either following priming or boosting. However, sera from the final bleed of mouse 4 
and mouse 1 showed reactivity with RSV antigen. The serum from animal number 4 
bound RSV antigen with an OD value that was three times the control negative serum, 
and serum from mouse 1 bound the RSV antigen with an OD value twice that o f  the 
negative control (Figure 6.6).
Antibody response following immunization with peptide 48
As with mice immunized with peptide 24, 36, and 41, mice immunized with peptide 
48 did not produce detectable anti-peptide antibodies either following priming or 
boosting. However serum from the final bleed o f one mouse (number 1) immunized 
with peptide 48 showed reactivity with RSV antigen with an OD value that was three 
times the negative control value (Figure 6.7).
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12  A  490 nm Peptide 41
1 □ seruml ■ serum2 □ serum3 □  serum4 ■  (+) ni (-) 0  Hmab
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Figure 6.6
Reactivity of sera from  mice immunized with peptide 41 against RSV antigen. The O D  shown is 
the maen of 2 OD readings.
Antibody binding is shown as OD values at A at a 1:10 serum dilution. (+ ) is the 
positive control used which is sera from  mice challenged three times with R S V  
intranasally/ (-) negative sera
Represents the HM ab RF2 w hich is used as a control for the assay for binding to
RSV
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1.2 A  490 nm Peptide 48
1 □ seruml ■  serum2 □  serum3 □  serum4 ■  (+) tu (-) 0  Hmab
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0.2
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Figure 6 .8
Immunoreactivity o f sera from mice immunized with peptide 48 against RSV. The OD shown is 
the m aen of 2 OD readings.
Antibody binding is shown as OD values at A 4W at a 1:10 serum dilution. (+) is the 
positive control used which is sera from mice challenged three times with RSV 
intranasally/ (-) negative sera
Represents the HMab RF2 which is used as a control for the assay for binding to
RSV
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6.2.2 Competitive inhibition assay using mouse anti-peptide 8 sera.
In order to verify that mouse anti-peptide 8 antibody indeed recognized the 
peptide that induced it, an inhibition assay was carried out. Plates were coated with 
peptide 8 overnight at a 5pg/ml as described in Chapter 2.
Half log peptide dilutions starting at 2mg/ml were prepared freshly and added 
to a dilution o f  the mouse serum and incubated for 3 hours. The mixture was added to 
each well o f  the peptide coated plate. As shown in Figure 6.9, peptide 8 in solution 
inhibited the binding o f anti-peptide 8 antibodies to peptide in the ELISA; a decrease 
o f 0.2 OD was observed with serum from animal 1, and a decrease o f  0.1 OD with 
sera from mice 2 and 3.
6.2.3 Competitive inhibition assay using anti-peptide 11 sera.
A competitive inhibition assay was carried out using the anti-peptide antibody 
induced by the immunization with peptide 11 as described above for peptide 8.
The presence o f peptide 11 free in solution inhibited the binding o f anti-peptide 11 
antibody to peptide 11 in ELISA as shown in (Figure 6.10); a decrease o f  0.2 OD was 
observed with serum from mouse 3, and a decrease o f 0.1 OD from mouse 4 and the 
inhibition was is in a concentration-dependent in sera from both mice.
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1.2 A  490 nm P8
1
0.8
0.6
0.4
0.2
m
□ Serum l ■  Serum2 □  Serum3 □ Serum4
Figure 6.9
Competitive inhibition ELISA using peptide 8 and mouse anti-peptide sera. The OD shown is the  
maen o f  2 OD readings.
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1.2 A 490 nm P11
0.8
iiriJlJJlIIII I
□  Serum3 ■  Serum4
Figure 6.10
Competitive inhibition ELISA using peptide 1 1 and mouse anti-peptide sera. The O D  shown is
the maen of 2 OD readings.
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6.2.4 Competitive inhibition assay using RSV antigen.
To determine of that the binding of the mouse anti-peptide serum with RSV in ELISA 
was specific for RSV, a competitive inhibition assay was carried out. Plates were 
coated with RSV Ag overnight at a 5pg/ml. Anti-peptide sera at a dilution of 1/50 
(final 1/25) were mixed with half-log dilutions o f  the corresponding peptide starting at 
2mg/ml, and added to the wells o f RSV-coated ELISA. Plates were incubated for 3 
hours. The anti-peptide sera were against peptide 24, 36,41, and 48.
RSV inhibitions assay using anti-peptide 24 sera:
The presence of peptide 24 free in solution did not affect the RSV binding activity in 
sera from mice immunized with peptide 24 (micel, and 2) to the RSV Ag in the 
ELISA (Figure 6.11), suggesting that the binding o f the anti-peptide serum to RSV 
antigen was not related to the anti-peptide reactivity.
RSV inhibitions assay using anti- peptide 36 sera:
The RSV binding activity in sera from mice immunized with peptide 36 (1, 2, and 4) 
was not effected by the presence o f the peptide free in solution (Figure 6.12). Again 
suggesting that the binding o f  the anti-peptide scrum to RSV antigen was not related 
to the anti-peptide reactivity..
RSV inhibitions assay using anti- peptide 41 sera 
The presence o f peptide 41 free in solution inhibited the binding o f anti-peptide 
antibody to the RSV Ag in the ELISA; a decrease of 0.2 OD reading binding was 
observed with sera from animal 4, and a decrease of 0.1 OD reading in the sera from 
animal 1. The inhibition observed was concentration-dependent in sera from both 
mice(Figurc6.13).
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RSV inhibitions assay using anti-peptide 48 sera 
The b inding o f  a nti-peptide 4 8 s  erum t o R S V w as n ot a ffected b y t he p resence o f  
peptide 48 in free solution, which again suggest that the binding o f the serum to RSV 
antigen was not related to the peptide binding reactivity (Figure 6.14).
These results suggest that o f  the peptides tested, only peptide 41 represents an 
epitope expressed on the RSV antigen to which the anti-peptide antibodies bound.
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0 5 A 490 nm P24
0.45
0.4
□ Seruml ■ Serum2
F igure 6.11
Com petitive inhibition ELISA using peptide 24 and mouse anti-peptide se ra  against RSV Ag 
O D  shown is th e  maen of 2 OD  readings.
0.45
0.5 A  490 nm p 3 g
□ Seruml ■  Serum2 □ Serum4
Figure 6.12
Competitive inhibition ELISA using peptide 36 and mouse anti-peptide sera against RSV Ag. The 
OD shown is the maen of 2 OD readings.
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Figure 6.14
Competitive inhibition ELISA using peptide 48 and mouse anti-peptide sera against RSV Ag.The 
OD shown is the maen of 2 OD readings.
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6.2.5 Antibody response following immunization with mimotopes
As described in Chapter 5, a human monoclonal antibody (RF2) that recognizes a 
conformational epitope on the fusion protein o f  HRSV was used to screen a solid 
phase combinatorial peptide library to identify mimotopes o f  this conformational 
epitope. Three potential sequences were identified:
RH1, 2, and 3.The immunogenicity o f these mimotopes was tested individually in 
groups of four o f female BALB/c mice. It was also hoped to be able to use the 
mimotopes in which the sequences had been modified by amino acid substitutions to 
give higher affinity binding by RF2. However lack o f time and problems in the 
Biological Service Unit o f the school seriously interfered with the planned 
experiments. BALB/c mice were sub-cutaneously immunized with 50pg of peptide in 
(CFA), and boosted three weeks later by the same route with the same dose of the 
same peptide in IFA. Sera from individual animals were collected prior to the boost 
and then 20 days after the boost. The ability o f  each peptide to induce an antibody 
response was assessed by direct peptide ELISA. Sera from the animals from each 
group w ere o btained j ust b efore t he s tart o f  t he experiment a nd u sed a s a n egative 
control for reactivity against both RSV Ag and the tested peptide in every assay. Two 
positive controls were included: (1) serum from mice intranasally immunized and 
challenged with RSV and (2) the RF2 Mab.
Since the mimotopes were only 8 amino acids long, simply attaching them to 
the ELISA plate (NUNC) would possibly induce a number o f  conformational changes 
that would influence antibody binding. Therefore, two other approaches were used to 
present the mimotope on the ELISA solid phase in addition to the direct coating o f  
peptides (RH1, RH2, and RH3):
1. peptides were coupled to KLH as a carrier protein ( KRH1.KRH2, and KRH3 - 
see Chapter 2 for details); and
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2. Peptides were biotinylated and bound to streptavidin coated plates (bRHl, 
bRH2, and bRH3-see Chapter 2 for details).
6.2.5.1 Antibody binding to mimotopes coated directly on the ELISA plate:
RH1
Sera from all four RH-1 immunized animals showed antibody binding at a dilution of 
1/10 that was greater than the negative controls and all the four sera had titres between 
2.2 and 2.5 respectively (Figure 6.15).
RH2
Sera from all the four RH2 immunized animals showed antibody binding at a dilution 
o f 1/10 that was 3 times the cut o ff  with titres between 2.2 and 2.5 (Figure 6.16).
RH3
Sera from all four immunized m ice (1, 2, 3, and 4) showed antibody binding at a 
dilution o f  1/10 that was greater than the negative controls at a titre of 2.2 (Figure 
6.17). It should be noted that although immunization with the mimotopcs induced 
anti-mimotope antibodies, none o f  these reacted to RSV antigen (data not shown).
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0.5 A  490nm RH1
□ serum
0.45
serum dilution ( log 10)
Figure.6.15
Antibody binding to mimotope RH1 coated directly on the ELISA plate. The O D shown is the 
maen of 2 O D readings.
■ serum
□ serum
□ serum 
■(+) 
■(-)
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serum dilution ( loglO)
3.1
□ serum 1 
■ serum 2
□ serum 3
□ serum 4 
■(+) 
n ( - )
Figure 6.16
Antibody binding to mimotope RH2 coated directly on the ELISA p late . The OD shown is the 
maen of 2 OD readings.
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A 490nm
1.9 2.2 2.5
serum dilution ( loglO)
2.8 3.1
□ serum 1 
■ serum 2
□ serum 3
□ serum 4 
■(+) 
nu(-)
Figure 6.17
Antibody binding to mimotope RH3 coated directly on the ELISA plate. The OD shown is the 
maen of 2 OD readings.
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6.2.5.5.2. Antibody binding response to mimotopes coupled to KLH on the 
ELISA plate.
KRH1
Sera from the three o f the four RH1 immunized animals (1 ,2 , and 3) showed antibody 
binding that was 3 and 4 times greater than the negative controls with titres between 
2.2 and 2.8(Figure 6.18).
KRH2
Sera from all RH2 immunized animals showed antibody binding at a dilution o f 1/10 
that was 3 times the cut o ff at 1/10 and with a titre o f 2.2 (Figure 6.19).
KRH3
Sera from the four RH3 immunized animals (1, 2, 3 and 4) showed antibody binding 
at a dilution o f 1/10 that was 3 times greater than the negative controls, with titres 
between 1.9 and 2.2 (Figure 6.20).
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o.» KRH1
□ sen
A 490nm
Serum dilution ( log 10)
■ sen
□ sen
□ sen
■ (♦ )
■ (-)
Figure.6.18
Antibody binding to mimotope RH1, coupled to KLH on the ELISA plate. The OD shown is the 
maen of 2 OD readings.
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0.9 A 490nm KRH2
1 1.3 1.6 1.9 2.2 2.5 2.8 3.1
Serum dilution ( Iog10)
□  serui 
■  serui
□  serui
□  serui 
■ (+ ) 
■ ( -)
Flgure.6.19
Antibody binding to mimotope R H 2, coupled to KLH on the ELISA plate. The O D  shown is the 
maen o f 2 OD readings.
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Figure.6.20
Antibody binding response to mimotope RH3, coupled to KLH on the ELISA plate. The OD 
shown is the maen of 2 OD readings.
□ setur 
■ serun
□ setun
□ serur 
■(+) 
■(-)
218
6.2.5.3 Antibody binding to the biotinylated mimotopes coupled to Streptavidin - 
coated plates 
bRHl
Sera from the four RH1 immunized mice showed antibody binding at a dilution of  
1/10 that was 3 times the cut off. Three of the sera (mouse 1, 2, and 3) had high 
binding at a dilution o f  1/20. The titre for all the immunized animals was 1.6 (Figure 
6 .21).
bRH2
Sera from all the four RH2 immunized animals (1,2, 3and 4) showed high level o f 
anti-body binding at a dilution 1/10 that was 3, and 4 tim es greater than that o f the 
negative controls, and four sera had titres between 1.9 and 2 .2  (Figure 6.22 ). 
bRH3
No detectable levels o f  anti-mimotope antibody were detected in any o f  the sera.
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A 490n m bRH11
0.9
0.8
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0 H  in  mi
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Serum dilution ( logiO)
□ serum 1
■ serum 2
□ serum 3
□ serum 4
■ (+)
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N XN
'OX
Figure 6.21
Antibody binding to  the RH1 biotinylated mimotope coupled to Streptavidin coated plates. The 
OD shown is the maen of 2 OD readings.
o
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0.9
0.8
0.7
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□ serum 1 
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Figure.6.22
Antibody binding to the RH2 biotinylated mimotopc coupled to Streptavidin coated plates. The 
OD shown is the maen o f 2 O D readings.
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6.2.6 The reactivity of the control sera to the mimotopes
Both the negative and the positive control varied in their response to the three 
mimotopes in their different form o f presentation on the plates.
□ (+) ■ ( - )
RH1 RH2 RH3 bRH1 bRH2 bRH3 KRH1 KRH2 KRH3
Figure.6.23
The reactivity of the control sera to the different mimotopes. The OD shown is the maen of 2 OD 
readings.
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6.2.7 Discussion
Results from this study are summarized in Table 6.1: only 2 o f  the linear peptides (8 
and 11) induced anti-peptide antibodies in the immunized mice. Sera from all the 
mice i mmunized w ith p eptide 8 h ad a nti-peptide a ntibodies, w hereas o nly 2 o f  t he 
animals immunized with peptide 11 showed anti-peptide antibody. None o f the sera 
reacted with RSV antigen in an ELISA. When the competition inhibition ELISA was 
preformed with the sera from mice immunized with peptide 8, peptide 8 did not 
inhibit the binding o f  the anti-peptide antibody to P8 on the plate. Similarly, in the 
competition inhibition ELISA preformed with peptide 11, the binding only slightly 
inhibited with the peptide in free solution. The main purpose of raising anti-peptide 
antibodies is to obtain a reagent capable of reacting with the original protein; the 
success o f  an immunization procedure depends on the cross-reactive properties o f the 
anti-serum and not solely on the titre o f  antibodies reactive with homologous peptide 
immunogen. Although none of the sera from mice immunized with peptide 8 or 11 
reacted with RSV Ag on the plate, this could be due to the w ay the RSV Ag was 
presented on the solid phase. These results do not totally rule out the possibility that 
peptide 8 and peptide 11 could represent real epitopes on RSV.
Sera from mice immunized with peptide 24, 36, 41, and 48 did not produce 
detectable anti-peptide antibodies either following priming or boosting in ELISA. 
Interestingly, some o f  these sera reacted with RSV Ag on the plate. This could be a 
result o f  few factors;
1) The peptides could have assumed an inappropriate conformation on the ELISA 
plate and therefore the antibody could not recognize the shape o f  the epitope that 
induced it in the first place. 2) The lack o f anti-peptide antibody could be also due to 
the lack o f  T-cell help even though there was a source o f  T-help presented in by co-
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immunizing with peptide TTB. 3) The nature o f  the adjuvant used as well as the route 
of immunization plays an important role in the induction o f  a protective anti-peptide 
antibody response (Obeid, Stanley et al. 1996) and thus these factors need to be 
studied.
In the case of sera from peptide 24 immunized mice, it is possible that the sera 
recognized a linear epitope on the RSV Ag, it should be noted that peptide 24 has 
been identified as a human B-cell epitope (see Table 1.3). When a competitive 
inhibition ELISA was carried out using the sera from the mice immunized with 
peptide 24, 36, 41, and 48, the presence o f  these peptides in solution did not inhibit the 
binding o f the sera to RSV Ag in the ELISA. Therefore, this suggests that these 
peptides do not mimic the structure in RSV to which the RSV binding activity was 
detected. Meanwhile, peptide 41 in free solution inhibited the RSV binding of 
reactivity in the ELISA which suggests that the peptide may represent an important 
epitope on the protein o f RSV.
Although peptides 4 and 14 were recognized by both the adult and children’s 
sera from Bissau, the hope that they would represent potential immunogen was not 
supported by the data obtained.
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peptides Antibody response
Anti-peptide Anti-RSV
+Ve Response Titre +Ve Response
4 0/4 - 0/4
8 4/4 1.6-2.2 0/4
11 3/4 2.5-2.8 2/4
14 0/4 - 0/4
19 0/4 - 0/4
20 0/4 - 0/4
24 0/4 - 2/4
32 0/4 - 0/4
36 0/4 - 3/4
41 0/4 - 1/4
48 0/4 - 1/4
Table 6.1
Antibody responses follow ing immunization groups of 4 B A l.B /c mice with the panel o f peptides 
recognized by human sera.
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The immunogenicity of the mimotopes was tested in the mice and the results 
are summarized in Table 6.2. Although immunization with the mimotopes induced 
anti-mimotope antibodies, none o f these antibodies cross- reacted with RSV. The anti- 
mimotope antibody titre was quite low and this could be because in this initial 
immunization, no source of T-cell helper was provided. In addition the mimotopes are 
short and therefore unlikely to be weak immunogens. It was also noted that 
biotinylating the mimotopes resulted in the detection o f  a lower antibody response. 
Furthermore, the biotinylated peptides were not recognized by the anti-RH3 sera. The 
controls used in all the ELISAs gave different levels o f reactivity towards the 
mimotopes presented in the various forms which highlights the difficulty in 
interpreting these data.
The failure o f  the mimotopes to induce anti-RSV antibodies could mean: 1) 
that RSV Ag on the plate does not present the epitopes in the right conformation for 
the antibody to react with them; 2) or that mimotopes are not true mimics o f the native 
epitopes on the F protein which implies that they are not likely to have any potential 
as vaccine candidates.
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Mimotopes in 
ELISA
Immunizing peptides
RH1 RH2 RH3
+Ve
Response
Titre +Ve
Response
Titre +Ve
Response
Titre
Directly on the 
plate
* 4/4 2.2-2.5 4/4 2.2-2.5 4/4 2.2
KLH Bound 4/4 2.2-2.8 4/4 2.2 4/4 1.9-2.2
Biotinylated 4/4 1.0 4/4 1.9-2.2 0/4
Table.6.2
Antibody responses in sera from  mice immunized with mimotopes in ELISA.
The mimotopes w ere coupled to the ELISA plates either directly, bound to KLH or 
biotinylated.
* number o f mice > negative control/ the number of m ice immunized.
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CHAPTER 7
CONCLUDING REM ARKS
Respiratory syncytial virus (RSV) is the most important cause of bronchiolitis and 
pneumonia in infants and young children worldwide and as yet, there is no effective 
vaccine against RSV infection. The development o f an epitope-based synthetic 
peptide vaccine that was able to induce virus-neutralizing antibodies against RSV 
would seem to be a suitable approach to this problem. However, this approach 
requires the identification o f  epitopes capable o f inducing the appropriate antibody (B- 
cell epitopes) and cellular (T-cell) immune responses. However, it seems that B-cell 
epitopes capable o f inducing virus-neutralizing, protective antibody responses are 
likely to be conformational in nature and therefore, the identification o f mimics 
(mimotopes) o f  these epitopes along with the linear epitopes (Steward 2001) would be 
valuable.
The aim of this work was to identify both linear, and conformational epitopes from the 
Fusion protein o f  HRSV to be used in an epitope based vaccine. Furthermore, it was 
proposed to try and gain a better understanding of repeated infections with RSV by 
analyzing the antibody response to the Fusion protein in sera from different stages of 
exposure to the virus. In this regard, no clear conclusions could be drawn from the 
results o f  the study presented in Chapter 4.This could be due to several factors that 
may have influenced the analysis o f  the data:
i) The negative controls we had were the so-called pre-primary infection samples 
which arc from children who did not have clinical RSV before 18 months o f  age- but 
they m ay w ell h ave h ad s ub-clinical i nfection which c  ould explain t he p rescncc o f 
anti-RSV antibody reactivity.
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ii) The negative or positive reactivity o f  some sera with RSV Ag was not always 
correlated with the presence o f antibodies to peptides, this caused confusion in 
interpreting the data.
iii) The presence o f  maternally-derived antibodies could have also interfered with the 
analysis o f the data. Maternal antibody has been shown in previous studies to interfere 
with how babies respond to RSV.
Analysis o f  the binding the adult sera to the mimotopes showed that mimotopes
M l, M2, RH1 and RH2 could represent epitopes that may have importance in 
generating a protective antibody response. However, when the reactivity o f RF2 with 
the detected mimotopes was tested in ELISA, no binding was detectable. This is 
possibly due to the conformation they adopt on binding to the solid phase in the 
ELISA plates. In order to both improve the binding o f RF2 to the identified 
mimotopes by presenting them in a more appropriate conformation to RF2, they were 
synthesized in the SPOTs system.
Although the results from experiments describing the substitutions o f  amino acids in 
the sequences o f  the detected mimotopes in Chapter S showed that amino acid 
substitution in the mimotopes could enhance their potential as vaccine candidates, 
there were difficulties in assessing the data. Furthermore, the fact that the binding 
results with certain peptides were not consistent was also a problem. These 
inconsistencies could have arisen from the relative insensitivity o f  the assay. The 
affinity o f  binding between RH1, RH2, and RH3 with RF2 needs to measure. This 
could highlight which of the mimotopcs could be of potential use as a vaccine. Data 
from the immunization study suggested that peptide 41 may represent an important 
epitope on the protein of RSV. However, it is also possible that peptides 8 and peptide 
11 could represent important epitopes on RSV.
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Although peptides 4 and 14 were recognized by both the adult and children sera from 
Bissau, data in Chapter 6 showed that they were unlikely to represent potential 
immuonogens.
The design o f  a successful peptide vaccine against R SV  will require further detailed 
knowledge o f the mechanisms o f  protective immunity involving B-cell and T-cell 
epitopes, as well as parameters that affect peptide immunogenicity, epitope sequence 
and structure. Also the need for carrier or adjuvant, changing the route of 
immunization and method of delivery could be considered in detail in future studies. 
In addition, an ideal peptide vaccine that can be used universally for all diverse high 
risk groups to RSV infection will not be easy.
Statistical Analysis:
•  To estimate the population mean from the same mean. The mean plus or minus 
2 standard errors would be calculated for all samples. This would represent 
that the population mean was 95 times out o f  100 of lying within the two 
standard errors.
•  Data from Chapter 3:
To determine the peptide which is going to be mostly reactive among the adults sera , 
the Kruskal- Wallis test will be used as shown in the table below to find out which of 
the 8 peptides has a significantly different proportion o f  individuals with OD readings 
that are equal or higher than the cut-off.
Peptide
Pepi Pep2 Pep3 Pep4 Pep5 Pepò Pep7 Pep8
Number of Individuals A B C D E F G H
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with OD reading > cut­
off
Number of individuals 
with OD reading < cut­
off
I J K L M N O P
TOTAL 9 9 9 9 9 9 9 9
•  Data from Chapter 4:
Peptides with a frequency o f  more than 40% among the children sera will be further 
analyzed. In children sera with pre and first-post infection samples the Student T-test 
will be applied to compare the differences between the mean ODs for all children in 
the pre-infection samples against the first-post infection samples.
In children sera with pre, first-post and second-post infection samples Kruskal Wallis 
test will be applied for each peptide individually to compare the means o f all ODs
observed for the peptide reactivity among the sera from the three sample groups. This 
will allow me to find out which peptides had significantly different mean ODs in pre, 
first-post and second-post infection samples.
Pre - infection First-post Second - post
samples infection samples infection samples
Peptide type Mean o f all ODs Means o f all ODs Means o f all ODs
Pepi Means o f all ODs Means o f  all ODs Means o f all ODs
Pep8 Means o f all ODs Means o f all ODs Means o f  all ODs
•  Data from Chapter 6:
To test the effect o f  inhibiting sera reactivity to the inducing peptide, data from 
immunised animals (using Peptide 8 and 11) will be arranged as shown below.
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The McNemar test will be applied to find out if inhibition causes a significant 
decrease in the proportion o f  animals that produced ODs above the cut-off.
Before inhibition After inhibition
Number of animals with ODs >cut off XI Y1
Number of animals with ODs <cut off X2 Y2
The McNemar test will also be applied on data from mice immunised with peptide 24, 
36, 41,48 individually to test the change in the reactivity o f  the sera against the
inducing peptides when the sera was inhibited by RSV Ag. Data will also be arranged 
as shown above.
The Kruskal-Wallis test w ill be applied to test the difference between the proportions 
of mice with ODs above and below the cutoff when immunized with each mimotope 
individually using the three different methods o f  peptide coatings on the plates. The 
data will be arranged as below:
Peptide on 
plate
Peptide/biotin Peptide/KLH
Number of mice with ODs >cut XI Y1 Z1
off
Number of mice with ODs <cut X2 Y2 Z2
off
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APPENDIX
Saaple Appendix 1 -PEPTIDE NUMBER
1 2 3 5 7 9 10 12 13 15 16 17 19 20 21 22 23 25
A 0.137 0 0.203 0.159 0 0.396 0.367 0.413 0.249 0.348 0.337 0.336 0.342 0.388 0.368 0.32 0.242 0.298
B 0 0 0 0.118 0.112 0.379 0.395 0.346 0.201 0.354 0.274 0.398 0.421 0.302 0.321 0.345 0.232 0.289
c 0.187 0.146 0.262 0.255 0.22 0.377 0.327 0.378 0.293 0.297 0.359 0.365 0.354 0.278 0.354 0.283 0.239 0.202
D 0.254 0 0.282 0.166 0.227 0.432 0.49 0.386 0.381 0.416 0.375 0.4 0.4 0.377 0.444 0.227 0.28 0.246
1 0.562 0.546 0.52 0.523 0.46 0.476 0.456 0.488 0.337 0.457 0.391 0.589 0.529 0.587 0.517 0.447 0.394 0.401
r 0.308 0.179 0.232 0.348 0.335 0.348 0.33 0.282 0.268 0.338 0.226 0.241 0.197 0.285 0.133 0.211 0.208 0.219
G 0.37 0.232 0.273 0.553 0.591 0.385 0.442 0.265 0.307 0.256 0.242 0.243 0.2 0.247 0.156 0.192 0.225 0.224
H 0.495 0.24 0.245 0.409 0.435 0.352 0.406 0.323 0.327 0.2 0.286 0.246 0.237 0.331 0.176 0.249 0.266 0.269
i 0.308 0.154 0.37 0.335 0.355 0.376 0.381 0.288 0.289 0.284 0.227 0.244 0.181 0.2 0.223 0.194 0.185 0.221
Sample Appendix!-PEPTIDE NUMBER
26 27 28 29 30 31 32 33 34 35 37 38 39 40 42 43 44 45
A 0.306 0.12 0.679 0.243 0.213 0.215 0.267 0.366 0.255 0.208 0.653 0.253 0.179 0.159 0.139 0.154 0.196 0.203
B 0.324 0.227 0.52 0.328 0.261 0.262 0.326 0.287 0.193 0.312 0.73 0.216 0.185 0.18 0.253 0.165 0.145 0.198
c 0.287 0.324 0.617 0.3 0.198 0.273 0.235 0.258 0.344 0.205 0.806 0.306 0.276 0.227 0.298 0.175 0.132 0.246
D 0.215 0.213 0.814 0.293 0.216 0.228 0.257 0.308 0.36 0.377 0.934 0.24 0.303 0.154 0.258 0.19 0.144 0.199
■ 0.407 0.364 0.876 0.383 0.379 0.313 0.274 0.387 0.397 0.332 1.407 0.452 0.388 0.249 0.325 0.245 0.256 0.324
F 0.234 0.252 0.274 0.229 0.23 0.165 0.313 0.178 0.128 0.475 0.67 0.207 0.406 0.321 0.184 0.138 0.184 0.204
G 0.214 0.227 0.275 0.305 0.227 0.168 0.276 0.195 0.14 0.402 0.373 0.176 0.379 0.258 0.159 0.138 0.187 0.227
H 0.233 0.197 0.389 0.211 0.254 0.276 0.345 0.268 0.18 0.333 0.8 0.221 0.485 0.321 0.214 0.159 0.241 0.307
I 0.262 0.178 0.225 0.221 0.221 0.18 0.188 0.227 0.187 0.378 0.665 0.198 0.4 0.246 0.207 0.139 0.208 0.234
Staple Appendix- 3 - PEPTIDE NUMBER
46 47 48 49 50 51 52 53 54 55
A 0.187 0.384 0.456 0.176 0.341 0.44 0.25 0.34 0.167 0.187
B 0.176 0.329 0.246 0.184 0.4 0.385 0.21 0.287 0.214 0.154
C 0.196 0.276 0.386 0.202 0.378 0.354 0.23 0.307 0.202 0.2
D 0.3 0.297 0.332 0.227 0.285 0.227 0.263 0.296 0.187 0.197
B 0.341 0.437 0.56 0.388 0.546 0.478 0.245 0.407 0.253 0.231
P 0.206 0.338 0.335 0.308 0.293 0.44 0.2 0.346 0.176 0.238
G 0.178 0.224 0.297 0.223 0.345 0.316 0.209 0.27 0.184 0.137
H 0.298 0.198 0.332 0.334 0.31 0.326 0.238 0.387 0.202 0.212
I 0.273 0.336 0.198 0.208 0.307 0.209 0.269 0.328 0.227 0.191
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Appedix 4
31/81%, 30/69%, 29/57-60%
Sequences producing s ig n if ic a n t  a lignm ents!
q iI  21689587|qbIAAM68160■ 1 I fu s ion  g lyc o p ro te in  [Human re s p i. . .  
qi|21263086|qbIAAM44851■ 1 I fu s ion  g lyc o p ro te in  [Human re s p i. . .  
qi|1912295lqblAAC57027■ 1| Fusion p ro te in  (F)
q iI  94063 Ip ir |  IB28929 c e ll  fu s io n  g lyc o p ro te in  - human re s p i. .  
qi|961615|qb|AAB38520■ 11 fu s io n  p ro te in  [Human re s p ira to ry  . .  
q iI  1353201|sp|P11209|VGLF HRSVR Fusion g lyc op ro te in  precurs.. 
qi|29290043|qblAA072325.1 1 fu s io n  p ro te in  [Human re s p ira to r . . 
qj|21689583lqblAAM68157.1 | fu s io n  g lyc o p ro te in  (Human re s p i..  
q iI  962937 5 I r e f | NP 044596.11 Fusion p ro te in  (F) [ re s p ira to ry . . 
q i|3 7 6747461qbIAAQ97027■ 1| fu s io n  p ro te in  precursor [Human .. 
q iI  74932Ip ir |  IVGNZR2 c e ll  fu s io n  g lyc o p ro te in  precursor - h . . 
a i l  37674754IqblAAQ97 031.1 1 fu s ion  p ro te in  precursor [Human . .
q iI  227299 Ip r f I  I1701388A fu s io n  g lyc o p ro te in
q iI  612111embICAA26143■ 11 unnamed p ro te in  product [Human re s .. 
q iI  961609 IqbIAAB38517■ 11 fu s io n  p ro te in  [Human re s p ira to ry  . .  
q i1 138250|sp|P1384 3|VGLF HRSV1 Fusion g lyc op ro te in  p re c u rso .. 
q iI  962 9206 I re f|N P  056863.11 fu s ion  p ro te in  [Human re s p ira to ..  
qi|1695263|qblAAC55970■ 11 fu s ion  g lyc o p ro te in  precursor [Hu.. 
qil961607|qb|AAB38516.1 1 fu s io n  p ro te in  [Human re s p ira to ry  ..  
q i|2  9290041|qb|AAQ72324.1 1 fu s ion  p ro te in  [Human re s p ira to r . .  
q iI  226438 Ip r f I  11512 372A fu s io n  p ro te in
qi|2582041|qbIAAB8244 6 .1 I fu s io n  p ro te in  [Human re s p ira to ry . . 
qj|376747 52|qblAAQ97030.1 1 fu s io n  p ro te in  precursor [Human .. 
q i|3 7 6747481qbIAAQ97028.1 1 fu s io n  p ro te in  precursor [Human .. 
q i|2 9 2 900391qbIAA072323■ 11 fu s io n  p ro te in  [Human re s p ira to r . .  
qi|961613|qblAAB38519■ 1 I fu s io n  p ro te in  [Human re s p ira to ry  .. 
qil38230490|qb|AAR14 266.1 1 F [Human R esp ira to ry  s yn c y tia l v . . 
qi|961611|qb|AAB38 518■ 11 fu s io n  p ro te in  [Human re s p ira to ry  .. 
q iI  4 80767|p ir I  IS37254 c e l l  fu s ion  p ro te in  - human re s p ira to ..  
q iI  138251|sp|P034 20|VGLF HRSVA Fusion g lyc op ro te in  p recu rso .. 
q i|3 7  67 4750lqblAAQ97029.1 1 fu s ion  p ro te in  precursor [Human .. 
q iI 138252 Isp|P12568|VGLF HRSVL Fusion g lyc op ro te in  p recurso .. 
q i|2 1 6895791qbIAAM68154■ 11 fu s io n  g lyc o p ro te in  [Human re s p i. .  
q j|3 7 6747441qbIAAQ97 026.1 1 fu s io n  p ro te in  precursor [Human .. 
q iI  195503361qbIAAL91342.11 fu s io n  p ro te in  [Ovine re s p ira to r . .  
q iI  13824 8 |sp|P23728|VGLF BRSVR Fusion g lyc op ro te in  precurso.. 
q iI  267344| sp|P297911VGLF BRSVA Fusion g lyc op ro te in  p recurso .. 
qi|3451386|embICAA7 6980■ 1 I F p ro te in  [Bovine re s p ira to ry  s y . . 
q iI  281366 I p i r |  IJQ1583 c e l l  fu s io n  p ro te in  precursor - b o v in .. 
q iI  138247|sp|P22167IVGLF BRSVC Fusion g lyc op ro te in  precurso.. 
q iI  425678 IqbIAAB284 58.1 I fus ion  p ro te in  F2 subunit [bovine ..  
a i l  9631275 I re f|N P  048055.11 fu s io n  g lyc o p ro te in  precursor; . .  
qi|17939990lqbIAAL4 9399■ 1 I fu s io n  p ro te in  [Bovine re s p ira to . . 
g1117 940002 | qb I AAI.4 9410.11 fu s io n  p ro te in  [Bovine re s p ira to . . 
q lI  6653464 IqbIAAF22722.1 1 fu s io n  p ro te in  [Bovine re s p ira to r . . 
q iI  24372027| r e f | NP 716069.11 a c o n ita te  hydratase 2 (Shewane. . 
q i1 113785 IspIP19584IAMYB THETU Beta-amylase, the rm op h ilic  p. . 
q iI  16759155 I re f|N P  454772.11 a c o n ita te  hydratase 2 ( c i t r a te . . 
q iI  15921053 I re f|N P  376722.11 572aa long hypo the tica l g ra n u l. .
s t i i  15799802 I re fIN P  285814.11 a c o n ita te  hydrase B [E scherich .. 
q lI  26246058|re fIN P  752097.11 A c o n ita te  hydratase 2 [E scheri..
44/92%, 41/84%,
Score E
(b its ) Value
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
53 6e07
44 3e04
41 0.004
41 0.004
41 0.004
41 0.004
41 0.004
41 0.004
41 0.004
41 0.004
41 0.004
31 3.3
30 4.5
30 6.0
29 11
29 11
29 11
29 11
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Appendix 5
Sequences producing significant alignments (peptide 8). Score/ldentity- 52/100%, 48/93%, 42/80%, 41/80%, 
38/73%, 36/73%,
30/76%, 28/45-76%, 26-60-100%
Sequences producing s ig n if ic a n t  a lignm ents:
q iI  138251|sp|P03420IVGLF HRSVA Fusion g lycop ro te in  precurso. . 
q iI  1912295 Iqb|AAC57027■ 11 Fus ion p ro te in  (F)
q i | 94063|p i r  | IB28929 c e ll  fu s io n  g lycop ro te in  - human re s p i..  
q iI  1353201 |sp |P11209|V G L F  HRSVR Fusion g lycop ro te in  p re c u rs . . 
q iI  9629375 I r e f  INP 044596.11 Fus ion  p ro te in  (F) [ re s p ira to r y . . 
q iI  74932|p i r I  IVGNZR2 c e ll  fu s io n  g lycop ro te in  p recursor - h . . 
q iI  612111 e m b ICAA2614 3■ 1| unnamed p ro te in  product [Human re s .. 
qj|1695263|qb|AAC55970■ 1| fu s io n  g lycop ro te in  precursor [Hu..
fu s io n  g lycop ro te in  [Human re s p i. .  
fu s io n  g lycop ro te in  [Human re s p i. .  
fu s io n  p ro te in  [Human r e s p ir a to r . . 
fu s io n  g lycop ro te in  [Human re s p i. .  
q i|2 2 7 2 9 9 |p r f | I 1701388A fu s io n  g lycop ro te in
q iI  29290041 IqbIAA072324.1 1 fu s io n  p ro te in  [Human r e s p ir a to r . . 
q i|2 2 6 4 3 8 |p r f | 11512372A fu s io n  p ro te in
q iI  2929003 9 IqbIAA072323■ 1 I fu s io n  p ro te in  [Human re s p ira to r . .  
q i|9 6 1 6 1 3 |q b |AAB38519.1| fu s io n  p ro te in  [Human re s p ira to ry  . .  
q i|4 8 0 7 6 7 |p ir |IS 3 7 2 5 4 c e ll  fu s io n  p ro te in  - human r e s p ir a to . . 
q i1 138252 IspIP12568IVGLF HRSVL Fusion g lycop ro te in  p recu rso .. 
q i 1216895791qb|AAM68154■ 11 fu s io n  g lycop ro te in  [Human re s p i. .  
q iI  1382 50 |s p |P I 3843 IVGLF HR3V1 Fusion g lycop ro te in  p recu rso .. 
q iI  9629206 I re f INP 056863.11 fu s io n  p ro te in  [Human r e s p ir a to . . 
qi|2582Q41 lq b |AAH62 446 .1 | fu s io n  p ro te in  [Human re s p ira to ry . .
q iI  21689587|qbIAAM68160■ 1 I 
g i  1 2 1 2 6 3 0  8 6  1 g b  I AAM4 4 8 5 1 .  1 1 
q i12929004 3 IqbIAA072325.1 I 
q i 12168 9583 I qb I AAM6815 7 .1J
q i | 9 6 1 6 0 9 | q b | A A B 3 8 5 1 7 . i l  
q i I  9 6 1 6 0 7 | q b l A A B 3 8 5 1 6 . 1 I 
9 i I 9 6 1 6 1  1 | g b | A A H 3 8 6 1  8 . I I 
g l I 9 6 1 6 1 5  I q b IA A B 3 8 5 2 0 . 1 1 
9 i | 3 7 6 7 4  7 4  6 | g b | A A Q 9 7 0 2  7 . 1  I 
9 i I 37  6 7  4 7 6 4 J  g b  I AAQ9 7  0  3 1 . 1 I 
g i  I 3 7 6 7 4 7 6 2  I 9 b  I AAQ 9 7 0 3 0 . 1  I 
9 1 I 1 7 6 7 4 7 4 8  I gb~|  AAQ9 7  0 2 8 . 1  I 
g i  I 3 7 6 7 4 7 6 0  I g b  I A A Q 9 7 0 2 9  T T f  
q i 1 3 7 6 7 4 7 4 4  I q b IAAQ9 7 0 2 6 . 1 1 
g i l l 9 6 6 0 3 3 6 | g b | A A L 9 1 3 4 2 . 1  
g i  I 3 8 2  3 0 4  9 0  1 g b i Ä A R l  4 2 6 6  ■ 1 I 
9 1 I 4 9 2  3 8  3 6 0  | e m b  I 07 0 - 2  7 6 7 4  . 1 J  
g l I 21955241 I re fINP 523865.21 
9 1 I 3 3 8 6 6 2 9 0  I r . - f  | NR  ' 8 9 6 8 4 9 .  1 I 
g i l l  5 6 0 3 6 8 1  I r e f | N P ~ 2 4 6 6 5 5 . 1 I 
g i  14 61 8 6 0  3 7  I r e f  | N P _ 9 8 2 7  54 . 1 I 
g i  I 4 7 2 1  4 8 0 1  | e m b l C A F 8 9 6 2 8 . 1 I 
g i  14 61 9 8 6 3 9  I r e f  I NP 9 8 6 6 6 8  . I I 
g i  1 2 8 8 2 9  1 7 4  I g b  I A A I . 8 8 7 2 7 . 2  I 
g 1 I 2 2 9 7  I 9 8 6  | r e f  I 7, P 0 0 0  1 8 8 9 4  . 
g i  I 4 6 6 7 9 9 3 5  I r e f  I Y P _ 0  I 0 7 4  1 . 11  
g i  I 4 9 1 2 4  1 6 3  I r e f  | X P  4 1 2 6 8 4 .  1 I 
g i  I 1 2 8 4  6 9 4  1 I d b j I H A H 2 7  3 7 1  . 1 I 
g i I 7 9 5 7 9  1 9 3  I e m b  I C A F . 5 7 0 0 0  . 1 I 
g i  I 7 9 5  9 2  6 9 6 I e m b  I OAF. 6 3 6 7 2 .  1 I
g i  I 2 2 0 2 8 4 2 2 | g b I A A H 3 4 9 0 1 . 1
g i I 83866 I jr i r I I .JQ1 4 69 h y p o th e tic a l 10 .IK p ro te in  
q iI 23593529 I re f IXP 135092.2 1 RIKEN cDNA 2510040D07
fu s io n  p ro te in  [Human re s p ira to ry  
fu s io n  p ro te in  [Human re s p ira to ry  
fu s io n  p ro te in  [Human re s p ira to ry  
fu s io n  p ro te in  [Human re s p ira to ry  
fu s io n  p ro te in  precursor [Human . .
fu s io n  p ro te in  precursor [Human . .
fu s io n  p ro te in  precursor [Human . .
fu s io n  p ro te in  precursor [Human . .
fu s io n  p ro te in  precursor [Human . .
fu s io n  p ro te in  precursor [Human . .
fu s io n  p ro te in  [Ovine re s p ira to r . .
F [Human Resp ira to ry  s y n c y tia l v . .  
h yp o th e tic a l p ro te in  [B a r to n e ll. .  
CG16778- PB [Drosophila melanog.. 
probable aminopeptidase N [Syn.. 
L ig  [P as teu re lla  m ultocida Pm7..  
ABL193Cp [Eremothecium gossypi . . 
unnamed p ro te in  product [T e tra o .. 
AFR121Wp [Eremothecium g ossyp i.. 
s im i la r  to  Homo sapienB (Human). . .  
1 I hyp o the tica l p ro te in  [C h lo ro .. 
conserved hyp o the tica l p ro te in . ,  
hypo the tica l p ro te in  AN8447.2 ..  
unnamed p ro te in  product [Mus mu.. 
H ypothe tica l p ro te in  CBQ24867 [ . .
H ypothe tica l p ro te in  CBQ08174 [ . .
2510040D07Rik p ro te in  [Mus muscu..
( INF56 re g i. .  
[Mus mus..
g i  1 2 2 9 6 9 0 1  / | r . : f  | Z P  0 0 0 0 6 6 7 6 .  
g 1 1 2 4 4 7 6 6  19 I d b j  I 117:622 M 6 . 1  I 
g 1 1 2 6  14 9 0 6 6  I d b g  I BAG 1 8 1 6 7  . I I 
g i  14 16  1 9 0 2 4  I t j i g  I DAA04 0 6 2 .1 I
1_L COG4176i ABC-type p r o l in e /g l. .  
v ite l lo g e n in  [Crassostrea gigas) 
unnamed p ro te in  product [Mus mu.. 
TPA: HDC13868 [Drosophila melan..
Score E
(b its ) Value
52 le06
48 2e05
48 2e05
48 2e05
48 2e05
48 2e05
48 2e05
48 2e05
45 2e04
45 2e04
45 2e04
45 2e04
45 2e04
45 2e04
45 2e04
45 2e04
45 2e04
45 2e04
45 2e04
45 2e04
42 0.001
42 0.001
42 0.001
42 0.002
41 0.002
41 0.002
41 0.004
41 0.004
41 0.004
41 0.004
41 0.004
41 0.004
41 0.004
38 0.031
36 0.099
30 6.1
28 20
26 86
26 86
26 86
26 86
26 86
26 86
26 86
26 115
26 115
26 115
26 115
26 115
26 115
26 115
26 115
26 115
26 115
26 115
26 115
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Sequences producing significant alignments (peptidell). Score/Identity=49/I00%, 46/100%, 43/92%, 
39/85%, 31/81%,
27/66-81%, 26/72-88%
Appenix 6
Saquancas producing a ig n if le a n t a lignm ents:
q iI 94063Ip ir I  IB28929 c e ll  fu s ion  g lyc o p ro te in  - human re s p i..  
q iI  612111embICAA26143■ 11 unnamed p ro te in  product [Human re s .. 
qj|16952 63lqbIAAC55970■ 11 fus ion  g lyc o p ro te in  precursor [Hu.. 
qj|961611|qbIAAB38518.1 1 fu s ion  p ro te in  [Human re s p ira to ry  . . 
q i1 1382511sp|P03420|VGLF HRSVA Fusion g lyc o p ro te in  precurso.. 
q i|3 7 6747461qbIAAQ97027■ 1| fu s io n  p ro te in  precursor [Human . .  
qj|37674754|qblAAQ97031■ 1 I fu s io n  p ro te in  precursor [Human . .  
q iI 226438Ip r f  | 11512372A fus ion  p ro te in
qi|37674752|qb|AAQ97030■ 11 fu s io n  p ro te in  precursor [Human . .  
q i|3 7 6747481qbIAAQ97028.1 1 fu s io n  p ro te in  precursor [Human .. 
q iI  480767|p i r |  IS37254 c e ll  fu s io n  p ro te in  - human re s p ira to . . 
q i|3 7 6747501qbIAAQ97029■ 11 fu s io n  p ro te in  precursor [Human .. 
q i1 138252 Isp|P12568|VGLF HRSVL Fusion g lyc op ro te in  p recurso.. 
qi|37674744lqb|AAQ97026■ 11 fu s io n  p ro te in  precursor [Human .. 
qil21263086|qb|AAM44 851.1 1 fu s io n  g lyc o p ro te in  [Human re s p i..  
qi|1912295|qbIAAC57 027■ 11 Fusion p ro te in  (F)
qi|961615lqbIAAB38520.1 1 fus ion  p ro te in  [Human re s p ira to ry  ..  
q i1 13532011sp |P I1209|VGLF HRSVR Fusion g lyc op ro te in  p recurs. . 
qi|29290043|qblAA072325.1 1 fu s io n  p ro te in  [Human re s p ira to r . .  
q i I 9629375 I re f  114P 044596.11 Fusion p ro te in  (F) [ re s p ira to ry . . 
q iI  74932|p i r |  IVGNZR2 c e ll  fu s io n  g lyc o p ro te in  precursor - h . . 
q iI  227299 Ip r f |  11701388A fu s io n  g lyc o p ro te in
q iI 961609|qb|AAB38517.1 1 fu s io n  p ro te in  [Human re s p ira to ry  ..
fu s io n  p ro te in  [Human re s p ira to ry  . . 
fu s io n  p ro te in  [Human re s p ira to r . . 
fu s io n  p ro te in  [Human re s p ira to r . . 
fu s ion  p ro te in  [Human re s p ira to ry  . . 
fu s io n  g lyc o p ro te in  [Human re s p i..  
fu s io n  g lyc o p ro te in  [Human re s p i..  
fu s io n  g lyc o p ro te in  [Human re s p i. .  
H yp o the tica l p ro te in  [Oryza s a t i . .  
q i1 138250 IspIP1384 3IVGLF HRSV1 Fusion g lyc op ro te in  precurso.. 
q iI  9629206|re f|N P  056863.11 fu s io n  p ro te in  [Human re s p ira to .. 
qi|2582041|qbIAAB8244 6 .1 1 fu s io n  p ro te in  [Human re s p ira to ry ..  
qil38230490|qbIAAR14266.1 1 F [Human R e sp ira to ry  s yn c y tia l v . .  
q i1 19112634|r e f  INP 595842.11 telom erase reverse t ra n s c r ip ts .. 
q iI  74934611p irI IT03838 telomerase c a ta ly t ic  chain - f is s io n . .  
q iI  49134466|re f |X P  413229.11 h y p o th e tic a l p ro te in  AN9092.2 .. 
q iI  42760033 IembICAE01390.1 1 tuber b o rc h ii wh ite  c o lla r -1  [T .. 
ql|23481167|qb|EAA17 525.1 1 AT hook m o t if ,  p u ta tive  [Plasmod.. 
qi|23482650|qblEAA1857 3.1 1 h y p o th e tic a l p ro te in  [Plasmodium.. 
q iI  23957740|re f|N P  705854.11 h y p o th e tic a l p ro te in  [Plasmodi.. 
qi|22208753lembICAA21447■ 2 I SPCC1442.13C [Schizosaccharomyc.. 
q i1 19075827|re fIN P  588327.11 h yp o th e tic a l p ro te in  [Schizosa.. 
q i1 15223158 I re f|N P  172303.11 DNA-directed DNA polymerase ep.. 
a i l  3721933 1db1IBAA337 60.1 1 o ro t id in e -5 ' -phosphate decarboxy.. 
q lI  118356|sp|P07817|PYRF ASPNG O ro tid in e  5 ' -phosphate decar.. 
Appendix 7
31/83%, 28/100%.
Sequences producing significant alignments:
q i1 13824 8 |sp|P23728IVGLF BRSVR Fusion g lycop ro te in  precurso 
q iI  267 344 IspIP297911VGLF BRSVA Fusion g lycop ro te in  precurso 
gi|3451386|embICAA7 6980■ 11 F p ro te in  [Bovine re s p ira to ry  sy 
q j|940 6 3 |p irlIB 2 8 9 2 9  c e ll fu s io n  g lyc o p ro te in  - human re s p i. .  
qi|6653464|qblAAF227 22■ 11 fu s io n  p ro te in  [Bovine re s p ira to r. . 
q iI  61211lemblCAA2614 3 .1 1 unnamed p ro te in  product [Human re s .. 
q iI  281366 Ip ir I  IJQ1583 c e ll fu s io n  p ro te in  precursor - b o v in .. 
qi|1695263lqbIAAC55970■ 11 fu s io n  g lyc o p ro te in  precursor [Hu..
q i | 961607|qbIAAB38516.1 I 
q iI  29290041|qb |AA072324.il 
q iI  29290039|q b |AA072323.il 
q iI  961613|q b IAAB38519.il 
q iI  21689587|qbIAAM68160.1 I 
q iI  21689583 IqbIAAM68157.il 
q iI  21689579 IqbI AAM68154 . i l  
q iI  227 4 8321|qbI AAN05323.il
Score B
(bits) Value
49 le05
49 le05
49 le05
49 le05
49 le05
46 9e05
46 9e05
46 9e05
46 9e05
46 9e05
46 9e05
46 9e05
46 9e05
46 9e05
43 9e04
43 9e04
43 9e04
43 9e04
43 9e04
43 9e04
43 9e04
43 9e04
43 9e04
43 9e04
43 9e04
43 9e04
43 9e04
39 0.013
39 0.013
39 0.013
31 3.4
31 3.4
31 3.4
31 3.4
31 3.4
27 48
27 48
27 48
27 64
27 64
27 64
27 64
27 64
27 64
26 86
26 115
26 115
6/93-100°/. 32/100%
Score B
(bite) Value
49 le05
49 le05
49 le05
49 leOS
49 le05
49 leOS
49 leOS
49 le05
249
ali  
a i  
a i  
a i  
a i  
a i  
a i  
a i  
a i  
a i  
a i  
a i  
a i  
a i  
a i  
a i  
a i
ai.
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
138247 | sp | P22167 IVGLF BRSVC Fusion g lyc o p ro te in  precurso. 
4 256781 qb IAAB28458.1 I fu s io n  p ro te in  F2 subunit [bovine .
9631275| r e f  | NP 048055.11 fu s io n  g lyc o p ro te in  precursor; 
138251 | sp | P03420 I VGLF HRSVA Fusion g lyc op ro te in  precurso. 
17939990|qbIAAL4 9399.1 I fu s io n  p ro te in  [Bovine re s p ira to .
17 94 0002 IqbIAAL4 9410.1 I
21689587 I qb I AAM68160.1 I
fu s io n  p ro te in  [Bovine re s p ira to , 
fu s io n  g lyc o p ro te in  [Human re s p i.
___________, „ _________________ _ . fu s io n  g lyc o p ro te in  [Human re sp i.
,912295 |qb | AAC57 027 . i l  Fusion p ro te in  (F)
961615| qb | AAB38520.1 1 fu s io n  p ro te in  [Human re s p ira to ry
21263086lqb| AAM4 4 8 51.1 I
1353201 Isp I P11209IVGLF HRSVR Fusion g lyc op ro te in  precurs 
2929004 3 1qbIAA072325 ■ 11 fu s io n  p ro te in  [Human re s p ira to r
________________________________ ___ fu s io n  g lyc o p ro te in  [Human re s p i.
9629375|re f |N P  044596,11 Fusion p ro te in  (F) [ re s p ira to ry .
21689583Iqb I AAM68157.1 I
74932|pir|IVGNZR2 c e ll fu s io n  g lyc o p ro te in  precursor 
227299|p rf I 11701388A fu s io n  g lyc o p ro te in  
3172522 IqbI AAC13601.1 1 fu s io n  p ro te in  [Human re s p ira to ry .
961609 IqbI AAB38517.1 1 fu s io n  p ro te in  [Human re s p ira to ry  
138250 I sp | P13843 IVGLF HRSV1 Fusion g lyc op ro te in  precurso. 
9629206|re f |N P  056863.11 fu s io n  p ro te in  [Human re s p ira to . 
961607 Iqb|AAB38516.1 1 fu s io n  p ro te in  [Human re s p ira to ry  . 
2929004 1 |qbIAA072324 ■ 1 1 fu s io n  p ro te in  [Human re s p ira to r .  
2582041|qbIAAB8244 6 .1 1 fu s io n  p ro te in  [Human re s p ira to ry . 
29290039|qb IAA072323■ 11 fu s io n  p ro te in  [Human re s p ira to r .  
961613 I qb|AAB38519.1 1 fu s io n  p ro te in  [Human re s p ira to ry  . 
382304901 qb IAAR14266.1 1 F [Human R e sp ira to ry  s yn c y tia l v . 
19550336 1qbIAAL91342.1 1 fu s io n  p ro te in  [Ovine re s p ira to r .  
9616111qb| AAB38518■ 11 fu s io n  p ro te in  [Human re s p ira to ryI r D i u u i n u m l i  i c o p n a L u i  y
___ _________________ c e ll  fu s io n  p ro te in  - human re s p ira to .
21689579 Iqbl AAM68154■ 11 fu s io n  g lyc o p ro te in  [Human re s p i.
480767 I p i r  I I S37254
3767474 6 I qbl AAQ97 027.1 fu s io n  p ro te in  precursor 
fu s io n  p ro te in  precursor
[Human 
[Human
[Human . 
[Human .
. . . .  _ _ _____________________. . .  __________r_____________r________________ [Human .
138252 Isp|P12568IVGLF HRSVL Fusion  g lyc op ro te in  precurso. 
376747 4 4 IqblAAQ97 026.1 1 fu s io n  p ro te in  precursor [Human . 
120841151 pdb 11G2CIA Chain A, Human R esp ira to ry  S y n c y t ia l. 
46133522 I re f|Z P  00203193.il COG0846: NAD-dependent p ro te . 
48868061 I re f|Z P  00321452.il COQ0846: NAD-dependent p ro te . 
2 1 3 7 5 7 7 |p ir | 1155466 N -m ethy l-D -asparta te  receptor subuni.
37674 754 I qb I AAQ97 031 ■ 1 
226438Ip r f  I I1512372A fu s io n  p ro te in  
37674752 Iqb|AAQ97030.1 I fu s io n  p ro te in  precursor 
376747481qbIAAQ97028■ 1 I fu s io n  p ro te in  precursor 
37 67 47 50 IqblAAQ97029 1 I fu s io n  p ro te in  precursor
Appendix 8
Sequences producing significant aligxunantsi
SLi
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
a i
2168 9587 | qb I AAM68160 ■ 1 |
2126308 6 1 qbl AAM4 4 851 . i l
19122951q b lAAC57027.il
[Human re s p i. 
[Human re s p i.
fu s io n  g lyc o p ro te in  
fu s io n  g lyc o p ro te in  
Fusion p ro te in  (F)
c e ll  fu s io n  g lyc o p ro te in  - human re s p i. 
961615|qb|AAB38520■ 11 fu s io n  p ro te in  (Human re s p ira to ry  . 
1353201| sp | P I1209|VGLF HRSVR Fusion  g lycop ro te in  precurB.
94063 I p i r  I I B28929
2168 958 3 I qb I AAM68157 ■ 1 I
9629375I re f I NP 044596.1
37674 74 6 I qbl AAQ97027.1 |
74932 I p i r  I IVGNZR2 c e ll  
37 67 4 7 54 Iqb|AAQ97031 ■ 1 I
227299 Ip r f I I1701388A
3172 522 1qbIAAC18601 ■ 1
61211lemblCAA2614 3 .11
961609 IqblAAB38517.1 I
1695263 I qb IAAC5597 0 ■ 1 1
961607|qb|AAB38516 ■ 1 I
120841151 pdb11G2CIA
29290041 I qbIAAQ72 324
2 2 6 4 3 8 I p r f I  11512372A
3 7 6 7 4 7 5 2  | <jb I AAQ97I I  30
fu s io n  g lyc o p ro te in  [Human re s p i.
Fusion p ro te in  (F) [ re s p ira to ry , 
fu s io n  p ro te in  precursor [Human . 
fu s io n  g lyc o p ro te in  precursor - h. 
fu s io n  p ro te in  precursor [Human . 
fu s io n  g lyc o p ro te in
fu s io n  p ro te in  [Human re s p ira to ry , 
unnamed p ro te in  product (Human res . 
fu s io n  p ro te in  [Human re s p ira to ry  .
fu s io n  g lyc o p ro te in  precursor (Hu. 
fu s io n  p ro te in  [Human re s p ira to ry  . 
Chain A, Human R esp ira to ry  S y n c y tia l.  
1 1 fu s io n  p ro te in  [Human re s p ira to r ,  
fu s io n  p ro te in
1 1 fu s io n  p ro te in  precursor [Human .
49 le05
49 le05
49 le05
49 le05
49 le05
49 le05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 6e05
46 le04
46 le04
46 1 e0 4
46 le04
46 le04
46 le04
46 le04
46 le04
32 1.9
31 3.4
31 3.4
28 26
%, 46/86-92%.
Score E
(bits) Val uà
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
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qi | 376747481qb1AAQ97028.1 1 fus ion  p ro te in p recu rso r [Human
qi 129290039 Iqb1AA072323. 1| fus ion  p ro te in [Human re s p ira to r
qi 19616111qbIAAB38518.11 fus ion  p ro te in  [Human re s p ira to ry
qi 1480767|p ir|IS 37254  c e ll fus ion  p ro te in - human re s p ira to
q i 11382511sp1P034201VGLF HRSVA Fusion q lyc o p ro te in  precurso
qi 1376747501qb|AAQ97029.11 fus ion  p ro te in p recurso r [Human
qi 11382521sp1P125681VGLF HRSVL Fusion q lyc o p ro te in  precurso
q i 12168957 9 |qb|AAM68154.1 I fus ion  g ly c o p ro te in  [Human resp i
q i 137 6747 4 41qb1AAQ97026.1 1 fus ion  p ro te in precurso r [Human
qi 19616131qblAAB38519.11 fus ion  p ro te in  [Human re s p ira to ry
q i 196292061 re f|N P 056863.11 fu s io n  p ro te in  [Human re s p ira to
qi 12582041|qb|AAB824 4 6 .1 I fus ion  p ro te in Human re s p ira to ry
qi 11382481sp|P23728|VGLF BRSVR Fusion q lyc o p ro te in  precurso
q i 1267344| sp iP297911VGLF BRSVA Fusion q lvc o p ro te in  precurso
qi 1107654091qb|AAG2303 3 .1 I fus ion  p ro te in [Bovine re s p ira to
q i 13451386|embICAA7 6980.11 F p ro te in  [Bovine re s p ira to ry  sy
q i 1107654 31IqblAAG23044.1 I fus ion  p ro te in [Bovine re s p ira to
q i 1107654251qblAAG2 3041.1| fus ion  p ro te in [Bovine re s p ira to
q i 1107 65417|qb|AAG23037.1 I fus ion  p ro te in [Bovine re s p ira to
q i 110765433lqblAAG2304 5.11 fus ion  p ro te in [Bovine re s p ira to
q i 1 66534 64IqblAAF22722.1 I fus ion  p ro te in [Bovine re s p ira to r
q i 1 10765419lqblAAG2 3038.11 fu s ion  p ro te in [Bovine re s p ira to
qi 1 107 65427|gblAAG23042.1 I fus ion  p ro te in [Bovine re s p ira to
q i 1138247| sp iP22167|VGLF BRSVC Fusion q lyc o p ro te in  precurso
q i 1425678|qbIAAB28458.11 fu s ion  p ro te in  F2 subunit [bovine
qi |9631275lrefINP 048055.11 fu s io n  g ly c o p ro te in  precursor;
qi 1195503361qblAAL91342.1 I fus ion  p ro te in [Ovine re s p ira to r
q i 1 17939990Iqb lAAL4 9 3 9 9 .il fu s io n  p ro te in [Bovine re s p ira to
qi 110765421|qb |AAG23039.il fu s io n  p ro te in [Bovine re s p ira to
qi 1 17 94 0002|qb|AAL49410.1 I fu s io n  p ro te in [Bovine re s p ira to
qi 1 107653891qbIAAG2302 3 .11 fu s io n  p ro te in [Bovine re s p ira to
a i 1107 65391|qb|AAG23024.1 I fu s io n  p ro te in [Bovine re s p ira to
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
52 le06
48 3e05
46 9e05
46 9e05
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
46 le04
Appendix 9
Sequences producing significant a lignments (peptide 19). Score/ldentity -  27/60%, 29/100, 51/100, 47/93, 
46/93%,
44/86%, 43/86%, 39/85%, 29/100%, 27/86%, 27/60%.
Score E
Sequences producing s ig n if ic a n t a lig nm ents: (b its )  Value
qll21689587|qb|AAM68160■ 11 fu s ion  g ly c o p ro te in  [Human re s p i. 
ql|21263086|qblAAM44851■ 11 fu s ion  g ly c o p ro te in  [Human resp i. 
q i1 1912295 IqbI AAC57027.il Fusion p ro te in  (F) 
q iI 94063 Ip ir I  IB28929 c e ll  fu s ion  g lyc o p ro te in  - human resp i. 
qi|961615|qblAAB38520.1 I fus ion  p ro te in  [Human re s p ira to ry  . 
q i 113532011sp|PI1209 IVGLF HRSVR Fusion g lyc o p ro te in  p recurs. 
qi|21689583lqbIAAM68157■ 1| fu s io n  g ly c o p ro te in  [Human resp i. 
q i I 962 9375 I re f|N P  044596.11 Fusion p ro te in  (F) [re s p ira to ry . 
q iI  74932 Ip ir I  IVGNZR2 c e ll fus ion  g lyc o p ro te in  precursor - h. 
q iI  227299 Ip r f I  I1701388A fus ion  g ly c o p ro te in
a i l  61211 | emb|CAA2614 3,11 unnamed p ro te in  product [Human res. 
qi|961609lqbIAAB38517■ 11 fus ion  p ro te in  [Human re s p ira to ry  . 
qi|1695263lqbIAAC55970.1 | fus ion  g ly c o p ro te in  precursor (Hu. 
q iI  961607 IqbIAAB38516■ 11 fus ion  p ro te in  [Human re s p ira to ry  . 
q j|2 9 2 900411qbIAA072324■ 11 fus ion  p ro te in  [Human re s p ira to r . 
q j|2 9 2 900391qb|AA07 2323■ 11 fu s io n  p ro te in  [Human re s p ira to r . 
qj|961613IqblAAB38519.11 fus ion  p ro te in  [Human re s p ira to ry  . 
qj|961611lqbIAAB38518.1 1 fus ion  p ro te in  (Human re s p ira to ry  . 
'J i l l  )K251 | mj> | I’O3420 I VGLF IIK.'IVA Fusion g lyc o p ro te in  precurso. 
q ll21689579|qb lAAM6B154■ 11 fu s io n  g lyc o p ro te in  [Human re s p i. 
q i |3 7 6747461qbIAAQ97027■ 11 fu s io n  p ro te in  precursor [Human . 
'J 1 I i7 6 74 7 ' A  I gb I AA0970 i 1 . 1 | fu s io n  p ro te in  precursor [Human . 
q iI  3172522IqblAACl8601■ 11 fu s io n  p ro te in  [Human re s p ira to ry . 
q i I 37674752 IqbIAAQ97 030■ 1 I fu s io n  p ro te in  precursor [Human . 
q iI  37 67 4748 IqbIAAQ97 028■ 11 fu s io n  p ro te in  precursor [Human . 
q iI  480767 lo i r  IIS37254 c e ll fu s io n  p ro te in  - human re s p ira to . 
q j |3 7 6747501qblAAQ97029.11 fu s io n  p ro te in  precursor [Human .
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51 3e06
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q i I 1382 52 IspIP125 68 IVGLF HRSVL Fusion g lyc op ro te in  precurso. . . 
q i 137674744 |qb| AAQ9702 6.1 I fus ion  p ro te in  p recursor [Human . . . 
q i I 292 9004 3 |qb|AA072325.1 1 fus ion  p ro te in  [Human r e s p ir a to r . . .  
q iI  226438 Ip r f I  I1512372A fu s io n  p ro te in
q iI  9629206 I re f INP 056863.11 fus ion  p ro te in  [Human re s p ira to . ..  
qi|2582041|qb IAAB8244 6 .1 1 fus ion  p ro te in  [Human re s p ira to r y . ..  
q i|38230490|qbl AAR14 266 ■ 1 I F [Human R esp ira to ry  s y n c y t ia l v . . . 
q i I 138250 IspI P I 3843|VGLF HRSV1 Fusion g lyc op ro te in  precurso. . . 
q i 1120841151pdbI1G2CIA Chain A, Human R esp ira to ry  S y n c y t ia l. . . 
q iI  267 344|sp | P29791|VGLF BRSVA Fusion g lyc op ro te in  p re c u rso ... 
q i|19682989|qblAAL92614■ 1 I hyp o the tica l p ro te in  [D ic ty o s te l. . .  
q i|10765409| qb I AAG2303 3.1 I fus ion  p ro te in  [Bovine re s p ira to . . . 
qj|3451386lemb|CAA7 6980.1 I F p ro te in  [Bovine re s p ira to ry  s y . . .  
q iI  38201765| r e f  | NP 938132.11 SefH [S e rra tia  entomophila] > g ... 
q ill0765425 |q b | AAG23041.1 I fus ion  p ro te in  [Bovine re s p ira to . . .  
q i|10765417|qbl AAG23037.1 | fus ion  p ro te in  [Bovine re s p ira to . . .  
qi|10765433|qblAAG23045■ 1 I fus ion  p ro te in  [Bovine re s p ira to . ..  
g i i  6653464 IqbIAAF22722■ 11 fus ion  p ro te in  [Bovine re s p ir a to r . . .  
q i|10765419lqbl AAG2 3038■ 1 I fus ion  p ro te in  [Bovine re s p ira to . . .  
qi|10765427|qb|AAG23042.1 I fus ion  p ro te in  [Bovine re s p ira to . ..  
q i1 138247 | s p  | P22167|VGLF BRSVC Fusion g lyc o p ro te in  p re c u rso .. .  
q iI  42567 8 | qb IAAB284 58■ 11 fus ion  p ro te in  F2 subunit [bovine . . .  
q i|19550336|qb|AAL91342■ 1 I fus ion  p ro te in  [Ovine re s p ira to r .  . .  
q i|17940002|qb| AAL4 9410.1 I fus ion  p ro te in  [Bovine re s p ira to . . .  
q j|1 0 7 653891qb| AAG23023.1 I fus ion  p ro te in  [Bovine re s p ira to . . .  
q i|10765391|qb | AAG23024■ 1 I fus ion  p ro te in  [Bovine re s p ira to . . .  
q iI  138248 | spi P23728IVGLF BRSVR Fusion g lyc o p ro te in  p recu rso .. .
47 5e05
47 5e05
46 6e05
44 3e04
43 9e04
43 9e04
43 9e04
39 0.009
29 15
27 36
27 36
27 36
27 36
27 36
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27 36
27 36
27 36
27 36
27 36
27 36
27 36
27 36
27 36
27 36
27 36
27 48
Appendix 10
Sequences producing significant alignments (peptide 20). Score/ldentity "  52/100%, 49/93%, 48/93%. 
46/92%, 45/86%, 44/86%.
Sequences producing significant alignments!
q i 121689587 I qb I AAM68160.1 I 
q i | 21263086 IqbIAAM44851 . 11 
q i 11912295 1 qbIAAC57027.1 | 
q i 1 94063Ip i r |  |B28929 c e l l  
q i l  961615 |qb|AAB38520.1 I 
q i 1 13532011s p |P I12091VGLF
fus ion  g lyc op ro te in  [Human re s p i. 
fus ion  g lyc o p ro te in  [Human resp i. 
Fusion p ro te in  (F) 
fus ion  g lyc o p ro te in  - human re s p i. 
fus ion  p ro te in  [Human re s p ira to ry  . 
HRSVR Fusion g lyc o p ro te in  precurs .
q i 121689583 | qb|AAM68157. 1 | fus ion  q lyc op ro te in  [Human re s p i. 
g i 19629375 | r e f  | NP 044596.11 Fusion p ro te in  (F) [re s p ira to ry .
q i 1 74932|p i r |  IVGNZR2 c e l l  fus ion  q lyc o p ro te in  precursor - h. 
q i 1 2272 99|p r f  | I1701388A fusion q lyc o p ro te in  
q i 161211lemb |CAA26143.1 1 unnamed p ro te in  product [Human res 
q i19616091qb| AAB38517.1 | fus ion  p ro te in  [Human re s p ira to ry  
g iI 961607 | gb| AAB38516.1 | fus ion  p ro te in  [Human re s p ira to ry  
q i1961613 1 qb |AAB38519. 1 | fus ion  p ro te in  [Human re s p ira to ry  
q i 1 9616111 qb 1AAB38518.1 | fus ion  p ro te in  [Human re s p ira to ry  
q i11382511 sp |P034201VGLF HRSVA Fusion q lyc o p ro te in  precurso
q i 12168 9579 | qbl AAM68154.1 I fu s ion  g lyc op ro te in  [Human resp i
q i 1 10765409 1 qb 1 AAG23033.1 I 
q i 1 107654251qblAAG23041 . 1 |
fu s io n  p ro te in  [Bovine re s p ira to  
fu s io n  p ro te in  [Bovine re s p ira to
q i 1 10765417 | qbl AAG2 3037.1 | fu s io n  p ro te in  [Bovine re s p ira to
q i 1 3767 4 74 6 |qblAAQ97027. 1 | fu s io n  p ro te in  p recurso r [Human
q i l 37674 754|qblAAQ97031.1 I 
q i 1 66534 64 I qbl AAF22722.1 I 
g i 1 3172522 1 qbl AAC18601.1 1
fu s io n  p ro te in  p recurso r [Human 
fus ion  p ro te in  [Bovine re s p ira to r  
fus ion  p ro te in  [Human re s p ira to ry
q i19629206 | re f|N P  056863.11 fu s io n  p ro te in  [Human re s p ira to  
q i1226438|p r f  | | 1512372A fus ion  p ro te in
q i1107654 1 9 |qb|AAG23038.11 fu s io n  p ro te in  [Bovine re sp ira to  
q i|1 3 8 2 4 7 |sp |P 2 21671VGLF BRSVC Fusion g lyc o p ro te in  precurso
q i 1 37 67 47 52 I qb 1 AAQ97030.1 I fu s io n  p ro te in  p recursor [Human
q i110765423|q b 1AAG23040 .1 | fu s io n  p ro te in  [Bovine re sp ira to
g l | 37674748| g b lAAO9702 8 .1 I fu s io n  p ro te in  p recursor [Human
g i196312751 re fIN P  048055.11 fu s io n  a lvc o o ro te in  p recursori
g i1382 304 9 0 |qblAAR14266.1 I 
q i1195503361qb1AAL913 4 2 .î I
F (Human R e sp ira to ry  s yn c y tia l v 
fu s io n  p ro te in  (Ovine re s p ira to r
Scora B
(bits) Valu«
52 le -0 6
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q iI  480767Ip ir I  IS37254 c e ll  fu s ion  p ro te in  - human re s p ira to . . .  49 
qi|376747 50|qbIAAQ97 02 9.1 1 fu s ion  p ro te in  p recu rso r [Human . . .  49 
q i1 138252|spIP12568|VGLF HRSVL Fusion g lyc o p ro te in  p recu rso ... 49 
qill0765421lqblAAG23039■ 11 fus ion  p ro te in  [Bovine re s p ira to . . . 49 
qill0765389lqb|AAG23023■ 11 fus ion  p ro te in  [Bovine re s p ira to . .. 49 
qi|10765391lqblAAG23024■ 11 fus ion  p ro te in  [Bovine re s p ira to . . . 49 
q i|3 7  67 4744|qb| AAQ97026 ■ 1 I fu s io n  p ro te in  p recurso r [Human . . . 4 9 
qi|29290043|qblAA072325 ■ 1 I fu s io n  p ro te in  [Human re s p ira to r . . .  48 
qi|1695263|qb|AAC55970■ 11 fus ion  g lyc o p ro te in  precursor [H u... 48 
qi|29290041|qb|AA072324■ 11 fus ion  p ro te in  [Human re s p ira to r . . .  48 
q i|292  90039|qb|AAQ72323.1 1 fus ion  p ro te in  [Human re s p ira to r. . . 48 
q i1 138250 Isp|P1384 3IVGLF HRSV1 Fusion g lyc o p ro te in  p recu rso ... 46 
q iI  2813661p ir| IJQ1583 c e ll  fus ion  p ro te in  p recurso r - b o v in ...  45 
qill7939990|qblAAL4 9399.1 1 fus ion  p ro te in  [Bovine re s p ira to . . .  45 
q iI  267 34 4 |sp|P297 91|VGLF BRSVA Fusion g lyc o p ro te in  p recu rso .. . 44 
qi|3451386|embICAA76980.11 F p ro te in  [Bovine re s p ira to ry  s y . .. 44 
qi|10765427|qblAAG23042■ 11 fu s io n  p ro te in  [Bovine re s p ira to . . . 44 
q i|17940002|qblAAL49410,11 fus ion  p ro te in  [Bovine re s p ira to . . .  44 
q i1 138248I s p iP23728IVGLF BRSVR Fusion g lyc o p ro te in  p recurso ... 44 
qi|10765431|qb|AAG2304 4■ 11 fus ion  p ro te in  [Bovine re s p ira to . . .  44
Appendix II
Sequences producing significant alignments (peptide 24). Score/Identlty =52/100%.
Score
Sequences producing s ig n if ic a n t alignm ents: (b its )
q i1 138248 IsplP23728|VGLF BRSVR Fusion g lyc o p ro te in  p recu rso ... 52
qi|21689587|qblAAM68160■ 11 fus ion  g lyc o p ro te in  [Human re s p i. . .  52
qill0765409|qb|AAG23033.1 I fus ion  p ro te in  [Bovine re s p ira to . . . 52
qi|21263086|qb|AAM44851■ 11 fus ion  g ly c o p ro te in  [Human re s p i. . .  52
qi|3451386| emb ICAA7 6980■ 11 F p ro te in  [Bovine re s p ira to ry  s y . . .  52
qi|1912295|qblAAC57027■ 11 Fusion p ro te in  (F) 52
q iI 94063 Ip ir I  IB28929 c e l l  fus ion  g lyc o p ro te in  - human re s p i. . .  52
qill0765431|qb|AAG2304 4 ■ 11 fu s io n  p ro te in  [Bovine re s p ira to . . .  52
qi|961615|qb|AAB38520■ 11 fu s io n  p ro te in  [Human re s p ira to ry  . . . 52
q i1 13532011sp |P I1209 IVGLF HRSVR Fusion g lyc o p ro te in  p recurs.. . 52
qi|29290043|qblAA072325.1 1 fus ion  p ro te in  [Human re s p ira to r. . . 52
qill0765425|qb|AAG23041.1 I fu s io n  p ro te in  [Bovine re s p ira to . . . 52
qi|21689583|qb|AAM68157■ 1| fu s io n  g ly c o p ro te in  [Human re s p i. . .  52 
q iI  96293751re f INP 044596.11 Fusion p ro te in  (F) [ re s p ira to ry .. .  52 
q i|1 0 7 654171qb|AAG23037■ 1| fus ion  p ro te in  [Bovine re s p ira to . . .  52
q i | 107654331qb|AAG2304 5.1 1 fu s ion  p ro te in  [Bovine re s p ira to . . .  52
qi|37674746|qblAAQ97027■ 1| fu s ion  p ro te in  precursor [Human . . .  52
q iI  74932Ip ir I  IVGNZR2 c e l l  fus ion  g lyc o p ro te in  precursor - h . . .  52
ai_ 37 6747 54 IqbIAAQ97031■ 11 fu s ion  p ro te in  precursor [Human . . . 52
qi|6653464|qb|AAF22722■ 1 I fus ion  p ro te in  [Bovine re s p ira to r. . . 52
q iI  227299|p r f |  11701388A fu s ion  g lyc o p ro te in  52
2 i_ 31 2522 I qb|AAC18601■ 1| fu s ion  p ro te in  [Human re s p ira to ry . . . 52
q iI  61211|embICAA2614 3.1 1 unnamed p ro te in  product [Human re s . . .  52
q i | 961609 Iqb|AAB38517.1 | fus ion  p ro te in  [Human re s p ira to ry  . . . 52
q iI  138250 IspIP1384 3|VGLF HRSV1 Fusion g lyc o p ro te in  p recu rso ... 52
q i1 2813661p irI IJQ1583 c e l l  fu s io n  p ro te in  precursor - b o v in ...  52
g iI  9629206|re f |N P  056863.11 fu s io n  p ro te in  [Human re s p ira to . . . 52
qi|1695263|qblAAC55970.1 | fu s ion  g lyc o p ro te in  precursor [H u... 52
2i_ 961607|qbIAAB38516■ 1 I fus ion  p ro te in  [Human re s p ira to ry  . . . 52
q iI  292900411qbIAA072324■ 11 fu s io n  p ro te in  [Human re s p ira to r . . .  52
q iI  226438 Ip r f I  I1512372A fus ion  p ro te in  52
q l125820411qbIAAB8244 6■ 1 I fu s io n  p ro te in  [Human re s p ira to ry . . . 52
g i l l 07654191qblAAG23038■ 1 I fu s io n  p ro te in  [Bovine re s p ira to . . .  52
gi|10765427|qbIAAG23042■ 1 I fu s io n  p ro te in  [Bovine re s p ira to . . . 52
q i1 138247 IspIP22167IVGLF BRSVC Fusion g lyc o p ro te in  p recurso .. .  52
qll425678|qblAAB284 58.1 I fus ion  p ro te in  F2 subunit [bovine . .  . 52
q j|3 7 6747521qblAAQ97030■ 11 fu s io n  p ro te in  precursor [Human . . . 52
q il l0 7  65423|qb|AAG23040■ 11 fu s io n  p ro te in  [Bovine re s p ira to . . .  52
q i|3 7 6747481qbIAAQ97028■ 11 fu s io n  p ro te in  precursor [Human . . .  52
q iI  9631275 I re fIN P  048055.ll fu s io n  g lyc o p ro te in  precursor; . . . 52
q iI  29290039 IqbIAA072323,1 1 fu s io n  p ro te in  [Human re s p ira to r . . .  52 
g i  | 9 6 1 6 1 3 | g b I  A A B 3 H 5 1 9 . 1 | fus ion  p ro te in  [Human re sp ira to ry  . . .  52
le -0 5  
le -0 5  
le -0 5  
le -0 5  
le -0 5  
le -0 5  
le -0 5  
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qi|38230490|qb| AAR14 2 66.1 I F [Human R esp ira to ry  s y n c y t ia l v . . . 52
q i | 195503361 qb | AAL91342.1 I fu s io n  p ro te in  [Ovine r e s p ir a to r . . .  52
9 l  I 961611 Iqb | AAB3 83 18■ 1 I fu s io n  p ro te in  [Human re s p ira to ry  . . .  52
q iI 480767|p i r |  IS37254 c e ll  fu s io n  p ro te in  - human r e s p ir a to . ..  52
q i1 1382 511sp I P03420 IVGLF HRSVA Fusion g lyc op ro te in  p re c u rs o ...  52
qi|17939990l qb I AAL49399.11 fu s io n  p ro te in  [Bovine r e s p ir a to . ..  52
q i | 37 67 4 7 50 | qb I AAQ97 029 ■ 11 fu s io n  p ro te in  precursor [Human . . . 52
q iI 138252 I sp| P12568IVGLF HRSVL Fusion g lyc op ro te in  p re c u rs o ... 52 
q i|21689579lqbl AAM68154■ 1 I fu s io n  g lyc op ro te in  [Human r e s p i. . .  52
qi|10765421| qb I AAG23039■ 11 fu s io n  p ro te in  [Bovine r e s p ir a to . . .  52
q i | 107 653891 q b IA A G 2 3 0 2 3 .1 1 fu s io n  p ro te in  [Bovine r e s p ir a to . ..  52
q ill0765391|qb  IAAG2 3024.1 I fu s io n  p ro te in  [Bovine r e s p ir a to . ..  52
qi|3767 4744|qb|AAQ9702 6 .1 1 fu s io n  p ro te in  precursor [Human .. . 52
Appendix 12
Sequences producing significant alignments (peptide 32). Score/ldentity -56/100%.
Score
Sequences producing significant alignmentsi (bits)
q iI 138248I spi P23728IVGLF BRSVR 
gi I 2 6 / 144 I .spi P29791 I VGLF BP5VA
Fusion g lyc op ro te in  p re c u rs o .. 
Fusion g lyc op ro te in  p recu rso ..
q i121689587 IqblAAM68160.il 
g i l l  0 7 6 5 4 0 9  I g b I A A G 2 3 U 3 3  . 1 I 
g i  1 2 1 2 6  3 0 8 6  I g b  I AAM4 4 8 5 1  . 1 I 
g J j / J 4  5 1 3 8 6  I i m i ;  I C A A 7 6 9 8 0  . l I  
qi 119122951 ab IAAC57027,1 1 
q iI 94063 Ip lr I  IB28929 c e l l  
g l  i 1 0 7 6 5 4 3 1  I g b j A A G 2 3 0 4 4 . 1  | 
g i  I 9 6 1 6 1 3  I g b  I A A B 3 9 5 2  0 .  f f  "
fu s io n  g lyc op ro te in  [Human re s p i..  
fu s io n  p ro te in  (Bovine r e s p ir a to . . 
fu s io n  g lyc op ro te in  [Human re s p i..  
F p ro te in  [Bovine re s p ira to ry  sy .. 
Fusion p ro te in  (F)
fu s io n  g lyc op ro te in  - human re s p i..  
fu s io n  p ro te in  [Bovine r e s p ir a to . . 
fu s io n  p ro te in  [Human re s p ira to ry  ..
gì I 1 3 5 3 2 0 1  I sp* I fJ l  1 209 I VGLK_HROVK Fusion g lyc op ro te in  precurs . .
gi 12929004 1 I gbIAAO/2 325. 1 I 
g i l l  07 654 2 5 I gbIAAG2 704 1 . 1 I 
g - 12 1 689583 I gb I AAM68 1 57 . 1 I 
g i I 9629375 I re f  | 111' 044 596 . 1 
gl I 1 07654 17 I gb I AAG2 1037. 1 I 
gi I 10765433 I gbIAAG2304 3. 1 I 
gi I 37674746 I g b i AAQ 9 7 0 2 7 f  1 I 
gi ' 749 32 Ip; r I I VGU/,82 c e ll  
gi 137674 754 I gb | AAÜ97031 . 1 | 
g i I 6653464 I gb I AAF22 7 2 2 .1 I 
g l1227299lprfI 11701388A 
g l 13172522 la b iAAC18601.1
fu s io n  p ro te in  [Human re s p ira to r . ,  
fu s io n  p ro te in  [Bovine r e s p ir a to . . 
fu s io n  g lyc op ro te in  [Human re s p i..
Fusion p ro te in  (F) [ re s p ira to ry . ,  
fu s io n  p ro te in  [Bovine r e s p ir a to . . 
fu s io n  p ro te in  [Bovine re s p ira to . . 
fu s io n  p ro te in  precursor [Human .. 
fu s io n  g lyc op ro te in  p recu rso r - h ..
fu s io n  p ro te in  precursor [Human .. 
fu s io n  p ro te in  [Bovine re s p ira to r .  . 
fu s io n  g lyc op ro te in
fu s io n  p ro te in  [Human r e s p ira to r y . .
g i l l  182 30 | .-¡p | p 1 184 3 | VGLF 118.5 VI Fus ion gl ycoprot t iB  p d O II  80 • ■ 
a i l  281366 |p i r |  IJQ1583 c e l l  fu s io n  p ro te in  precursor - b o v in .. 
g i I 962 9206 | r *■  1 | MB 036863.il fu s io n  p ro te in  [Human re s p ira to . ,  
gi I 1 693263 | gbI AAC33970.il fu s io n  g lyc op ro te in  p recu rso r [Hu., 
ai. 9004 1 | f j t j  | AAQ72 324 . 1 I fu s io n  p ro te in  [Human re s p ira to r . ,  
g i I 2264 JO jp r f I I 1 91 2372A fu s io n  p ro te in
gi | 258204 1 I gb I AAH82446.1 I fu s io n  p ro te in  [Human re s p ira to ry . ,  
g i I 1 o 7 f/,4 1 9 | gb | A/\', / 'jo }8 . 1 | fu s io n  p ro te in  [Bovine re s p ira to . .
• j i I 1 07 004 27 | gb I AAf ' > / 504 2 . 1 I fu s io n  p ro te in  [Bovine re s p ira to . ,
g i | 1 38247 I sp | P22 1 07 | VNLF_HKOVN Fusion g lyc op ro te in  p recurso .. 
g i | 425678 | gb I AAH2B4 58 . 1 I fu s io n  p ro te in  F2 subunit [bovine .. 
j i  I 57674752 | gbIAA097O3Q . 1 I fu s io n  p ro te in  p recursor [Human ..
fu s io n  p ro te in  [Bovine re s p ira to . . 
fu s io n  p ro te in  precursor [Human . .
fu s io n  g lyc op ro te in  p re c u rso r; . . 
fu s io n  p ro te in  [Human re s p ira to r .  . 
q iI 961613 | qb|AAB38519.1 | fu s io n  p ro te in  [Human re s p ira to ry  ..  
g ii 5 82 J0 4 90 I gb I AAH14 266. 1 I F [Human R esp ira to ry  s y n c y t ia l v . .
g i I 1 9 9 9 o 3 3 f j  | gb | AAI/i 1 34 2. 1 I fu s io n  p ro te in  [Ovine re s p ira to r . ,
gi I 480767 |p i r I | .937254 c e ll  fu s io n  p ro te in  - human re s p ira to .,  
gi 1138251 | .sp | PO3420 I VNLF HB9VA Fusion g lyc op ro te in  p recurso.. 
q i 117939990 I qbl AAL49399» 11 fu s io n  p ro te in  [Bovine re s p ira to .,  
g ii r /f//4 /9 0  | gb ) AA997029.1 I fu s io n  p ro te in  p recursor [Human .. 
gi I 1 3B292 I «p )Pl 29f»B j VOLF HH9VL Fusion g lyc o p ro te in  precurso.. 
g i I 2 I t . u  997 '♦  1 gb I AAM9H 1 94 . 1 | fu s io n  g lyc op ro te in  [Human re s p i.. 
g i l l  076942 1 I gb I AAr;2'!0 19 . 1 | fu s io n  p ro te in  [Bovine re s p ira to .,  
g iI 1 7940002 IgbIAAL494 1 0 .1 1 fu s io n  p ro te in  (Bovine re s p ira to ..
gi I 1070942 ! I < j \ >  I AA'i2 1040.1 | 
gì I 17074748 I gb|AA09 /028. 1 | 
gì 190 112791 re f  INI' 048099. 1 I 
gì I 2 92 900 19 I gb I AAO/2 32 3.1 |
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q i I  107653891gbIAAG2 3023.1 | 
q i I 107 65391 IqbIAAG23024. 1 | 
q i I  3767474 4 IqbIAAQ97 026. 1 |
le -07
le-07
le -07
fu s io n  p ro te in  [Bovine re s p ira to . . .  56 
fus ion  p ro te in  [Bovine re s p ira to . ..  56 
fus ion  p ro te in  p recu rso r [Human . . . 56
A p p e n d i x  1 3
Sequences producing significant alignments (peptide 36). Score/ldentity ■ 39/73%,41/80%, 46/86%, 49/93%, 
51/100%.
Score E
Sequences producing s ig n if ic a n t  alignm ents: (b its ) Value
94063 Ip ir I  IB28929 c e l l fu s ion  q lyc op ro te in  - human resp i
q i 138251|sp|P03420|VGLF HRSVA Fusion q lyc o p ro te in  precurso.
q i 212 6308 6 |qb|AAM4 48 51.1 I fu s ion  g lyc o p ro te in  [Human re sp i.
q i 3767474 6 IqbIAAQ97027.1 | fu s io n  p ro te in  p recu rso r [Human
q i 37 67 4 7 541qb1AAQ97031.1 I fu s io n  p ro te in  p recu rso r [Human
q i 3172522|qb|AAC18 601.1 I fu s ion  p ro te in  [Human re s p ira to ry .
q i 61211lemb|CAA26143.11 unnamed p ro te in  product [Human res
q i 1695263|qb|AAC55970.1 I fu s io n  g lyc o p ro te in  precursor [Hu
q i 961607|qb|AAB38516.1 I fu s io n  p ro te in  [Human re s p ira to ry
q i 226438|p rf||1512372A  fu s ion  p ro te in
q i 37 674 7 52 Iqb1AAQ97 030.1 1 fu s io n  p ro te in  p recu rso r [Human
q i 3767474 8 |qbIAAQ97028.1 I fu s io n  p ro te in  p recurso r [Human
q i 480767| p i r 11S37254 c e l l  fu s io n  p ro te in  - human re sp ira to
q i 37 67 4 7 50|qb|AAQ97029.1 I fu s io n  p ro te in  p recurso r [Human
q i 138252 | sp 1 P12568 | VGLF HRSVL Fusion q lyc o p ro te in  precurso
q i 3767474 4 IqbIAAQ97026.1 1 fu s io n  p ro te in  p recurso r [Human
q i 2168 9587|qbIAAM68160.1 I fu s io n  g lyc o p ro te in  [Human resp i
q i 19122951gb|AAC57 027.1 | Fusion p ro te in  (F)
q i 9616151qb1AAB3852 0 .1 I fus ion  p ro te in  [Human re s p ira to ry
q i 13532011 SPI P I1209|VGLF HRSVR Fusion q lyc o p ro te in  precurs
q i 2929004 3 1qb1AA072325.1 I fu s io n  p ro te in  [Human re s p ira to r
q i 21689583|qb|AAM68157.1 I fu s io n  g lyc o p ro te in  [Human resp i
q i 96293751 re f  1NP 044596.11 Fusion p ro te in  (F) [re sp ira to ry
q i 74932IpirlIVGNZR2 c e l l fu s io n  g lyc o p ro te in  precursor - h
q i 2272991p rf||1701388A  fu s io n  q lyc op ro te in
q i 961609|q b IAAB38517.il fu s io n  p ro te in  [Human re s p ira to ry
qi 2 92 90041|qbIAA072 32 4.11 fu s io n  p ro te in  [Human re s p ira to r
q i 29290039|qbIAA072323.il fu s io n  p ro te in  [Human re s p ira to r
q i 961613|qb|AAB38519.1 I fu s io n  p ro te in  [Human re s p ira to ry
qi 9616111qb1AAB38518.1 I fus ion  p ro te in  [Human re s p ira to ry
qi 21689579|qb|AAM68154.11 fu s io n  g lyc o p ro te in  [Human resp i
qi 138250 | sp | P1384 3 | VGLF HRSV1 Fusion q lyc o p ro te in  precurso
qi 9629206|re f|N P  056863.11 fu s io n  p ro te in  [Human re sp ira to
qi 2582041|qb|AAB824 4 6 . 1 I fu s io n  p ro te in  [Human re s p ira to ry
qi 382304 90|qb|AAR14266.1 I F [Human R e s p ira to ry  syn c y tia l v
qi 13824 8 1 sp 1 P23728 | VGLF BRSVR Fusion q lyc o p ro te in  precurso
qi 26734 4 1 sp 1 P29791 | VGLF BRSVA Fusion q lyc o p ro te in  precurso
qi 10765409|qb|AAG23033.1 I fu s io n  p ro te in  [Bovine re sp ira to
qi 34513861embICAA76980.11 F p ro te in  [Bovine re s p ira to ry  sy
qi 107 654 31|qb1AAG2 304 4.11 fu s io n  p ro te in  [Bovine re sp ira to
qi 10765425|qb|AAG23041.1 I fu s io n  p ro te in  [Bovine re sp ira to
qi 10765417|qblAAG23037.1 | fu s io n  p ro te in  [Bovine re sp ira to
qi 10765433|qblAAG230 4 5.1 I fu s io n  p ro te in  [Bovine re sp ira to
qi 66534 64 IqbIAAF227 22 .1 I fu s io n  p ro te in  [Bovine re s p ira to r
qi 281366|p ir ||JQ 1 5 8 3  c e ll fu s io n  p ro te in  p recursor - bovin
qi 10765419|qblAAG23038.1 I fu s io n  p ro te in  [Bovine re sp ira to
qi 10765427|qb|AAG23042.1| fu s io n  p ro te in  [Bovine re sp ira to
a i 138247| s p iP22167|VGLF BRSVC Fusion q lyc o p ro te in  precurso
qi 425678|qbIAAB284 58.1 I fu s io n  p ro te in  F2 subunit [bovine
qi 107 654 23 |qblAAG2304 0 .1 I fu s io n  p ro te in  [Bovine re sp ira to
qi 9631275|re f|N P  048055.11 fu s io n  q lyc o p ro te in  precursor;
a i 19550336|qb|AAL91342.11 fu s io n  p ro te in  [Ovine re s p ira to r
qi 179399901qbl AAL4 9 399.1 ! fu s io n  p ro te in  [Bovine re sp ira to
qi 10765421|qb|AAG23039.1 I fu s io n  p ro te in  [Bovine re sp ira to
qi 17940002 1qb| AAL4 9 4 1 0 .il fu s io n  p ro te in  [Bovine re sp ira to
qi 10765389|qblAAG23023.11 fu s io n  p ro te in  [Bovine re sp ira to
«JÌ 107 653911qb|AAG2302 4 .1 I fu s io n  p ro te in  [Bovine re sp ira to
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Sequences producing significant alignments (peptide 41). Score/ldentity = 28/80%, 48/100%, 50-51/100%.
Score E
Sequences producing s ig n if ic a n t  a lignm ents: (b its ) Value
q i 1138248 IspIP23728IVGLF BRSVR Fusion g lyc op ro te in  precurso. . .  
q iI  267344 I 3 p  I P29791 I VGLF BRSVA Fusion g lyc op ro te in  precurso. . . 
qi|21689587| qb I AAM68160.1 I fus ion  g lyc o p ro te in  [Human resp i . . .
qi|21263086|qb|AAM4 4 851.1 I fus ion  g lyc o p ro te in  [Human r e s p i . . .
qi|3451386l emb I CAA7 6980.1 1 F p ro te in  [Bovine re s p ira to ry  s y . . . 
q i|1912295|qbl AAC57027.1 | Fusion p ro te in  (F)
q i I 94063 Ip ir I  IB28929 c e ll  fu s io n  g lyc o p ro te in  - human re s p i. . . 
qi|961615|qb|AAB38520■ 11 fu s io n  p ro te in  [Human re s p ira to ry  . .  . 
q iI  2 92 90043 IqbI AA072325■ 11 fus ion  p ro te in  [Human re s p ira to r .  . . 
qj|21689583|qblAAM68157 ■ 1 1 fus ion  g lyc o p ro te in  [Human r e s p i . . .  
q iI  9629375 I r e f  INP 044596.11 Fusion p ro te in  (F) [ r e s p ira to ry . . . 
qj|37674746|qblAAQ97027■ 1 I fus ion  p ro te in  precursor [Human . .  .
q i|37674754lqbl AAQ97031■ 1 I fus ion  p ro te in  precursor [Human . .  .
q i I 227299 Ip r f I  I1701388A fu s io n  g lyc o p ro te in
q i|3172522|qb| AAC18601■ 11 fus ion  p ro te in  [Human re s p ira to r y . . . 
q iI 612111embICAA2 614 3■ 11 unnamed p ro te in  product [Human re s . . . 
qi|961609|qbIAAB38517■ 11 fu s io n  p ro te in  [Human re s p ira to ry  . .  . 
q i1 138250 IspIP13843IVGLF HRSV1 Fusion g lyc op ro te in  precurso. . . 
q i I 281366 Ip ir I  IJQ1583 c e l l  fus ion  p ro te in  precursor - b ov in . . . 
q iI 9629206 I r e f  INP 056863.11 fus ion  p ro te in  [Human r e s p ir a to . . . 
qi|16952 63|qblAAC55970■ 1| fus ion  g lyc o p ro te in  precursor [Hu. . . 
q i|961607|qblAAB38516.1 1 fu s ion  p ro te in  [Human re s p ira to ry  . . . 
qil29290041lqbIAA072324■ 1 I fus ion  p ro te in  [Human r e s p ir a to r . . .  
q i I 226438 Ip r f I  11512372ft. fu s io n  p ro te in
q i|2582041lqb| AAB824 46 .1 1 fus ion  p ro te in  [Human r e s p ir a to r y . . .  
q i1 138247 IspIP22167 IVGLF BRSVC Fusion g lyc op ro te in  precurso. . . 
q iI 37 674 7 52 IqbIAAQ97 030.1 I fus ion  p ro te in  precursor [Human . . . 
q i|3 7 6747481qbIAAQ97028.1 I fus ion  p ro te in  precursor [Human . . . 
q iI 9631275 I r e f  INP 048055.11 fu s io n  g lyc o p ro te in  p recursor; . . . 
q iI  29290039 IqbIAA072323■ 1 I fus ion  p ro te in  [Human r e s p ir a to r . . .  
q i|961613|qblAAB38519.1 1 fus ion  p ro te in  [Human re s p ira to ry  . . . 
qi|38230490|qbIAAR14266■ 1 I F [Human R esp ira to ry  s yn c y tia l v .  . . 
q i|19550336l qbIAAL91342.1 I fu s ion  p ro te in  [Ovine r e s p ir a to r . . .  
q j|961611|qb l AAB38518.1 I fus ion  p ro te in  [Human re s p ira to ry  . . . 
q iI  4 807 67 Ip i r  I IS37254 c e l l  fu s ion  p ro te in  - human r e s p ir a to . . .  
q i1 1382511spIP03420IVGLF HRSVA Fusion g lyc op ro te in  precurso. . .  
qi|17939990lqbIAAL4 9399■ 1 I fus ion  p ro te in  [Bovine r e s p ir a to . . .  
q j|3 7 6747501qbIAAQ97 029■ 1 I fu s ion  p ro te in  precursor [Human . . . 
q i1 138252 IspIP12568IVGLF HRSVL Fusion g lyc op ro te in  p re c u rs o ...  
q i|2 1 6895791 qbIAAM68154.1 I fu s io n  g lyc o p ro te in  [Human re s p i . . . 
q ill7940002 l qbIAAL4 9410■ 1 I fu s io n  p ro te in  [Bovine r e s p ir a to . . .  
a i. 37674744 IqbIAAQ97026■ 1 I fu s io n  p ro te in  precursor [Human . . . 
q iI  1353201 IspIP11209IVGLF HRSVR Fusion g lyc op ro te in  precurs . . . 
q iI  74932 Ip ir  I IVGNZR2 c e l l  fus ion  g lyc o p ro te in  precursor - h . . .  
q iI  425678 IqbIAAB284 58.1 I fus ion  p ro te in  F2 subunit [bovine . . . aL 23485704 lqb|EAA2 0535. 1 I h yp o th e tic a l p ro te in  [Plasmodium ... 
q i1 11128019 I re fIN P  061820.11 cytochrome c [Homo sapiens] >g . . . 
aL 46250408 IqblAAH68464 ■ 1 I Cytochrome c [Homo sapiens] 
q iI 654 36 Ip i r  I ICCCZ cytochrome c - chimpanzee ( te n ta tiv e  seq . . .  
qj|15929398lqbIAAH15130■ 11 CYCS p ro te in  [Homo sapiens]
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Appendix IS
Sequences producing significant alignments (peptide 48). Score/Identlty -  SI/100%.44/86%, 32/78%, 
30/80%, 28/88-100%
Score ■
Sequences producing significant alignments: (bits) Value
q i 121689587 | qb I AAM68160 ■ 1 I 
g l 121263086 IqblAAM44851 ■ 1 I 
q iI  19122951qbIAAC57027 ■ 1 I 
g l I 94063I p i r I IB28929 c e l l  
g l I 9616151 qb IAAB38520 ■ 1 I 
g l I 1353201 IapI P I1209 I VGLF 
g l I 2929004 3 IgblAA072325. 1 1 
g l 121689583 IqblAAM68157■ 11
fu s io n  g lyc o p ro te in  [Human re s p i.  
fu s io n  g lyc o p ro te in  [Human re s p i.  
Fusion p ro te in  (F)
fu s io n  g lyc o p ro te in  - human re s p i.  
fus ion  p ro te in  [Human re s p ira to ry  . 
HRSVR Fusion g lyc op ro te in  p recu rs . 
fu s io n  p ro te in  [Human re s p ira to r ,  
fu s io n  g lyc op ro te in  [Human re s p i.
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q i I 962937 5 I re f INP 044596.11 Fusion p ro te in  (F) [ re s p ira to ry . . 
qj|37674746|qb|AAQ97 027.1 1 fu s io n  p ro te in  p recursor [Human .. 
q i|74932|p ir|IVG NZR2 c e ll fu s io n  g lyc o p ro te in  precursor - h. . 
qj|37674754lqbIAAQ97031.1 1 fu s io n  p ro te in  precursor [Human .. 
q j|227299 |p rflI1701388A  fu s io n  g lyc op ro te in
qi|3172522|qblAAC18601■ 11 fu s io n  p ro te in  [Human re s p ira to ry . . 
q i I 612111embICAA2 614 3■ 1 I unnamed p ro te in  product [Human re s .. 
qi|961609|gb|AAB38517■ 11 fu s io n  p ro te in  [Human re s p ira to ry  . . 
q i I 1382 50 I sp | P1384 3 I VGLF HRSV1 Fusion g lyc o p ro te in  precurso. . 
q iI  96292061 refINP 056863.11 fu s io n  p ro te in  [Human re s p ira to .. 
qj|1695263|qbIAAC55970■ 11 fu s io n  g lyc o p ro te in  precursor [Hu.. 
q i|961607 | qbIAAB38516 .1 1 fu s io n  p ro te in  [Human re s p ira to ry  . . 
q iI  292 90041|qb|AA072324 ■ 1 1 fu s io n  p ro te in  [Human re s p ira to r . .  
q i|2 2 6 4 3 8 |p r f |11512372A fu s io n  p ro te in
qi|2582041lqblAAB82446.11 fu s io n  p ro te in  [Human re s p ira to ry . . 
qi|12084116lpdbI1G2CIB Chain B, Human R e sp ira to ry  S y n c y tia l. .  
qi|37674752lqblAAQ97 030■ 11 fu s io n  p ro te in  precursor [Human .. 
qi|37674748|qbIAAQ97 028■ 11 fu s io n  p ro te in  precursor [Human . . 
q i|2 9 2 900391qb|AA072323■ 11 fu s io n  p ro te in  [Human re s p ira to r. . 
qj|961613lqbIAAB38519.1 1 fu s io n  p ro te in  [Human re s p ira to ry  . . 
q iI  38230490 IqbIfiARl4 266,11 F [Human R e s p ira to ry  s yn c y tia l v . . 
qi|961611|qblAAB38518.1 1 fu s io n  p ro te in  [Human re s p ira to ry  . . 
q i|4 8 0 767 |p ir|IS 37254  c e ll  fu s io n  p ro te in  - human re s p ira to . . 
q iI  1382511sp|P03420|VGLF HRSVA Fusion g lyc o p ro te in  p recu rso .. 
q iI  376747501qbIAAQ97 029■ 1 1 fu s io n  p ro te in  p recursor [Human .. 
q iI  1382 52 IspIP12568|VGLF HRSVL Fusion g lyc o p ro te in  p recurso .. 
q i 1216895791qblAAM68154■ 11 fu s io n  g lyc o p ro te in  [Human re s p i..  
q iI  37 67 47 44|qbIAAQ97026■ 11 fu s io n  p ro te in  p recursor [Human . . 
q iI  138248 IspIP23728|VGLF BRSVR Fusion g lyc o p ro te in  p recurso .. 
q i I 267344 I sp| P29791 I VGLF BRSVA Fusion g lyc o p ro te in  precurso.. 
qi|3451386|embICAA7 6980.1 I F p ro te in  [Bovine re s p ira to ry  sy. . 
q iI  281366|p ir I  IJQ1583 c e ll  fu s io n  p ro te in  p recursor - bovin. . 
q iI  138247|sp|P22167|VGLF BRSVC Fusion g lyc o p ro te in  precurso.. 
qi|425678|qb|AAB28456.1 1 fu s io n  p ro te in  F2 subunit [bovine ..  
q iI  9631275|re f|N P  048055,11 fu s io n  g lyc o p ro te in  precursor; .. 
q iI  195503361qb|AAL91342 ■ 1 I fu s io n  p ro te in  [Ovine re s p ira to r . .  
q iI  17939990 IqbIAAL49399.11 fu s io n  p ro te in  [Bovine re s p ira to . . 
q iI  179400021qbIAAL49410.11 fu s io n  p ro te in  [Bovine re s p ira to .. 
q iI  45525184|r e f  IZP 00176429.11 h y p o th e tic a l p ro te in  Cwat361.. 
q i I 46119850|re f |Z P  00177482.21 COG1900; Uncharacterized con.. 
3* I 47 222570lemblCAG02935.1 1 unnamed p ro te in  product [Tetrao. . 
q iI  2 311474 6 |re f |Z P  00100032.11 COG1502: P h o sp h a tid y lse rin e /. . 
q iI  488381511 re f|Z P  00295099.il h y p o th e tic a l p ro te in  Meth020..
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